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ABSTRACT 
Aneuploidy is common in human preimplantation embryos. This thesis examines 
aneuploidy detection using an array platform, aneuploidy in embryos from fertile 
couples and recombination in gametes through the detection of cross-over events in 
embryos.  
 
The first aim of this project was the optimisation of array comparative genomic 
hybridisation (aCGH) to examine all chromosomes in single blastomeres and 
trophectoderm samples from embryos, prior to clinical implementation. Accurate 
detection of errors was possible on single cells from epithelial cell lines of known 
chromosomal status. The same cell lines were used to mimic mosaic trophectoderm 
samples to examine the effect of mosaicism on aCGH. Aneuploidy could be 
confidently detected when more than 50% of the cells in the sample were abnormal. 
 
Aneuploidy studies have been mainly performed on embryos, from couples 
undergoing preimplantation genetic screening (PGS), which are expected to be 
highly abnormal. The second aim was to determine the aneuploidy level in embryos 
from couples undergoing preimplantation genetic diagnosis (PGD) for monogenic 
disorders. Fluorescence in situ hybridisation (FISH) was used to examine five 
chromosomes in 86 embryos from 19 couples and all chromosomes were examined 
in 53 embryos from six couples by aCGH. Diploid mosaic embryos were the most 
predominant group when FISH analysis was carried out, whereas the majority of 
embryos were euploid after aCGH. Post-zygotic rather than meiotic errors were 
more common in embryos from PGD cycles when compared to embryos from PGS 
cycles.  
 
Aneuploidy is known to associate with aberrant recombination. The third aim was to 
examine meiotic recombination. Polymorphic markers on five chromosomes were 
used to detect cross-over events in 77 embryos from 10 couples. Female 
recombination was higher than male. Increasing age had a negative effect on 
recombination. No significant effect of recombination on morphology and aneuploidy 
was observed, however euploid embryos had more recombination than aneuploid.  
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1.1 Aneuploidy 
Aneuploidy is defined as the deviation from a multiple of the haploid number of 
chromosomes in a cell. In humans, studies have shown that aneuploidy is the 
primary cause of pregnancy loss and birth defects as well as failure to establish a 
pregnancy following assisted reproduction technologies (ART, Nagaoka et al, 2012).  
Aneuploidy may even be the reason of poor fertility in humans when compared to 
other species (Delhanty, 2001). It has been estimated that, almost 5% of human 
conceptions are aneuploid. It is known that among all recognised pregnancies 
around 15% to 20% result in spontaneous abortions (Hassold, 1986). Analysis of 
spontaneous abortions during the first trimester of pregnancy has revealed that up 
to 70% carry a chromosomal anomaly (Fritz et al, 2001). Aneuploid pregnancies that 
survive to term will lead to the birth of children with developmental defects and 
mental retardation. Many studies have been performed presenting the varying level 
of aneuploidy at different developmental stages. A recent study has reported that 
43.8/10000 births carry a chromosomal anomaly (Wellesley et al, 2012). These are 
all values from established pregnancies during which analysis is possible. Early loss 
during the first weeks of gestation of aneuploid pregnancies may go undetected and 
therefore the true level of aneuploidy may be higher. Indeed, this can be proven by 
studies performed in preimplantation embryos and gametes. 
 
1.1.1 Cell division – Mitosis and Meiosis 
Mitosis is the process of the division of all somatic cells (reviewed by Mitchison and 
Salmon, 2001). The number of chromosomes in the daughter cells, the products of 
mitosis, is the same as in the progenitor cell. Mitosis follows interphase and DNA 
replication. The steps of mitosis include prophase, when chromosomes condense 
and the microtubules of the mitotic spindle are formed from tubulin. The next stage 
is metaphase when the chromosomes attach to the spindle and align at the centre 
of the cell, called the equatorial plate, followed by anaphase when sister 
centromeres part and sister chromatids of each chromosome move to the opposite 
poles of the cells. Sister chromatid separation is possible through cleavage of 
chromatid cohesion by separase (Hauf et al, 2001). Aurora B kinase is responsible 
for the association of separase with the centromeres at the onset of anaphase 
(Yuan et al, 2009). Securin ensures the correct timing of separase function, as it 
inhibits separase until anaphase (Nasmyth et al, 2000). Mitosis is completed by 
telophase when the two daughter cells are formed by cytokinesis.   
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Through the process of meiosis haploid gametes are generated, carrying only one 
copy of all the chromosomes. Meiosis consists of two cell divisions between which 
the DNA is not replicated, meiosis I (MI) and meiosis II (MII). As in mitosis, meiosis 
starts after a cell cycle, during which DNA is replicated. This generates the primary 
gametocytes that contain a pair of all chromosomes each comprised of two sister 
chromatids [4C DNA (four chromatid DNA), figure 1.2] (Handel and Schimenti 2010).  
 
The stage of prophase in meiosis I, which is the longest, is comprised of four sub 
stages. In summary, during leptotene and zygotene chromosome pairing occurs. In 
pachytene, the chromosomes synapse and finally desynapse at the diplotene stage. 
Looking at prophase I in detail, the chromosomes condense and the meiotic spindle 
is formed. The bivalents, pairs of homologous chromosomes, one paternal and one 
maternal in origin, line up during synapsis. This is possible with the formation of the 
synaptonemal complex (SC) along each chromosome. Meiosis-specific proteins of 
the cohesin group compose the SC. During leptotene, the synaptonemal complex-
specific proteins 2 (SYCP2) and 3 (SYCP3) are responsible for forming the axial 
elements (AE) of the SC. During zygotene, they align to create the SC’s lateral 
elements (LE) that are separated by the central zone. Important proteins 
responsible for the formation of the central zone are SYCP1 and the synaptonemal 
complex central element proteins 1 (SYCE1), 2 (SYCE2) and 3 (SYCE3), as well as 
the testis-expressed sequence 12 (TEX12) protein. Synapsis is completed by the 
pachytene stage (reviewed by Fraune et al, 2012) (figure 1.1). The SC 
disassembles at the end of prophase I. 
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Figure 1.1: Stages of prophase I 
Figure 1.1: Presentation of the formation of the synaptonemal complex to complete 
chromosome synapsis, as well as the initiation of double strand breaks and recombination at 
the leptotene through to the pachytene stage. Prophase I is completed at the diplotene stage 
with the disassembly of the synaptonemal complex and the formation of chiasmata. 
(Adapted by permission from Macmillan Publishers Ltd: Nat Rev Genet. Handel and 
Schimenti, 2010) 
 
Another important event occurring during prophase I, is recombination between 
homologous chromosomes. Meiotic recombination is responsible for variation 
between individuals, as well as the correct segregation of chromosomes in the 
daughter cells (Smith and Nicolas, 1998).  It is initiated by double-strand breaks of 
the DNA by a meiosis-specific topoisomerase-like protein, SPO11 (Keeney et al, 
1997). The double strand breaks trigger the homologous recombination repair 
machinery; γH2AX is formed after phosphorylation of the histone H2AX, which in 
turn induces the binding of recombination proteins, including DMC1 and RAD51, at 
the recombination nodules along the AEs of the synaptonemal complex. These 
proteins aid in the strand invasion between chromatids (Masson and West, 2001). 
At the pachytene stage, mismatch repair proteins MLH1 and MLH3 localise at the 
recombination nodules. Recombination is completed with the formation of cross- 
overs  (Handel and Schimenti 2010) (figure 1.1). The visible result of recombination 
between homologous chromosomes is a chiasma, which involves two of the four 
chromatids of one bivalent (figure 1.1). One of the important functions of a chiasma 
is to stop separation of the homologous chromosomes prior to the beginning of 
anaphase I (Carpenter, 1994). There is a correlation between the length of the SC 
and the number of recombination events and gene density, which is irrespective of 
the physical length of the chromosome. For example, a longer SC has been 
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observed in the gene rich, high in recombination frequency chromosome 19 than in 
chromosome 18 that is similar in physical length and gene-poor (Sun et al, 2004). 
Moreover, the length of the SC is around two times longer in females than in males, 
resulting in increased of recombination in females, as discussed later in section 
1.1.1.1 (Tease and Hultén, 2004). 
 
The next step of MI is metaphase I, when homologous chromosomes align at the 
equatorial plate attached by the spindle at the opposite poles. The attachment to the 
microtubules of the spindle happens via the sister kinetochores, which are located in 
the centromeres. Tension is created that pulls away the maternal from the paternal 
chromosomes but they do not disjoin due to the chiasmata and sister chromatid 
cohesion (SCC) (Petronczki et al, 2003). SCC is maintained at the centromeres until 
anaphase II, in order to prevent separation of the sister chromatids. This 
maintenance is achieved by the function of cohesin proteins, like SMC1, SMC3 and 
STAG3 in mammalian cells (Prieto et al, 2001). A protein essential for the 
association of kinetochores with microtubules is SCC1 (Hoque and Ishikawa, 2002).  
 
Attachment of all kinetochores to the microtubules is ensured prior to the onset of 
anaphase I, through the spindle assembly checkpoint (SAC). If any of the 
kinetochores are not attached, the SAC is activated and the process arrests at 
metaphase I (Sun and Kim, 2012). The SAC is also present during mitosis of all 
somatic cells with the same checkpoint function (Musacchio and Salmon, 2007).  In 
anaphase I, SAC is silenced, provided that all kinetochores are properly attached to 
the microtubules of the spindle and the bivalents are separated. The centromeres of 
each chromosome do not part and finally recombined homologues move to the 
opposite poles at telophase I ending the first cycle of meiosis with two newly formed 
cells containing half the number of chromosomes (2C DNA, figure 1.2).  
 
Meiosis II is a process similar to mitosis during which sister chromatids segregate, 
instead of whole chromosomes that segregate during meiosis I. Chromosomes 
again condense in prophase II, move to the equatorial plate in metaphase II, the 
centromeres separate in anaphase II, the centromere cohesion is lost and single 
chromatids move to the opposite poles. Similarly to meiosis I, the SAC regulates the 
transition, from metaphase to anaphase, to ensure that all kinetochores are 
attached to the spindle (Sun and Kim, 2012). Meiosis II ends in telophase II, when 
four haploid cells are formed (1C DNA, figure 1.2).  
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Despite the fact that the general features of meiosis are consistent between males 
and females, there are important differences in the timing needed for completion 
between the sexes (Hunt and Hassold, 2002). In females, meiosis starts during fetal 
life and arrests at prophase I before birth. At puberty meiosis I resumes in some 
oocytes, resulting in the production of a secondary oocyte and the first polar body. 
Meiotic arrest occurs again at the stage of metaphase II and is only resumed upon 
fertilisation when meiosis II is completed resulting in the formation of a mature 
oocyte and the second polar body. Meiosis in males is initiated at puberty and 
continues with no arrests throughout their lives. Meiosis I results in the production of 
two secondary spermatocytes and meiosis II in four haploid spermatids as shown in 
figure 1.2 (Handel and Schimenti, 2010).  
 
 
Figure 1.2: Gametogenesis 
Figure 1.2: The two meiotic divisions in spermatogenesis and oogenesis. The starting 
materials in both sexes are cells containing two pairs of all chromosomes with two 
chromatids each (4C DNA), following DNA replication. After MI in females, the secondary 
oocyte and the first polar body (PB) are formed and in males two secondary spermatocytes, 
all containing one pair of each chromosome with two chromatids each (2C DNA). After MII 
the mature oocyte and the second PB are formed in females upon fertilisation and in males 
four spermatids are formed that will give rise to spermatozoa. The products of MII in both 
sexes are all haploid cells containing one chromatid (1C DNA).  
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1.1.1.1 Recombination. Differences between individuals and chromosomes. 
Diversity between individuals is generated through meiotic recombination, when a 
new combination of alleles is formed. Several methods can be used to quantify 
recombination. This can be done directly, by examining chiasmata at the pachytene 
stage of gametogenesis. Immunofluorescence is utilised to detect the DNA 
mismatch repair protein MLH1 that has been found to localise at sites of crossing 
over during meiosis in mice (Baker et al, 1996) and humans (Barlow and Hultén et 
al, 1998). Although it is a reliable method in measuring cross-over events in sperm, 
in oocytes, detecting cross-overs through MLH1 is not as accurate. MLH1 
immunofluorescence in prophase oocytes from fetal ovaries has revealed fewer 
cross-over events than that predicted from linkage analysis (Cheng et al, 2009). 
Another difficulty faced in studying recombination directly in the gametes is the 
scarcity of the samples, especially the oocyte.  
 
Indirect approaches are more applicable, for example linkage analysis in families, 
utilising polymorphic markers across the genome and examining them across 
generations (Lamb et al, 2005). Genotyping is performed with the aid of genetic 
maps that show the order of the markers across the chromosomes, as well as the 
distances between each locus. These are genetic distances indicating the chance of 
recombination occurring between two loci and are measured in centiMorgans (cM, 
Lynn et al, 2004). The ability to analyse polymorphic markers across the genome 
has led to the creation of the International HapMap project. The purpose of this 
project is the identification of common sequence variants across different 
populations with the ultimate goal being the discovery of variants that are linked to 
common diseases and the development of new diagnostic and therapeutic tools 
(International HapMap Consortium, 2003). Mapping of over 3.1 million single 
nucleotide polymorphisms (SNPs) in four populations was described in Phase II of 
the HapMap. The populations were geographically diverse of European, African, 
Chinese and Japanese ancestry (International HapMap Consortium, 2007). 
Recently, HapMap 3 was published incorporating seven additional populations as 
well as the analysis of copy number polymorphisms (CNPs) (International HapMap 
3 Consortium, 2010).  
 
The non-random association of alleles at different loci in a haplotype is termed 
linkage disequilibrium (LD) and maps based on LD have been created (Slatkin, 
2008). The metric LD maps are based on linkage disequilibrium units (LDU) that can 
describe the underlying structure of LD (Maniatis et al, 2002). These maps can be 
 27 
visualized by plotting marker location in LDU against the marker distances in 
kilobases (kb). The LDU maps can provide information about current and historic 
recombination at a very fine resolution. Plotting these LDU maps reveals the non-
linear relationship between physical distance and the underlying LD together with 
the “Block-Step” structure of a region. “Blocks” of LD represent areas of low 
haplotype diversity and therefore low recombination, whereas “Steps” define LD 
breakdown mainly caused by recombination since cross-over profiles have been 
shown to agree with LD patterns (Webb et al, 2008). 
 
Recombination is not uniform across the genome. Some sites show increased 
recombination (hot spots) and other sites show lower or no recombination (silent 
spots) (Yu et al, 2001). Recombination hotspots occur on average every 200 
kilobases or less in the human genome (McVean et al, 2004). The mammalian 
protein PRDM9 has been found to control the level of recombination in hotspot 
areas (Cheung et al, 2010). In humans, PRDM9 recognises a specific 13-mer that is 
in high abundance in recombination hotspots (Baudat et al, 2010). Recombination 
frequency is enhanced in telomeric and subtelomeric regions (Dib et al, 1996). 
There are differences between the chromosomes as well. Shorter chromosomes 
exhibit higher recombination rate. For example the recombination rate of the short 
chromosomes 21 and 22 is double than that observed on the long 1 and 2 
chromosomes (Kong et al, 2002). Among all the autosomes, the highest 
recombination has been observed in chromosome 19 (Dib et al, 1996).  
 
Recombination varies between sexes and individuals (Cheung et al, 2007). 
Recombination is higher in females than in males (Hassold et al, 2000). The 
recombination in the telomeric regions of the chromosomes is higher in males, 
whereas females show higher rates around the centromere. Moreover, variation in 
the recombination of the 22 autosomes between individuals has been observed 
within females (Broman et al, 1998; Kong et al 2002). This has also been observed 
in males, as analysis of MLH1 loci for the detection of recombination events in 
sperm from males with normal sperm parameters, has shown that there is variation 
between individuals in the distribution of cross-over events for all chromosomes 
(Sun et al, 2006b). Specifically for chromosome 19, recombination is quite uniform 
across the chromosome for females, whereas in males, as seen in other studies, it 
is greater around the telomeric regions (Mohrenweiser et al, 1998). Recombination 
hotspots are not the same between sexes as well. After comparing female and male 
maps it has been observed that 15% of recombination hotspots are specific to one 
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sex (Kong et al, 2010). An effect of advanced age has been observed in female 
recombination, in that it is increased, whereas no effect has been observed in male 
recombination (Kong et al 2004).  
 
1.1.2 Incidence of aneuploidy 
1.1.2.1 Cytogenetic and molecular cytogenetic methods to study aneuploidy 
A variety of methods have been applied to gametes and embryos to study their 
chromosomal status. Initial studies were performed by traditional karyotyping 
(Jamieson et al, 1994). The main difficulty in this technique was the lack of 
metaphase spreads to perform the analysis. Fluorescence in situ hybridisation 
(FISH) was then utilised on interphase nuclei, easily accessible in gametes and 
embryonic cells. However, only a few chromosomes could be analysed. The most 
recent and comprehensive technique is comparative genomic hybridisation (CGH), 
with which all chromosomes can be analysed. The outcome of studies that have 
utilised either FISH or CGH may not be associated due to differences, advantages 
and limitations in these two techniques. These are presented in sections 1.2.3.1 and 
1.2.3.2 of the Introduction.  
 
1.1.2.2 Incidence of aneuploidy in the gametes 
Chromosomal aneuploidy is more common in the oocytes than the sperm. 
Aneuploidy in the gametes and the embryos is studied post ART. Findings, however, 
in these couples may not reflect the general population. 
 
Around 4% of sperm is aneuploid with the sex chromosomes having the highest 
frequency of aneuploidy (Templado et al, 2011). Contradictory to females, 
increasing male age does not contribute to an increase in aneuploidy frequency 
(Luetjens et al, 2002).  
 
Aneuploidy analysis of the female gamete can either be performed by direct 
assessment of the chromosomal status of the oocyte or indirectly, through analysis 
of the polar bodies. Through a variety of studies, it is estimated that around 15-20% 
of human oocytes carry a chromosomal abnormality (Pellestor et al, 2006). 
Aneuploidy in the oocyte and the polar bodies is common even in females of young 
reproductive age. Two studies on oocyte and polar body complexes using 
comprehensive chromosome analysis by CGH from two groups of young women, 
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average age 22 and 32.5 years in each group, revealed an aneuploidy rate of 3% 
and 22% respectively (Fragouli et al, 2006; 2009). On the other hand, analysis of 
both polar bodies from 117 zygotes from a group of patients with repeated 
implantation failure and an average age of 39.1 years, showed an aneuploidy level 
as high as 65.5% (Fragouli et al, 2010). Even higher aneuploidy levels (72%) have 
been reported in polar bodies from women of advanced maternal age (average age 
= 40 years, Geraedts et al, 2011). Smaller chromosomes have been found to be 
more commonly involved in aneuploidy during oogenesis (Cupisti et al, 2003).  
 
1.1.2.3 Incidence of aneuploidy in preimplantation embryos 
Preimplantation embryo development starts after fertilisation (Day 0) of an oocyte by 
a sperm, with the formation of two pronuclei (2PN), one paternal, one maternal in 
origin. This is followed by a series of cleavage divisions that last three days resulting 
in embryos comprising of six to ten cells. During that period, embryonic genome 
activation (EGA) also occurs (Braude et al, 1988). Compaction occurs after EGA as 
the cells form tight junctions between them and the morula is formed, on day four. 
During the morula stage, the cells within the embryo start differentiating into two 
distinct cell lineages. By day five and six and after many cell divisions the embryo 
reaches the blastocyst stage. The features of a blastocyst are a fluid-filled blastocyst 
cavity and the inner cell mass (ICM) that is surrounded by the trophectoderm (TE). 
The ICM and the TE are two differentiated cell lineages. ICM will give rise to the 
embryo, whereas the placenta will be formed from the TE (Huppertz and Herrler, 
2005). Implantation occurs on around day seven, post fertilisation (Niakan et al, 
2012). Figure 1.3 presents the embryo preimplantation development. 
 
Figure 1.3: Preimplantation embryo development 
Figure 1.3: Normal fertilisation occurs with the formation of the two pronuclei at the start of 
the preimplantation embryo development. A series of cell divisions follows, during which 
embryonic genome activation takes place. This is called the cleavage stage and lasts three 
days. On day four of development the cells compact and form the morula and on day five, 
after differentiation of the cells in two cell lineages, the inner cell mass and the 
trophectoderm, the blastocyst is formed.  
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The majority of data on the level of aneuploidy in embryos comes from the results of 
preimplantation genetic diagnosis and screening cycles, as well as follow-up 
analysis of these cycles. Most of the studies use FISH to analyse chromosomes. 
However, complete disaggregation of embryos and analysis of all the chromosomes 
in every single cell reveals in detail the extensive aneuploidies that can be present 
in an embryo, such as mosaic and chaotic cell lines and chromosome breakage, 
apart from uniform aneuploidies originating in meiosis (Wells and Delhanty, 2000).   
 
Abnormalities in the chromosome number of preimplantation embryos are very 
common and the majority can only be detected at that stage of development as up 
to 90% of the aneuploidies seen in the cleavage stage embryo do not survive the 
first trimester of pregnancy (Munné et al, 2004). Embryonic aneuploidy may be a 
result of meiotic error occurring during the production of the gametes but also mitotic 
error during the first cellular embryonic divisions, leading to mosaicism. A high rate 
of chromosomal abnormalities, mitotic and meiotic in origin, exists in both normally 
and abnormally developing embryos (Munné et al, 1993). Analysis of all cells from 
cleavage stage embryos has revealed that only 25% carry no aneuploid cells 
(Mantzouratou and Delhanty, 2011). Generally, monosomy is more frequent than 
trisomy in embryos. There are also differences in the rate of aneuploidy between 
chromosomes in cleavage stage embryos, with 22, 16, 21 and 15 being most 
commonly involved, whereas abnormalities affecting chromosomes 14, X, Y and 6 
are the least common. These results were obtained after FISH analysis for 14 
chromosomes in over 2000 embryos (Munné et al, 2004).  
 
Uniform aneuploidies in the embryo can persist to the last stage of preimplantation 
development, the blastocyst. More than 50% of blastocysts are aneuploid (Fragouli 
and Wells, 2011). Trisomies, as well as monosomies (such as monosomy for 
chromosomes X and 21) that are known to exist in the first trimester of pregnancy, 
have been detected in blastocysts (Sandalinas et al, 2001). Apart from aneuploidy 
of whole chromosomes, either meiotic or mitotic in origin, structural chromosomal 
abnormalities are present in the preimplantation embryo. These segmental changes 
have been found to occur in 7-23% of embryos following analysis by CGH (Voet et 
al, 2011). 
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1.1.2.3.1 Preimplantation embryo mosaicism 
Mosaicism is very common in embryos of the preimplantation stage. Mosaic 
embryos carry cells of more than one chromosomal complement and may be 
morphologically normal (Harper et al, 1995). Another, more extreme, chromosomal 
situation has been described in embryos, when each cell carries a different 
chromosomal complement. These are called chaotic embryos (Delhanty et al, 1997). 
It is estimated that over 50% of embryos generated through in vitro fertilisation (IVF) 
are mosaic (Delhanty, 2005).  
 
Mosaicism arises through errors in the first mitotic divisions of the embryo post 
fertilisation (Kalousek, 2000). However, there have been suggestions that the fourth 
mitotic division in an embryo is the one generating most aneuploid blastomeres 
(Gonzalez-Merino et al, 2003). Mosaicism is irrespective of maternal age, as it has 
been found to exist in high levels in embryos from young women (Baart et al, 2006). 
In contrast to errors in meiosis that are mostly maternal in origin, mosaicism may be 
a result of paternal contribution. This was made apparent in cases of severe male 
infertility and especially those of non-obstructive azoospermia (NOA), in which the 
rate of chromosomal abnormalities due to mosaicism increased, when compared to 
cases of males with normal sperm parameters (Magli et al, 2009).  
 
Mechanisms that lead to mosaicism, include post-zygotic chromosome loss, when 
cells carry monosomies, which results after anaphase lag, during which whole 
chromosomes show a delayed movement to the spindle pole, chromosome gain, 
represented with cells carrying trisomies, caused by chromosome duplication and 
mitotic non-disjunction, when cells carry reciprocal monosomies and trisomies of the 
same chromosome (Coonen et al, 2004). In some studies, chromosome loss has 
been found to be the most common mechanism of post-zygotic errors leading to 
mosaicism (Daphnis et al, 2005; Daphnis et al, 2008), whereas a different study has 
shown that mosaicism may arise by chromosome gains and losses at a similar rate 
(Fragouli et al, 2011a).  
 
Malsegregation of the chromosomes, which will lead to mosaicism, may occur due 
to the deregulation of mitosis and malfunction of the centromeres during the first 
post-zygotic divisions (Kalousek, 2000). It has been observed that separation of the 
sister chromatids is not essential for the exit from mitosis or DNA replication in the 
next cell cycle. Therefore, defects in the cleavage of sister chromatids cohesion by 
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separase will not lead to a block of the cell cycle (Hauf et al, 2001). Moreover, 
increased levels of securin, the protein that controls separase function, may lead to 
malsegregation of chromosomes (Nasmyth et al, 2000). In early studies of 
mosaicism in embryos, it was suggested that abnormalities in cell cycle checkpoints 
were a source of error (Delhanty and Handyside, 1995). Analysis of gene 
expression in cleavage stage embryos revealed overexpression of cell cycle drivers 
resulting in the rapid division of cells and increase in the gene copy number but also 
to susceptibility of chromosome abnormalities (Kiessling et al, 2010).  
 
1.1.2.3.2 Mosaicism during different stages of preimplantation embryo 
development and pregnancy 
Mosaicism can persist at high levels through all stages of preimplantation 
development. Its clinical significance is not yet clear, however there is a hypothesis 
that diploid mosaic embryos with a high proportion of diploid cells have the ability to 
lead to a normal fetus (Fragouli et al, 2011a). A large number of studies have been 
performed to determine the presence and levels of mosaicism at all developmental 
stages with some presenting contradictory results. Mosaicism has been reported in 
up to 88% of embryos of all developmental stages, along with the hypothesis that it 
is a normal condition of in-vitro generated embryos (Gonzalez-Merino et al, 2003). 
One study showed that the frequency of mosaicism increased as the embryos 
developed. Of the 33 blastocysts analysed, 90.9% were found to be mosaic, 
carrying mostly diploid and polyploid cells. On the other hand, mosaicism in arrested 
embryos was represented by more chaotic abnormalities (Bielanska et al, 2002). A 
different study led to similar findings, where 95% of the blastocysts contained 70% 
or more diploid cells, whereas 65% of arrested mosaic embryos carried the same 
proportion of diploid cells (Ruangvutilert et al, 2000a). Conversely, lower levels of 
mosaicism in blastocysts when compared to arrested embryos, have also been 
reported (Evsikov and Verlinsky, 1998; Fragouli et al, 2008). Comparison of the 
aneuploidies occurring at the cleavage stage, in blastocysts and in first trimester 
pregnancies, showed that haploid, monosomic and some trisomic abnormalities 
seen in early preimplantation stages are lost in the blastocyst. On the other hand, 
abnormalities seen in early pregnancies are already established in the blastocyst 
(Clouston, 2002). In mosaic blastocysts the degree of aneuploidy is similar between 
the two cell lineages, the trophectoderm and the inner cell mass (Derhaag et al, 
2003).  
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The decrease of the levels of mosaicism from the cleavage through to the blastocyst 
stage may be due to the ability of the embryos to compensate for these errors. An 
example of this is the extrusion of a micronucleus carrying the extra chromosome in 
trisomic cells (Li et al, 2005). Decrease of the level of mosaicism has also been 
observed even after the blastocyst stage on cultured day 14 embryos (Munné et al, 
2005). Duplication of a monosomic chromosome is another form of error correction, 
which, however will result in uniparental disomy (UPD). Bi-parental inheritance will 
be lost, as the chromosomal pair will derive from one parent (Engel, 2006). This is 
detrimental if the chromosome that has undergone UPD contains imprinted genes. 
For example, Beckwith-Wiedermann syndrome can be caused by the duplication of 
the paternal chromosome 11, whereas Prader-Willi syndrome by the duplication of 
maternal chromosome 15 (Butler, 2009). Another possibility of correction during late 
stages of preimplantation development may arise through mitotic arrest of abnormal 
cells, through control of the cell cycle that is activated with EGA (Los et al, 2004).  
 
Mosaicism has also been detected in chorionic villi samples (CVS) from early 
pregnancies at around 2%. Mosaicism in pregnancies may be localised in the 
placenta and is called confined placental mosaicism (CPM). CPM for trisomies of 
chromosomes 2, 3, 7, 8, 9, 16 and 22 have been found to occur in between nine 
and 91 pregnancies per 100000 (Wolstenholme, 1996). Mosaicisim has also been 
detected in the whole of the fetus and is called true fetal mosaicism (TFM, Grati et al, 
2006). Mitotic non-disjunction followed by anaphase lag during the first post-zygotic 
divisions may also be the reason for detectable mosaicism in patients with mosaic 
trisomy 13, a viable condition with varying phenotypes (Jinawath et al, 2011).  
 
 
1.1.3 Origin of aneuploidy 
The parental origin of aneuploidies, as well as the stage at which they occur, vary 
between chromosomes. Most importantly, aneuploidy in the oocytes is more 
common than in sperm. In women, there is clear evidence on the positive correlation 
of increasing chromosomal errors in oocytes with increasing age (Hassold et al, 
2007). Comprehensive chromosomal analysis of both polar bodies from zygotes has 
revealed that the effect of advancing female age is more profound in the occurrence 
of MII errors (Fragouli et al, 2011b).  
 
Trisomy of chromosome 16, which leads to spontaneous abortion, can only be 
maternally derived from errors occurring in meiosis I (Hassold et al, 1995). Similarly, 
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95% of trisomy 21 cases, leading to Down’s syndrome, are caused by errors in 
maternal meiosis (Antonarakis and the Down Syndrome Collaborative Group, 1991). 
Origin of aneuploidy among the acrocentric chromosomes 13, 14, 15, 21 and 22 is 
similar with errors arising in paternal meiosis not exceeding 17% of the cases. The 
majority of maternal errors occur in MI, whereas nondisjunction in paternally derived 
cases occur mostly in MII (Zaragoza et al, 1994). More than 96% of trisomy 22 
cases are maternally derived with 90% of them resulting from errors during MI (Hall 
et al, 2007a). Similarly, the majority of Patau syndrome cases, trisomy 13, are 
maternally derived with 67% of the errors occurring during MI and the rest during MII 
(Hall et al, 2007b). The most frequent stage of error that leads to trisomy 18, or 
Edwards syndrome, is in maternal meiosis MII (Bugge et al, 1998).  
 
Abnormalities of the sex chromosomes occur with a prevalence of 1.88 per 10000 
births, with the most common being the 47,XXY condition, or Klinefelter’s syndrome 
(Boyd et al, 2011). Maternal and paternal, mainly MI errors equally contribute to the 
generation of Klinefelter’s syndrome (MacDonald et al, 1994). Autosomal 
monosomies are lethal for the early embryo. Therefore, information on the origin can 
only be obtained for the 45,X condition, Turner’s syndrome (Hassold and Hunt, 
2001). Molecular analysis of individuals with Turner’s syndrome revealed that the 
majority of cases arise from errors during spermatogenesis (Jacobs et al, 1997).  
 
1.1.4 Causes of aneuploidy 
Aneuploidy in the gametes may arise through a variety of errors. Meiotic non-
disjunction is the term used for the mal-segregation of chromosomes or chromatids 
during meiosis. Mechanisms that lead to meiotic non-disjunction of whole 
chromosomes, are “true” non-disjunction, when a bivalent fails to resolve chiasmata 
and both homologues segregate together, as well as non-disjunction resulting from 
the premature resolution or absence of chiasmata that may cause independent 
segregation of the homologues (Hassold and Hunt, 2001). These are illustrated in 
figure 1.4 Malsegregation of single chromatids during meiosis I may lead to the 
production of aneuploid gametes (Angel, 1991). Studies on a cohort of 100 oocytes 
showed that this may occur through the premature separation of the sister 
chromatids (PSSC) during anaphase of meiosis I (Angell et al, 1994). Recent CGH 
analysis on polar bodies revealed that single chromatid errors were more common 
than whole chromosome errors caused by non-disjunction in oocytes (Gabriel et al, 
2011). Generation of aneuploid gametes following PSSC depends on the 
 35 
segregation of the extra chromatid in anaphase II, post fertilisation. In 50% of cases 
the extra chromatid will pass to the second polar body and therefore the oocyte will 
be euploid (Angell et al, 1993).  
 
 
Figure 1.4: Chromosome and chromatid errors in meiosis I and meiosis II 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: During meiosis I, “true” and “achiasmate” non-disjunction of whole chromosomes, 
as well as premature separation of sister chromatids may occur. In meiosis II, aneuploidy 
may arise through non-disjunction of the sister chromatids. (Adapted by permission from 
Macmillan Publishers Ltd: Nat Rev Genet. Hassold and Hunt, 2001) 
 
One of the causes of non-disjunction is aberrant recombination during both meiotic 
divisions. A lot of information on the effect of recombination in the segregation of 
chromosomes comes from studies on trisomy 21, as it is the most common viable 
trisomy of the autosomes (Hassold et al, 1996). Early studies have shown that 
recombination is reduced along chromosome 21, causing non-disjunction during 
meiosis, thus resulting in the birth of children with Down’s syndrome (Warren et al, 
1987). The location of multiple recombination events on chromosome 21, and more 
specifically, at the location of 21q is important in the correct segregation of the 
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chromosome. A study on families with an infant carrying trisomy 21 using 15000 
SNPs on 21q showed that the average distance of recombination events in maternal 
MI errors was reduced when compared to normal controls (Oliver et al, 2012). 
Recent data have shown that the cases of chromosome malsegregation due to 
changes in recombination, leading to maternal MII errors for chromosome 21, 
increased with maternal age (Oliver et al, 2008). Since 1968, it has been observed 
that the number and location of chiasmata were reduced as maternal age increased 
(Henderson and Edwards, 1968). Reduced recombination is also observed among 
non-disjoined chromosomes 21 in cases of Down’s syndrome that are paternal MI in 
origin, but there is no difference in paternal MII errors (Savage et al, 1998). 
Recombination is also reduced in cases of non-disjunction of chromosome 16, 
especially around the centromere (Hassold et al, 1995), acrocentric chromosomes 
13 and 22 (Hall et al, 2007a; 2007b) and in non-disjunction of the sex chromosomes 
in cases of 47,XXY and 47,XXX (MacDonald et al, 1994).  
 
Meiotic abnormalities in sperm have been analysed with a variety of techniques 
(reviewed by Egozcue et al, 2005). Direct analysis of the synaptonemal complexes 
was performed using light and electron microscopy. Recent advances in 
immunofluorescence allow the analysis of synapsis and meiotic recombination. This 
is performed by analysing specific proteins of the synaptonemal complex (SYCP1 
and SYCP3) along with the visualisation of a DNA repair and recombination protein, 
MLH1, located at the sites of chiasmata (Sun et al, 2005). This can be done in 
conjunction with multiplex FISH on sperm in order to assess recombination and 
aneuploidy simultaneously (Ma et al, 2006). Immunofluorescence methods have 
revealed complete absence of chiasmata in the sex chromosomes and 
chromosomes 21 and 22 in MI spermatocytes (Uroz et al, 2011). PSSC has also 
been detected as a mechanism for non-disjunction (Uroz et al, 2008) as well as 
defects in chromosome synapsis (Sun et al, 2007) in sperm.  
 
Aneuploidy occurs at a significantly higher rate in sperm from infertile men than 
fertile (Sun et al, 2008) affecting the sex chromosomes in a higher frequency than 
the autosomes (Martin et al, 1996). A reduction in the recombination frequency has 
been observed in sperm from men with non-obstructive azoospermia (NOA) and 
men with sperm maturation arrest, than those with normal sperm parameters 
(Gonsalves et al, 2004). Evidence shows that decrease in recombination among the 
sex chromosomes in infertile men increase the occurrence of sperm with XY disomy 
(Ferguson et al, 2007). However, errors in meiosis occur regularly even in the sperm 
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of fertile men with the sex chromosomes, as well as chromosomes 21 and 22 being 
more susceptible to non-disjunction (Sun et al, 2006a).  
 
Despite the fact that meiotic errors are common during spermatogenesis, the 
aneuploidy level observed in sperm is much lower than that observed in the oocyte. 
This may be due to the presence of a checkpoint during spermatogenesis that does 
not allow the progression of aneuploid sperm (Uroz and Templado, 2012). Indeed, 
aneuploid oocytes lack the chromosome-mediated checkpoint control that is needed 
for meiotic arrest or delay of the metaphase to anaphase transition in the case of 
unaligned chromosomes along the meiotic spindle (LeMaire-Adkins et al, 1997). The 
increased risk of aneuploidy in older women may be attributed to the fact that during 
the extended stage of prophase I, cohesion within the bivalents is weakened, 
leading to PSSC (Wolstenholme and Angel, 2000). Moreover, aging oocytes do not 
have the ability to resolve poor recombination and the SAC’s efficiency is 
deteriorating resulting in an increase of chromosome malsegregation (Wang et al, 
2011).  
 
Another cause of aneuploidy that will lead to uniform abnormalities in the embryo is 
germline or gonadal mosaicism. In this situation, the errors do not occur during the 
meiotic divisions of gametogenesis, but have already been established in the germ 
cells prior to the onset of meiosis. Errors occurring in the premeiotic divisions will 
result in germline mosaicism. Gonadal mosaicism is the term used to describe 
mosaic cells that are present in the embryonic gonad (Delhanty, 2005). Analysis of 
oocyte and polar body complexes has revealed the presence of extra chromosomal 
material in both the oocyte and the first polar body, suggesting a trisomic germ cell 
line in chromosomally normal women (Cozzi et al, 1999, Mahmood et al, 2000). 
Evidence for gonadal mosaicism comes from direct cytogenetic analysis of ovarian 
fetal tissue. In a study on female fetuses, it was revealed that all eight analysed had 
a proportion of trisomic 21 ovarian cells at an average rate of 0.54%, with the 
abnormality occurring in meiotic and pre-meiotic cells (Hultén et al, 2008). This 
finding can be an explanation of recurrent aneuploid conception in young women. 
On the other hand, analysis of fetal testicular cells from male fetuses revealed that 
none of them were trisomic for chromosome 21, providing an extra explanation of 
the higher rate of cases of Down’s syndrome that are maternal in origin (Hultén et al, 
2010). The above finding is in line with the hypothesis that more stringent cell cycle 
control checkpoints exist during spermatogenesis than oogenesis. 
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1.2 Preimplantation genetic diagnosis and screening 
Preimplantation genetic diagnosis (PGD) and preimplantation genetic screening 
(PGS) are performed after IVF and biopsy of oocytes or embryos. Genetic analysis 
of polar bodies or embryonic cells can reveal those embryos carrying a genetic or 
chromosomal abnormality and only those that are unaffected are chosen for transfer 
back to the uterus (Wells and Delhanty 2001). Surplus, normal, good quality 
embryos can be cryopreserved and transferred in a later cycle. Cryopreservation of 
biopsied embryos does not affect their implantation and developmental potential 
when compared to cryopreserved blastocysts that have not undergone biopsy (El-
Toukhy et al, 2009). Recently a new method for cryopreservation has been 
developed, called vitrification, which, when compared to slow freezing, shows 
significantly higher embryo survival, pregnancy and implantation rates (Keskintepe 
et al, 2009).  
 
1.2.1 Biopsy 
Biopsy of the oocyte or the embryo is essential in PGD and PGS to retrieve the 
sample for genetic analysis. Three different types of biopsy are used, all with 
several advantages and drawbacks. These are: biopsy of the polar bodies from the 
oocytes, biopsy of single blastomeres from cleavage stage embryos and biopsy of 
TE samples from blastocysts.  
 
1.2.1.1 Polar body biopsy 
Biopsy of the first polar body from the oocyte and/or the second polar body from the 
zygote can be performed. Biopsy of both polar bodies can either be sequential 
(Kuliev and Rechitsky, 2011), or simultaneous (Geraedts et al, 2011). The polar 
bodies, as resulting cells of meiosis, are not needed for fertilisation and embryo 
development. Polar body biopsy was first introduced for the detection of alpha-1-
antitrypsin deficiency in a couple in which the woman was a carrier for the disorder. 
Diagnosis and selection of unaffected embryos was possible without the removal of 
embryonic samples (Verlinsky et al, 1990). The removal of the polar body can be 
performed after the opening of the zona pellucida by a laser followed by aspiration 
(Montag et al, 2004). Biopsy of the first and/or the second polar body is also used 
for the detection of chromosomal aneuploidies, since the majority of errors arise in 
maternal meiosis. Biopsy of just the first polar body is beneficial as errors in whole 
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chromosomes in the oocyte will be reciprocal in the polar body (Verlinsky et al, 
1996).  
 
The main disadvantage of biopsy at that stage is that indirect analysis of the oocyte 
through the polar bodies will miss the detection of errors that are paternal or post-
zygotic in origin (Delhanty, 2011).  Moreover, compensation of chromosomal errors 
arising through PSSC in meiosis I, which are present in the first polar body, may 
occur in meiosis II. As mentioned in section 1.1.4, following the segregation of 
chromatids in anaphase II, there is a 50% chance that the zygote will be euploid, 
whereas the second polar body will carry an abnormality reciprocal to the first polar 
body. This was demonstrated with the birth of a normal child from an oocyte with 
reciprocal aneuploid polar bodies (Scott et al, 2012a).  
 
1.2.1.2 Cleavage stage biopsy 
The removal of blastomeres from the cleavage stage embryo does not impair its 
further preimplantation development in vitro (Hardy et al, 1990). Moreover, a large 
prospective comparative follow-up study on babies born after PGD with biopsy at 
this stage showed that it did not impose any extra risks in regards to complications 
in the health of the babies at birth (Desmyttere et al, 2012). At cleavage stage 
biopsy single blastomeres are removed from day three embryos that have reached 
the six- to eight-cell stage by aspiration through a small opening drilled at the zona 
pellucida, which surrounds the embryo, usually by a laser.  
 
A two-cell biopsy reduces the chance of error during diagnosis and increases the 
number of unaffected embryos that can be transferred (Lewis et al, 2001). A small, 
comparative study on the effects of the removal of one, two or three cells, performed 
on 188 cycles concluded that the implantation and pregnancy rates after two-cell 
removal were acceptable (Van de Velde et al, 2000). However, a larger study 
showed that the live birth rate in cases where one cell was biopsied was significantly 
higher than in those where two cells were biopsied and similar to standard ICSI 
cases, where no biopsy was performed (De Vos et al, 2009). Similarly, a 
randomised controlled trial (RCT) concluded that biopsy of one cell was less 
invasive than two, but on the other hand the diagnosis rate was significantly 
increased in PGD cases that utilised PCR for the analysis. A small but not 
statistically significant decrease in the live birth rate was observed after biopsy of 
two cells (Goossens et al, 2008). According to the European Society of Human 
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Reproduction and Embryology (ESHRE) PGD Consortium guidelines, two cells 
should be removed from one embryo only if it contains six or more cells (Harton et al, 
2011a). 
 
1.2.1.3 Blastocyst biopsy 
Biopsy of TE from the blastocyst occurs at day five or six. An opening in the zona 
pellucida of the embryo is made one or two days before the biopsy by a laser 
through which the TE herniates allowing biopsy of around six cells with the 
assistance of a laser. The hole is made on the opposite side of the inner cell mass, 
which will lead to the formation of the embryo proper (Veiga et al, 1997). The ability 
to perform the diagnosis on a small number of cells overcomes issues faced in 
single-cell analysis, especially when single-cell DNA is amplified for the detection of 
single gene disorders (McArthur et al, 2005). One of the drawbacks of blastocyst 
biopsy is that not all embryos manage to reach that stage in vitro and as a result 
fewer embryos are available for analysis. On the other hand, a high pregnancy rate 
per oocyte retrieval has been reported post blastocyst biopsy with diagnosis of 
single gene disorders and structural chromosomal abnormalities (McArthur et al, 
2008). Comparison between cleavage stage and blastocyst biopsy has shown that 
the latter results in higher implantation rates (Kokkali et al, 2007).  
 
1.2.2 Preimplantation genetic diagnosis 
Preimplantation genetic diagnosis (PGD) is an option for couples that are at risk of 
transmitting a genetic disease to their offspring or are carriers of structural 
chromosomal rearrangements and want to avoid the termination of an affected 
pregnancy following prenatal diagnosis (Verlinsky et al, 2004). It was first developed 
and applied for the determination of the sex of the embryo in cases of X-linked 
disorders with the use of polymerase chain reaction (PCR) amplification of loci on 
the Y chromosome (Handyside et al 1989; 1990). Fluorescence in situ hybridisation 
(FISH) was then used to replace PCR for the sex determination in cases of X-linked 
diseases (Delhanty et al, 1993) and for the detection of structural chromosomal 
abnormalities in couples with a balanced translocation (Munné, 2001). Suitable and 
optimised protocols, based on the amplification of embryonic DNA, are used for the 
diagnosis of autosomal dominant and recessive, as well as X-linked single gene 
disorders with a high diagnosis rate among the embryos analysed (Fiorentino et al, 
2006). According to the latest data collection of the ESHRE PGD Consortium, 1363 
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cycles with oocyte collection for monogenic disorders and 774 for structural 
chromosomal abnormalities were performed between January and December 2008 
(Goossens et al, 2012).  
 
1.2.2.1 Techniques used in PGD for the detection of monogenic disorders 
PCR amplification of embryonic cells is the most common technique used in PGD 
for monogenic disorders. Specific loci of interest can be amplified in a single PCR 
reaction on the biopsied cells, however, the number of loci is limited and the time 
needed for extensive optimisation of suitable protocols may be long (SenGupta and 
Delhanty 2012). Amplification of the whole genome, in order to facilitate the analysis 
of multiple loci across the genome, is an alternative technique. PGD using WGA 
was performed for the diagnosis of Familial Adenomatous Polyposis Coli (Ao et al, 
1998) and since then, with suitable optimisation, a variety of whole genome 
amplification (WGA) methods have been applied clinically in PGD.  
 
The WGA methods that have been successful in amplifying the minute amount of 
DNA found in a single cell are primer-extension preamplification (PEP, Zhang et al, 
1992), degenerate oligonucleotide-primed-PCR (DOP-PCR, Telenius et al, 1992) 
and multiple displacement amplification (MDA). MDA is an isothermal whole 
genome amplification technique that uses φ29 DNA polymerase and random 
primers to produce fragments of amplified product that are larger than 10 kb long, 
representing the genome uniformly (Dean et al, 2002). MDA is able to amplify the 
whole genome of a single cell producing satisfactory results in PCR based 
downstream reactions (Handyside et al, 2004, Hellani et al, 2004, Spits et al, 2006) 
and has been used in PGD for the detection of a variety of monogenic disorders 
including fragile X syndrome, β-thalassaemia, cystic fibrosis and Marfan syndrome 
(Burlet et al, 2006, Hellani et al, 2004, Lledó et al, 2006). WGA is also used in 
preimplantation genetic haplotyping (PGH), which is indirect detection of mutations 
through linkage, using a large number of polymorphic markers linked to the disease-
causing gene (Renwick et al, 2010). 
 
Analysis of minute amounts of DNA, such as those in single cells, poses several 
problems and limitations, which, if not addressed, may lead to misdiagnosis. 
Contamination, allele drop out (ADO) and amplification failure may occur during 
manipulation and analysis of the samples, however, measures can be taken in order 
to minimise their effect. The first procedures performed during a PGD case, the 
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biopsy, tubing of the sample and the first amplification are more prone to 
contamination. Sources of contamination include the maternal cumulus cells 
surrounding the oocyte, sperm and external DNA (Wilton et al, 2009). Maternal and 
paternal contamination can be avoided by complete removal of the cumulus cells 
and the use of ICSI for fertilisation respectively. The use of gloves and protective 
clothing, UV decontamination and general clean conditions can be used for the 
limitation of external contamination. Finally, contamination can be monitored through 
the use of reaction negatives as well as the use of polymorphic markers in multiplex 
amplification reactions (Harton et al, 2011c).  
 
Allele drop out occurs commonly during amplification of small DNA quantities. It is 
the failure of amplification of one of the two alleles in a heterozygote sample 
resulting in the appearance of a homozygote (Piyamongkol et al, 2003). Since ADO 
could be detrimental in the diagnosis, if undetected, the use of polymorphic markers 
linked to the mutation-causing gene was introduced. The mutation site and the loci 
of the linked markers can be amplified simultaneously in a multiplex PCR reaction. 
With the haplotype of the alleles determined, amplification of an affected sample 
with ADO on the mutation site can be detected when the marker allele in phase with 
the mutation is present (Rechitsky et al, 1998).  
 
1.2.3 Preimplantation genetic screening 
Preimplantation genetic screening (PGS) is performed in order to increase the 
implantation and pregnancy rates in a specific group of patients by analysing the 
chromosomal status of oocytes or embryos. In this way, embryos that are aneuploid 
are not selected for transfer and miscarriages as well as abnormal pregnancies are 
avoided (Munné et al, 1993). PGS is offered in couples of advanced maternal age 
(AMA), usually older than 37 or 38 years of age, couples that have gone through 
recurrent miscarriage (RM), which is established after three consecutive pregnancy 
losses, those that have had three or more repeated IVF failures (RIF) and finally 
those couples with severe male factor infertility, for example cases of non-
obstructive azoospermia (NOA) or obstructive azoospermia (OA) with a normal 
karyotype, (Donoso et al, 2007). These groups of infertile patients have a high 
incidence of chromosomally abnormal embryos (Rubio et al, 2005). Indeed, in 
embryos from couples undergoing PGS, there is a significantly higher number of 
arrested aneuploid and mosaic embryos than euploid embryos (Rubio et al, 2007). 
A large number of PGS cycles are performed, as indicated by the latest data 
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collection of the ESHRE PGD Consortium. The number of PGS cycles with oocyte 
collection for the period between December 2008 and October 2009 was 3401 (with 
AMA as the most common indication), a much higher number than the overall 
number of PGD cycles for monogenic disorders and structural chromosomal 
abnormalities (Goossens et al, 2012).  
 
PGS can be performed post polar body, cleavage stage embryo and blastocyst 
biopsy. There are benefits and drawbacks for each stage of biopsy. Analysis of the 
embryos for aneuploidy screening on day three, at cleavage stage, causes concerns 
especially due to mosaicism. Biopsy of one cell from a cleavage stage mosaic 
embryo may not be representative of the chromosomal status of the whole embryo. 
In a mosaic embryo, biopsy of a diploid blastomere will lower the proportion of these 
blastomeres and lead to the transfer of an embryo with a higher proportion of 
aneuploid cells. On the other hand, biopsy and analysis of an aneuploid blastomere 
will increase the number of diploid cells and therefore hamper possible viability of an 
embryo, which will be discarded due to the result (Harper et al, 2009). Comparison 
on the outcome of PGS analysis post polar body and blastocyst biopsy indicated a 
higher pregnancy rate after blastocyst biopsy (69.2%) than after polar body biopsy 
(21.4%) in a group of patients with repeated IVF failure (Fragouli et al, 2010).  
 
Based on a valid theory, that transfer of euploid embryos will result in higher 
success rates, many IVF clinics started offering PGS in the above mentioned 
couples analysing chromosomes by FISH. Initial studies showed promising results. 
It was shown that PGS was beneficial in increasing implantation and pregnancy 
rates in couples with AMA and RIF, however two to four embryos were transferred 
(Gianaroli et al, 1997; 1999). PGS also seemed to be beneficial for RIF patients 
when compared to fertile controls receiving diagnosis for X-linked diseases 
(Pehlivan et al, 2003). Retrospective analysis of IVF cycles with either PGS or no 
PGS showed an increase in successful implantation rates and decrease in 
miscarriage in patients with AMA (Munné et al, 1999, Munné et al, 2003) as well as 
decrease of spontaneous abortion in patients with RM (Garrisi et al, 2009). However, 
it has been argued that studies showing good results post PGS, lack the needed 
strength to prove that PGS is indeed beneficial (Shahine et al, 2006). Several RCTs 
were published to evaluate the efficacy of PGS when FISH analysis was performed. 
Despite the fact that there were differences in the set up of the trials, including 
different time of biopsy, different number of probes used and blastomeres biopsied, 
the day of transfer, the patient cohort and the primary outcome, all of them showed 
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that PGS had no positive outcomes. Some of them even showed a negative impact 
in the implantation, pregnancy and live birth rates. A summary of all these RCTs is 
found in table 1.1.  
 
Table 1.1: RCTs performed to evaluate the efficacy of PGS. IR: Implantation rate, which 
is the ratio of the number of gestational sacs with a fetal heartbeat over the total number of 
embryos that were transferred (Staessen et al, 2004). PR: Pregnancy rate. LBR: Live birth 
rate. *: Statistically significant lower measures. **: Number of couples randomized. ***: This 
study did not present the patients’ indication for PGS.  
 
PGS is controversial due to its important limitations that are both technical and 
biological (reviewed by Go et al, 2009). Technically, not all chromosomes can be 
analysed by FISH as described below and biologically, embryos at the 
preimplantation stage may be mosaic.  
 
1.2.3.1 Fluorescence in situ hybridisation 
Fluorescence in situ hybridisation (FISH) involves the hybridisation of labelled DNA 
on genomic targets, which in the case of PGS are interphase nuclei (Speicher and 
Carter, 2005). The most important limitation of FISH is that analysis does not cover 
the whole genome and is only limited in the detection of abnormalities in a few 
chromosomes (Stumm et al, 2006). Probes for the chromosomes most commonly 
Table 1.1: RCTs to evaluate PGS  
Study No of 
couples
** 
No of 
probes 
Indication Stage of 
biopsy 
IR (%) PR (%) LBR (%) 
     PGS No 
PGS 
PGS No 
PGS 
PGS No 
PGS 
Stevens et 
al, 2004 
40 9 AMA Cleavage 32 44 60 88.9 - - 
Staessen et 
al, 2004 
400 7 AMA Cleavage 17.1 11.5 19.6 27.7 - - 
Blockeel et 
al, 2008 
200 7 RIF Cleavage 21.4 25.3 21.4 25.3 - - 
Hardarson et 
al, 2008 
109 7 AMA Cleavage 11.4 18.9 11.4 18.9 5.4 18.9 
Jansen et al, 
2008 
101 5 Infertile*** Blastocyst - - 45.5 60.9 35.7 58.7 
Mastenbroek 
et al, 2007 
408 5 AMA Cleavage 11.7 14.7 11.7 14.7 24* 35 
Mersereau et 
al, 2008 
53 7 No 
indication 
Cleavage 20.0 25.4 20.0 25.4 29.2 39.3 
Staessen et 
al, 2008 
240 7 No 
indication 
Cleavage - - 48.6 43.9 34.6 34.6 
Meyer et al, 
2009 
47 8 No 
indication 
Cleavage 31.7* 62.3 31.7* 62.3 28.6* 68.2 
Schoolcraft 
et al, 2009 
62 9 AMA Cleavage 36.5 37.3 67.7 76.6 78 67.74 
Debrock et 
al, 2010 
55 7 AMA Cleavage 15.0 16.0 15.0 16.0 9.4 14.9 
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involved in aneuploidies, more specifically those that are detected frequently in 
spontaneous abortions and live births, including chromosomes 13, 15, 18, 21, 22, X 
and Y, are used (Munné et al, 1998). Analysis of chromosomes can be performed in 
consecutive FISH rounds (Liu et al, 1998). A successful FISH protocol on embryonic 
nuclei, analysing all 24 chromosomes has only been described for research 
purposes (Ioannou et al, 2012), however in a clinical setting, protocols with probes 
for up to 12 chromosomes have been performed (Colls et al, 2009). Moreover, the 
accuracy of each probe is not 100%; it varies between 92 and 99%. The accuracy of 
a set of multiple probes, used in consecutive FISH rounds, which is needed in PGS, 
is, therefore, even lower (Mastenbroek et al, 2008). A false result may be obtained 
by FISH due to further technical limitations, for example signals that are split or 
overlapped or even lost before the analysis (DeUgarte et al, 2008). Finally, the 
outcome of FISH could be compromised by the fixation of the biopsied sample, 
which is essential for this technique (Coulam et al, 2007). All the limitations imposed 
to PGS because of FISH can be overcome with the use of comparative genomic 
hybridisation. 
 
1.2.3.2 Comparative genomic hybridisation 
Comparative genomic hybridisation (CGH) involves the analysis of all the 
chromosomes in one sample. The sample and a reference DNA are differentially 
labelled and compete with each other for complementary hybridisation sites. 
Analysis of the ratios of the sample to reference fluorescence gives an indication of 
chromosomal gain or loss (Speicher and Carter, 2005). The amount of DNA needed 
for analysis by CGH, which is around 1 microgram (μg), is much higher than that 
found in a single cell, 5-10 picograms (pg). For this reason, WGA of the biopsied 
DNA is essential in order to reach the required amount of DNA (Wells et al, 2008).  
 
Two different CGH techniques have been applied in PGS with different hybridisation 
targets. In metaphase CGH (mCGH) the hybridisation site is metaphase spreads 
and in array CGH (aCGH) hybridisation is performed on mapped clones of the 
genome, for example in the form of bacterial artificial chromosomes (BAC) or 
oligonucleotides (figure 1.5). mCGH was developed as a molecular technique for 
the analysis of all 24 chromosomes and as an alternative to G-banding (Kallioniemi 
et al, 1992). The most suitable WGA technique prior to mCGH is DOP-PCR (Wells 
et al, 1999) and with suitable optimisation it can be applied successfully in the 
analysis of single blastomeres from embryos (Wells and Delhanty, 2000) with a 
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resolution of around 40 megabases (Mb) (Voullaire et al, 1999). mCGH was used 
clinically for the analysis of all chromosomes in single blastomeres for a case of 
AMA/RIF (Wilton et al, 2001). Comparison of PGS by mCGH to PGS by FISH in 
patients with RIF showed that the use of mCGH led to an increase of implantation 
and pregnancy rates, although without statistical significance, due to the small 
number of cases (Wilton et al, 2003). Despite the fact that mCGH can be performed 
for analysis of embryonic samples, its clinical application is difficult as it is a lengthy 
process and cryopreservation of embryos is needed when cleavage or blastocyst 
stage analysis is performed. Moreover, it requires molecular and extensive 
cytogenetic expertise to analyse the results (Wells et al, 2008).  
 
Figure 1.5: Comparative genomic hybridisation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Biopsied samples are subjected to whole genome amplification to increase the 
amount of DNA. The test and a reference DNA are then differentially labelled and hybridised 
either on metaphase spreads to perform mCGH (A) or slides containing clones representing 
the whole genome to perform aCGH (B). [Reprinted from Fertility and Sterility, 94 (4), Harper 
and Harton, The use of arrays in preimplantation genetic diagnosis and screening, 1173-
1177, Copyright (2010), with permission from Elsevier] 
 
Array comparative genomic hybridisation (aCGH) is a technique used to detect 
chromosomal imbalance. It was developed as an alternative to metaphase CGH, in 
order to improve the resolution and detect small copy number gains and losses 
(Solinas-Toldo et al, 1997) initially for the analysis of cancer (Pinkel et al, 1998). It is 
quicker, more automated and simpler than mCGH making it ideal for use in PGS. 
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Successful aCGH with interpretable results can be performed in a clinical setting 
within 12 to 13 hours (Magli et al, 2011). It involves the hybridisation of labelled DNA 
on clones, which are fabricated on a solid platform, scanning of the platform and 
analysis of the results by a suitable software (Glentis et al, 2006). Obtaining a 
satisfactory result in aCGH is influenced by many factors, since a number of 
experimental steps are involved in the technique. A low signal to noise ratio, as well 
as a low standard deviation (SD) of the intensity ratios obtained from the 
fluorochores on all the clones are essential for a good quality result. Another 
important quality indicator of an aGCH experiment is the number of clones included 
in the analysis, as bad quality may cause some clones to fail (Vermeesch et al, 
2005).  
 
aCGH on single cells has been successful using a variety of WGA methods and 
clones on cells from tumor and other cell lines, euploid or carrying known 
aneuploidies. Combinations include DOP-PCR amplified samples hybridised on 
DOP-PCR amplified chromosome-specific libraries (Hu et al, 2004), MDA 
amplification and oligonucleotide clones (Le Caignec et al, 2006), GenomePlex, a 
type of adaptor-linker PCR amplification and BAC DNA clones (Fiegler et al, 2007) 
and finally combinations of three different WGA methods, DOP-, adaptor-linker PCR 
and MDA on BAC and oligonucleotide clones (Fuhrmann et al, 2008). BAC clones 
consist of DNA fragments that correspond to specific chromosomal regions of a size 
150-200kb. Despite the fact that BAC arrays have fewer clones than other type of 
arrays, they are enough for comprehensive chromosome screening. Since sites of 
the genome are represented multiple times on each array, WGA artefacts like 
amplification failure or ADO can be supressed (Sills et al, 2012). 
 
aCGH has been applied clinically for the detection of chromosomal aneuploidies in 
PGS. Again a variety of WGA methods and array platforms are used. The first 
application, after blastomere biopsy, involved the use of MDA with oligonucleotide 
arrays (Hellani et al, 2008). aCGH has also been clinically applied for the analysis of 
biopsied polar bodies and trophectoderm samples (Fishel et al, 2010, Fragouli et al, 
2011a). When aCGH is applied during PGS on trophectoderm samples from 
blastocysts, the result obtained is an average of all the cells in the biopsied sample. 
Mosaicism is not detected in detail as in FISH, when each cell is analysed 
separately. The importance of this in the clinical outcome is not yet known. However, 
one hypothesis is that this low-level mosaicism might not be of clinical importance 
and that embryos of this constitution might lead to a normal pregnancy (Fragouli et 
al, 2008).  
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One major disadvantage of aCGH is that, in some cases, it cannot detect 
abnormalities in the ploidy of the analysed sample, such as haploidy or triploidy 
(Harper and Harton, 2010). The detection of structural chromosomal 
rearrangements is possible with aCGH. However, no distinction can be made 
between chromosomally normal and balanced carrier embryos (Alfarawati et al, 
2011, Fiorentino et al, 2011). The ESHRE PGS task force will perform an RCT 
(Geraedts et al, 2011) on the efficacy of aCGH in PGS with polar body analysis. 
Recently, a randomised pilot study was performed in good prognosis patients to 
examine the outcome of single blastocyst transfer after selection of embryos by 
aCGH and by morphology alone. Results showed significantly higher pregnancy and 
ongoing pregnancy rates in the couples that had aCGH than those who had a 
transfer based on morphology (Yang et al, 2012).  
 
1.2.3.3 Single nucleotide polymorphism arrays 
Screening of the whole genome can also be performed by the use of single 
nucleotide polymorphism (SNP) arrays. These are oligonucleotide arrays of high 
density, which are able to detect copy number changes at the nucleotide level 
(Speicher and Carter, 2005). In addition to the ability to identify changes in copy 
number of chromosomes, SNP arrays can also detect monogenic disorders through 
haplotyping, as well as, other multifactorial inherited diseases like autism and 
diabetes (Harper and Harton, 2010). Analysis by SNP arrays is possible on single 
cells (Treff et al, 2010) and has been shown to have high overall predictive value 
(Scott et al, 2012b).  
 
Clinical application of SNP arrays during PGS for AMA has been described post 
biopsy of both polar bodies (Scott et al, 2012a). SNP arrays have also been used 
after blastocyst biopsy and vitrification, in couples with RIF, RM and AMA. A very 
high implantation (67%) rate per embryo transferred and live birth rate 55.9% per 
oocyte retrieval for 130 cycles was reported (Schoolcraft et al, 2011). Finally, Treff 
et al, have described the ability to distinguish between balanced and normal 
chromosomes in embryos from a couple with a female translocation carrier. This 
was again performed in a clinical setting following blastocyst biopsy, resulting in the 
birth of a male with a normal karyotype (Treff et al, 2011).   
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1.3 Aims 
1.3.1 Aim 1: Validation of aCGH for clinical use in PGS 
The first aim of the study was to validate aCGH for the clinical use in PGS. This was 
performed first through the utilisation of cell lines of known chromosomal status. The 
efficacy of aCGH post cleavage stage biopsy was assessed on single cells isolated 
from the cell lines. The effect of mosaicism in a biopsied sample from a blastocyst 
was examined by the use of mosaic models containing euploid and aneuploid cells 
from the most stable cell lines. The second step of validation was to test aCGH on 
embryonic samples and examine concordance between a biopsied TE sample and 
the remaining of the blastocyst. The final step was to confirm the clinical aCGH 
result in PGS cases after cleavage and blastocyst stage biopsies on untransferred 
embryos, through the use of FISH. 
 
1.3.2 Aim 2: Examination of aneuploidy level in embryos from 
couples undergoing PGD 
The second aim of the study was to determine the level of aneuploidy in embryos 
from couples undergoing PGD for single gene disorders. One group of embryos was 
analysed by FISH testing all cells for a small number of chromosomes and a second 
group by aCGH analysing all chromosomes in whole embryos. Through the 
aneuploidy analysis, it was aimed to examine the effect of aneuploidy in embryonic 
development, the effect of age in the rate of aneuploidy and the origin of 
abnormalities. Comparison with the level of aneuploidy in embryos from PGS cycles 
was performed, aiming to identify distinct differences in the aneuploidy level in 
embryos from PGD and PGS cycles. 
 
1.3.3 Aim 3: Investigation of recombination in embryos 
The third and final aim was to investigate recombination in embryos. Polymorphic 
markers on known areas of the genome of high and low recombination were utilised 
to identify cross-over events in embryos from couples undergoing PGD and PGS. 
Recombination was calculated per family and per embryo with the aim to identify 
differences in the recombination between chromosomes, sexes and different age 
groups. The possibility of differences in recombination between embryos and the 
general population was also examined.  
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2 Materials and Methods 
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2.1 Materials and methods outline 
The Material and Methods chapter has been organised in three main sections: 
1. Sample collection and preparation: describes all the samples used and the 
techniques followed to collect and prepare them prior to all subsequent 
experiments.  
2. Sample processing: describes the three main procedures used for examining 
the samples depending on the analysis that followed. This included 
amplification of DNA and hybridisation of chromosomes with fluorescent 
probes.  
3. Sample analysis: presents the methods employed to analyse and interpret 
the results of the tests conducted on the samples.  
The techniques used in each section to fulfil appropriate aims are shown in table 2.1. 
Figures 2.1, 2.2, 2.3 are flowcharts for each aim presenting the samples and 
techniques used.  
All reagents and general laboratory consumables were from VWR, International, 
unless otherwise stated. All fluorescent primers were from Eurogentec, UK and all 
fluorescent probes were from Abbott Molecular, UK.  
Consumables and solutions that needed sterilisation were autoclaved using the New 
Swiftlock autofill steriliser (Astell Scientific, UK). General laboratory equipment 
included a microcentrifuge (MicroCentaur, Sanyo, UK) and a benchtop centrifuge 
(Heraus, Labofuge 300, Thermo Scientific, USA). The thermal cyclers used were the 
Mastercycler gradient, Mastercycler ProS (both Eppendorf, UK) or the GeneAmp 
PCR System 9700 (Applied Biosystems, UK). 
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Table 2.1: Techniques used for sample collection, preparation, processing and analysis to fulfil all aims of this thesis 
 
 
 
Aim 
Sample collection and preparation 
(Materials and Methods section) 
Sample processing           
(Materials and Methods section) 
Sample analysis                      
(Materials and Methods section) 
1 
Single cell isolation (2.3.1.2) 
 
Mosaic trophectoderm and blastocyst models 
(2.3.1.3) 
 
Embryo disaggregation and tubing (2.3.2.3) 
 
Whole genome amplification (2.4.1) 
 
 
FISH (2.4.2) 
aCGH (2.5.2) 
 
 
Fluorescent microscope analysis (2.5.3) 
2 
Embryo spreading (2.3.2.4) 
 
Embryo disaggregation and tubing (2.3.2.3) 
 
FISH (2.4.2) 
 
Whole genome amplification (2.4.1) 
Fluorescent microscope analysis (2.5.3) 
 
aCGH (2.5.2) 
3 
DNA extraction (2.3.3.1) 
 
Embryo disaggregation and tubing (2.3.2.3) 
 
Whole genome amplification (2.4.1) 
 
FPCR (2.4.3) 
aCGH (2.5.2) 
 
STR analysis (2.5.4) 
 
Haplotype analysis (2.5.4.1) 
 53 
Figure 2.1: Aim 1 - Validation of aCGH for clinical use in PGS 
 
 
Figure 2.1: Aim 1. Epithelial cell lines and embryos were used for the validation of aCGH to 
be used clinically during PGS for the detection of numerical chromosomal abnormalities.  
 
Figure 2.2: Aim 2 - Examination of aneuploidy level in embryos from couples 
undergoing PGD 
 
 
Figure 2.2: Aim 2. Embryos from patients that had undergone PGD for single gene 
disorders were analysed by FISH and aCGH to determine the aneuploidy level. 
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Figure 2.3: Aim 3 - Investigation of recombination in preimplantation embryos 
 
 
Figure 2.3: Aim 3. Recombination and aneuploidy levels were determined by FPCR and 
aCGH respectively in embryos from couples undergoing PGD and PGS.  
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2.2 General laboratory practice 
Techniques prior to DNA amplification that needed clean conditions, like single cell 
isolation, preparation of mosaic models, embryo disaggregation, as well as all 
primer reconstitutions and setting up of PCR and WGA amplifications were 
performed in a clean room used by designated staff. This room was constantly 
maintained under positive pressure and the total volume of air was changed 20 
times per hour. Dedicated lab coats were available and disposable fresh hat, 
overshoes and gloves were worn before entering. All consumables, apart from 
samples and primers, brought in the clean room were placed under ultraviolet (UV) 
light in the AirClean 600, PCR Workstation, AirClean Systems (Starlab, UK) for at 
least 10 minutes. All amplification reactions were set up under a Microflow Bio-
safety cabinet class II, equipped with a UV light for decontamination. All pipettes, 
double-filtered, sterile, DNA- and RNA-free pipette tips and tubes were kept inside 
the safety cabinet and were decontaminated daily. All post amplification work was 
performed in areas separated from the clean room with dedicated pipettes and any 
other consumables needed.  
 
2.3 Sample collection and preparation 
2.3.1 Epithelial cell lines 
Ovarian epithelial cell lines were used for the validation of aCGH for clinical 
application in PGS (Aim 1). The cell lines were provided by the Translational Lab, 
Institute for Women’s Health, University College London and were received as 
pellets.  
 
2.3.1.1 Description and pre-treatment 
Overall, four different cell lines were used: TOV-21G, SKOV3, IOSE-1 and IOSE-19. 
The first two lines carried known aneuploidies and the last two, IOSE-1 and IOSE-
19, were euploid. FISH was performed in all the cell lines, as described in section 
2.4.2 of the Materials and Methods, to confirm the presence or absence of 
aneuploidies and to examine possible cell-to-cell variation within each line. All cell 
lines were from the same passage, minimising differences that may arise in the 
cells’ constitution of one cell line from different passages.   
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Cell lines were received as pellets in 15 millilitre (ml) Falcon tubes. The pellets were 
resuspended in 15ml of Dulbecco’s 1x phosphate-buffered saline (PBS, Invitrogen, 
UK) and centrifuged at 1300 revolutions per minute (rpm) for 15 minutes (min) in a 
benchtop centrifuge. The supernatant was discarded and the pellets were re-
washed twice with 15ml of PBS and pelleted by centrifugation at 1300rpm for 15 min. 
After the final wash the pellets were resuspended in 2ml of PBS and kept at 4C 
until use. 
 
2.3.1.2 Single cell isolation from epithelial cell lines 
Isolation of single cells was performed under an inverted microscope (Nikon, USA). 
Small, 3 microliters (l), wash drops of Dulbecco’s 1xPBS (Invitrogen, UK) 
containing 1% polyvinyl alcohol (PVA, Sigma-Aldrich, UK) were aliquoted on a Petri 
dish together with a bigger, 12l PBS/PVA suspension drop. Three l of cell 
suspension were transferred to the suspension drop on the dish. Transfer and 
isolation of cells was performed with a 0.2-millimeter (mm) polycarbonate 
microcapillary (Biohit, Finland) attached to a mouth or a hand pipette (Cook, UK). A 
small number of cells were transferred from the suspension drop to the first wash 
drop. Cells were transferred to consecutive wash drops until there was only one cell 
visible in the drop. The single cell was then washed in three fresh drops and finally 
aliquoted to an empty 0.2ml, thin walled, RNase-, DNase-, DNA- and pyrogen-free, 
non sterile, microfuge tube (Molecular BioProducts, UK). After tubing, all cells were 
pulse spun in a microcentrifuge and were kept at -20C until use. For the validation 
of aCGH for PGS after biopsy of single blastomeres, all single cells were coded at 
this stage for blind analysis.  
 
2.3.1.3 Mosaic trophectoderm and blastocyst model preparation 
For the validation of aCGH for clinical application in PGS after biopsy of a 
trophectoderm sample, mosaic trophectoderm and blastocyst models were prepared 
using two of the above mentioned epithelial cell lines, TOV-21G, which consisted of 
aneuploid cells, carrying trisomy for chromosome 10 and the euploid IOSE-19. 
Similar to the single cell isolation procedure, PBS/PVA drops were prepared on a 
Petri dish. Cells were transferred in the suspension drop and were washed in fresh 
PBS droplets. For the mosaic TE models a total of eight cells were prepared for 
each 0.2 microfuge tube, with the number of euploid:aneuploid cells to be 8:0, 6:2, 
5:3, 4:4, 3:5, 2:6 and 0:8, in duplicates (TE group A and TE group B). All the cells 
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required for each sample were transferred in the final drop and then into a fresh 
0.2ml microfuge tube.  
 
The total number of cells in the mosaic blastocyst models was 100 and 10 samples 
were prepared, in which the euploid:aneuploid number of cells was 100:0, 75:25, 
50:50, 25:75, 0:100, again in duplicates (Blastocyst group A and Blastocyst group B, 
figure 2.4). Due to the high number of cells in each sample and in order to avoid 
transfer of excessive PBS/PVA, the cells were transferred in 0.2ml PCR microfuge 
tubes in groups of 10.  
 
 
Figure 2.4: Mosaic trophectoderm and aneuploid models 
 
 
 
\ 
 
 
 
Figure 2.4: Aneuploid (red) and euploid (black) cells were used to generate mosaic TE and 
blastocyst models with different levels of aneuploidy (right), mimicking a mosaic blastocyst 
(left).  
 
 
2.3.2 Human embryos from IVF, PGD and PGS cycles 
To achieve the three aims of the project (figure 2.5) human embryos were collected 
from patients attending the Centre for Reproductive and Genetic Health (CRGH) 
who had given informed written consent to donate their embryos for research. This 
work was licenced by the Human Fertilisation and Embryology Authority (HFEA 
project reference: RO113) and ethical approval was granted by the national 
research ethics service (NRES), research ethics committee (REC reference 
number: 10/H0709/26).  
 
For the aCGH validation (aim 1), frozen blastocysts donated for research from 
routine IVF patients were thawed and biopsied by the embryologists at the CRGH. 
The TE biopsied samples as well as the remainder of the blastocysts were tubed 
separately for analysis. Embryos from PGS patients were also included in this study. 
Once aCGH was applied clinically, embryos that were found to be aneuploid were 
spread onto slides (Materials and Methods section 2.3.2.4) to confirm the presence 
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of chromosomal anomalies seen during the diagnosis in the whole embryo by FISH 
(Materials and Methods section 2.4.2). The WGA product from some PGS cases 
was also used for the aneuploidy and recombination studies (aim 2 and 3). 
 
Embryos from patients undergoing PGD for single gene disorders were used to 
determine the level of aneuploidy in these couples (aim 2) and examine 
recombination events (aim 3). Those were embryos that had been diagnosed as 
affected with a single gene disorder after PGD or were unaffected but unsuitable for 
transfer due to developmental arrest. The embryos were either spread whole for 
FISH analysis, or tubed whole for aCGH and haplotype analysis.  
 
 
 
Figure 2.5: Use of human embryos in different projects 
 
2.3.2.1 IVF cycle 
All IVF cycles were performed at the CRGH and the embryologists conducted the 
embryo fertilisation and morphology checks as well as the embryo biopsy. Fertility 
checks were done in all couples to verify their suitability for the IVF procedure. An 
ovarian reserve test (ORT) was performed in all women at day two or day four of 
their cycle. Sperm parameters were checked for all men prior to IVF. Vaginal oocyte 
collection was performed 35 hours after the administration of human chorionic 
gonadotrophin (hCG). hCG injection was given when the two lead follicles had 
reached 18mm, following ovarian stimulation. Fertilisation of all the embryos used in 
this thesis was performed by intracytoplasmic sperm injection (ICSI). A single sperm 
was injected into each mature oocyte 41 hours after hCG administration. Sixteen to 
20 hours post insemination, on day one, the embryologists checked for the 
formation of pronuclei in each embryo. On day two, the morphology of the embryos 
was scored and on day three, 68 to 72 hours post insemination, cleavage stage 
General IVF 
embryos 
PGS embryos PGD embryos 
aCGH validation Aneuploidy Recombination 
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biopsy of single blastomeres was performed. Blastocyst biopsy was performed on 
day 5 or day 6, when trophectoderm had started to hatch from the hole drilled in the 
zona on day three. 
 
Cleavage stage biopsies and zona drilling for blastocyst biopsies were performed 
using an Octax laser (MTG, Germany). For PGD and PGS cleavage stage biopsies, 
two blastomeres were removed from embryos that had more than five cells and one 
was removed from the rest. For the biopsy, embryos were placed into calcium and 
magnesium (Ca2+/Mg2+) -free media to stop compaction of the cells (SAGE media, 
Biopharma, USA). For PGS embryos that were analysed by aCGH, blastocyst 
biopsy was performed in media that contained Ca2+/Mg2+ (HEPES media, Invitrogen 
UK).  
 
2.3.2.2 Embryo collection from the Centre for Genetic and Reproductive 
Health 
Embryos donated from IVF, PGD and PGS patients and were used in this thesis 
were transferred from the CRGH to the UCL Centre for PGD in culture dishes, in an 
insulated box. The embryologists in the CRGH performed the scoring of the 
embryos at the day of collection. They were kept in an incubator at 37C until use.  
 
2.3.2.3 Whole embryo tubing 
Embryos were tubed whole for molecular, haplotype analysis and/or molecular 
cytogenetic analysis by aCGH. This procedure was performed in the clean room. 
Petri dishes were prepared with 3l PBS/PVA drops. Embryos were observed under 
an inverted microscope to confirm the developmental stage and morphology 
provided by the embryologists. They were then transferred from the culture dish to a 
PBS/PVA drop with a 0.2mm or 0.35mm microcapillary (Biohit, Finland), attached to 
a mouth or a hand pipette, depending on the size of the embryo. Initially, the embryo 
was removed from the zona completely. For biopsied embryos, this was performed 
by gentle pipetting of the embryo in and out of the microcapillary in order for it to be 
released from the zona through the biopsy hole. If the embryo had not been 
biopsied or was not possible to aspirate it through the biopsy hole it was transferred 
to a 3l Acid Tyrode’s (MediCult Ltd, UK) drop. It was then observed until the zona 
had dissolved and then immediately transferred to a fresh PBS/PVA drop. Finally, 
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the embryo was tubed whole in separate 0.2ml microfuge tubes. The tubes were 
pulse centrifuged and kept at -80C until use.  
2.3.2.4 Embryo spreading 
The embryos were spread on slides coated with poly-L-lysine to be analysed by 
FISH. The slides were prepared by incubating them for 5 minutes in a coplin jar 
containing poly-L-lysine (Sigma-Aldich, UK) diluted 1:10 in deionised water (dH2O). 
They were then left to dry at room temperature and were stored at 4C.  
 
For the spreading, a circle was made on the bottom of the slide with a diamond 
marker. The circle was filled with 10l spreading solution, which was prepared fresh 
[0.01N hydrochloric acid (HCl)/0.1% Tween 20, Sigma-Aldrich, UK]. A 10l drop 
1xPBS was placed adjacent to the spreading drop [for 1000ml, 5 tablets of PBS 
(Sigma-Aldrich, UK) were dissolved in 1000ml of dH2O] and was used for washing. 
The embryo was transferred from the culture dish to the PBS drop with a 0.2mm or 
0.35mm microcapillary under a dissecting microscope (Nikon, USA). From the PBS 
drop the embryo was transferred to the spreading drop and the slide was transferred 
on an inverted microscope (Olympus, UK). The spreading solution was agitated 
carefully and the embryo was observed for the cell membrane to start to lyse and 
the cytoplasm to be washed away. The slide was left to dry, then incubated in PBS 
for 5 minutes and then dehydrated in 70%, 90% and 100% ethanol for 5 minutes 
each (ethanol series dehydration) at room temperature. When the slide was dry the 
co-ordinates of the location of the spread embryo was recorded under a phase 
microscope with an England Finder (Optech, UK). The slides were stored for up to 2 
weeks at 4C until FISH was performed.   
 
2.3.2.5 Blastocyst biopsy and trophectoderm tubing 
Blastocyst biopsy and tubing of the TE sample of embryos donated for research 
from general IVF couples was performed at the CRGH for the validation of aCGH. 
These were frozen blastocysts and were thawed for this purpose. Biopsy was 
performed by the embryologists in those embryos that showed satisfactory 
expansion post thawing. 
 
TE tubing was performed at the CRGH under a laminar flow class II cabinet, 
equipped with a UV bulb for decontamination prior to use. All tubes, ice racks and 
solutions needed for the tubing were kept clear from DNA contamination. Petri 
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dishes with a diameter of 5 centimetres (cm), containing 1xPBS/PVA drops were 
prepared. A new petri dish and microcapillary were used for each embryo. Biopsied 
samples were provided from the embryologists in the biopsy dish. The sample was 
located in the drop containing biopsy media under a dissecting microscope (Nikon, 
USA) and transferred with a 0.2mm microcapillary to a PBS/PVA drop. The TE 
sample was washed three times in fresh drops and transferred to a labelled 0.2ml 
PCR tube. A witness performed the labelling of the tubes and checking of the 
embryo identification.  
 
2.3.3 Genomic DNA 
Patient DNA was extracted from whole blood for analysis in the recombination study 
(aim 3). Blood samples were received from couples undergoing PGD and PGS at 
the CRGH in ethylenediaminetetraacetic acid (EDTA) tubes.  
2.3.3.1 DNA extraction from whole blood using the Qiagen QIAmp® Blood 
Maxi Kit 
The “spin protocol” was carried out according to the manufacturer’s guidelines 
(Qiagen, UK). All the steps were performed in a Class II safety cabinet and all 
supernatants and used pipettes were discarded in a beaker containing 5 PreSept 
tablets (Johnson + Johnson, UK) diluted in 1000ml of H2O, for decontamination 
purposes. Briefly, 3-5ml of whole blood were mixed thoroughly with 500µl protease 
enzyme and 6ml of buffer AL to lyse the cells. The samples were incubated at a 
70°C water bath for 10 minutes. Five ml of 100% ethanol were added and the 
samples were shaken vigorously to ensure sufficient binding to the membrane of the 
QiAmp Maxi column inserted in 50ml centrifuge tubes, where the samples were then 
transferred. The samples were centrifuged at 3000rpm in a benchtop centrifuge 
(Heraus, Labofuge 300, Thermo Scientific, USA) for 3 minutes. After removal of the 
filtrate, the DNA bound on the membrane was washed once with 5ml of buffer AW1 
and once with 5ml of buffer AW2, by centrifugation at 5000rpm for 1 minute and 15 
minutes respectively. The filtrate was removed between the washes. Any remaining 
ethanol on the membranes was evaporated by incubation at 70C for 10 min, 
without the tube lids. Finally, DNA was collected by adding 600μl of elution buffer 
AE on the membrane and centrifuging once at 5000rpm for 2 minutes. Six hundred 
µl of elution buffer were added again on the filter, the samples were incubated at 
room temperature for 5 minutes and then centrifuged at 5000rpm for 5 minutes. The 
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DNA was washed with elution buffer twice in order to achieve maximum yield. 
Samples were then stored at 4ºC. This technique of DNA extraction produced 
samples with a DNA concentration of around 80ng/l.  
 
2.4 Sample processing 
2.4.1 Whole genome amplification 
Whole genome amplification (WGA) was performed for representative amplification 
of the whole genome and was used for further analysis by aCGH and/or haplotyping. 
GenomePlex (Sigma-Aldrich, UK) was used for the amplification of DNA from 
single cells isolated from epithelial cell lines for the clinical validation of aCGH at 
single blastomeres. SurePlex (BlueGnome Ltd, UK) was used for all other samples 
that were amplified by WGA (mosaic TE and blastocyst models, embryos). Both of 
these WGA methods were based in a similar technology.  
2.4.1.1 GenomePlex® 
The GenomePlex® single cell whole genome amplification (WGA-4) kit (Sigma-
Aldrich, UK) was used, with the modification described by Fiegler et al (2007). The 
amplification procedure of the single cells was performed by BlueGnome Ltd, UK.  
2.4.1.2 SurePlex 
SurePlex (BlueGnome Ltd, UK) provided representation of 70-90% of the genome 
resulting in an amplified sample of 2-5g and it was performed following the 
manufacturer’s protocol. The sample was first lysed, followed by the pre-
amplification step, during which DNA libraries of short, overlapping amplimers were 
constructed with self-inert degenerative primers that were annealed at multiple sites 
of the genome. In the final amplification step multiple fragments spanning each site 
were created (figure 2.6).  
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Figure 2.6: WGA amplification with SurePlex (BlueGnome Ltd, UK) 
 
Figure 2.6: Small amount of DNA was amplified reaching a 70-90% representation of its 
whole genome at a quantity of 2-5g 
 
The samples were first pulse centrifuged to ensure all contents were at the bottom 
of each tube. It was assumed that the volume of PBS/PVA with the isolated cell in 
the tube was 2l. Three l of Cell extraction buffer were added in each sample to 
make up to 5l of total volume. For the cell lysis and DNA extraction, 4.8l of 
Extraction enzyme dilution buffer and 0.2l of Cell extraction enzyme were aliquoted 
in each tube. The samples were then incubated at 75C for 10 min followed by 4 
min at 95C in a thermal cycler. For the preparation of the library of short, 
overlapping amplimers, 4.8l of SurePlex pre-amp buffer and 0.2l of SurePlex pre-
amp enzyme were added in each sample and were placed in the thermal cycler for 
the pre-amplification procedure seen in table 2.2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.2: Pre-amplification by SurePlex. DNA libraries were prepared in this procedure in 
a thermal cycler.  
 
 
Table 2.2: SurePlex pre-amplification program 
Temperature Time Cycles 
95C 2 min 1 cycle 
95C 15 sec 
12 cycles 
15C 50 sec 
25C 40 sec 
35C 30 sec 
65C 40 sec 
75C 40 sec 
4C Hold 1 cycle 
Isolated single 
cell(s) in PBS 
Cell lysis and 
dilution buffer 
Cell lysis and 
DNA extraction 
Pre-amplification 
mix 
Amplification mix 
DNA library 
preparation 
DNA library 
amplification 
aCGH and/or 
FPCR 
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When pre-amplification was complete, the tubes were pulse centrifuged and 25l 
SurePlex amplification buffer, 0.8l SurePlex amplification enzyme and 34.2l 
nuclease-free water were added in each sample. The DNA of the samples was then 
amplified in a thermal cycler following the program seen in table 2.3.  
 
 
 
Table 2.3: SurePlex amplification program 
Temperature Time Cycles 
95C 2 min 1 cycle 
95C 15 sec 
14 cycles 65C 1 min 
75C 1 min 
4C Hold 1 cycle 
Table 2.3: Amplification by SurePlex. Constructed DNA libraries of amplimers were 
amplified during this program in a thermal cycler.  
 
Amplified products were kept at -20C until use. If more than two samples were 
amplified at the same time then reaction mixes were prepared for the extraction, 
pre-amplification and amplification procedures, containing the required volume of 
each reagent and the required volume of the reaction mix was added to each 
sample to minimise aliquoting.  
 
2.4.2 Fluorescence in situ hybridisation (FISH) 
The chromosomal constitution of embryos post PGD and PGS was analysed by 
FISH as part of the aCGH validation (aim 1) and the examination of the level of 
aneuploidy in couples undergoing PGD (aim 2). A variety of fluorescent probes was 
used in sequential rounds of FISH. A general outline of the procedure is given below 
and details of all the probes used and conditions are listed in table 2.4.  
2.4.2.1 Slide preparation 
After spreading on poly-L-lysine coated slides the embryos were digested to remove 
the cytoplasm and make the nuclei accessible for the fluorescent probes to 
hybridise. The digestion solution, 0.01HCl [49ml dH2O, 0.5ml 1M HCl (for a 50ml 
Coplin jar)] was prepared in a 50 or 100ml Coplin jar (depending on the number of 
slides) and warmed up to 37C in a water bath. Once the solution had reached the 
desired temperature, 0.5ml of pepsin (10mg/ml – Sigma-Aldrich, UK) were added 
and mixed using a Pasteur pipette. The slides were then placed in the Coplin jar and 
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incubated for 15 minutes in the 37C water bath. The HCl/Pepsin solution was 
poured and the slides were washed once with dH2O and once with 1xPBS. The 
samples were then fixed on the slides by incubation for 10 minutes in 1% 
paraformaldehyde/PBS [49ml 1xPBS, 1.34ml paraformaldehyde [to make 500ml 1% 
paraformaldehyde: 5cm of sodium bicarbonate (NaHCO3) in a one litre (L) bottle 
were measured, 500ml formaldehyde were added and the solution was left to 
saturate overnight)] at 4C. The slides were then rinsed again once with 1xPBS and 
twice with dH2O.  
 
2.4.2.2 1st round FISH 
The slides were first dehydrated through an ethanol series and were left to air dry on 
a rack in a vertical position. The probe mix was prepared containing the desired 
fluorescent probe(s), the suitable buffer and dH2O in a 0.5ml autoclaved microfuge 
tube. Depending on the probe(s) used, denaturation of the probe(s) and the slides 
was performed simultaneously (co-denaturation) or separately (sep-denaturation). 
All work with the FISH fluorescent probes was performed under darkened conditions.  
If co-denaturation was used, 13mm round glass cover slips were arranged and five 
l of probe mix were aliquoted on each slip. Each slide was inverted on each cover 
slip at the position of the marked area of the sample. The slides and probes were 
then denatured at 75C for 5 minutes. They were then placed in a dark humid 
chamber (humidity was created by a wet tissue at the bottom of the chamber) and if 
overnight hybridisation was performed the cover slips were sealed with Fixogum 
rubber cement (QBiogene, UK).  
 
For the probes that required sep-denaturation, the probe mix was prepared in a 
0.5ml tube as described above and denatured at 75C for five minutes in a 
denaturation oven. It was then kept at a 37C water bath until use. The slide 
denaturation solution was prepared by mixing 70l of deionised formamide, 20l of 
dH2O and 10l of 20xSaline sodium citrate [SSC – 175.3g of 3M Sodium Chloride 
(NaCl), 88.2g of 3M Sodium Citrate, dissolved in 1000ml of dH2O and adjusted with 
1M HCl or 1M sodium hydroxide (NaOH) to pH 7.0] for each slide. This 70% 
deionised formamide solution was then pipetted onto 55x22mm glass cover slips, 
100l for each slide and the slides were inverted on them. Denaturation of the slides 
was performed at 75C for five minutes. The cover slips were removed and the 
slides were dehydrated in 70% ice-cold ethanol for five minutes, followed by 
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dehydration at 90% and 100% ethanol for three minutes each. The denatured probe 
mix was aliquoted on 13mm round glass cover slips and applied on the slides as 
described above and hybridisation was initiated straight after. Post hybridisation the 
slides were washed to removed any unbound probe as described in section 2.4.2.4.  
2.4.2.3 Reprobing of slides, 2nd round of FISH 
For the majority of experiments, a second round of FISH was performed to increase 
the number of chromosomes tested.  Following hybridisation (Materials and 
Methods 2.4.2.2) and analysis (Materials and Methods 2.5.3) the coverslips were 
removed from analysed slides that needed to be reprobed. They were incubated for 
five minutes in a Coplin jar filled with 1xPBS at room temperature on a rocking plate 
under bright light to remove the 1st round probes. The slides where then dehydrated 
through an ethanol series and left to air-dry in a vertical position. Co- or separate 
denaturation of the slides and the probe(s) was then performed as described in 
section 2.4.2.2.  
2.4.2.4 Post-hybridisation washes 
All post-hybridisation washes were performed in the dark in a suitably warmed water 
bath. Cover slips sealed with rubber cement were carefully removed with a pair of 
tweezers. All 1st round slides were washed three times for three minutes in a pre-
warmed formamide/2xSSC solution. The concentration of the formamide and the 
temperature depended on the probe mix. Details for these conditions are found in 
table 2.4. All slides, regardless of the probe mix, were then washed three times for 
three minutes each in 2xSSC at 40C.  
 
Second round slides were again washed with a formamide/2xSSC solution, once for 
five minutes followed by one wash with 2xSSC. The washed slides were dehydrated 
through an ethanol series and left vertically to air-dry. Cover slips of 55x22mm size 
were positioned and 10l of Vectashield 4’,6-diamidino-2-phenylindole [DAPI: 1ml 
Vectashield + 6l of 0.2mg/ml DAPI (both from Vector labs, UK)] were aliquoted for 
each hybridisation area to stain the nuclei. Slides were inverted on the cover slips 
and kept at 4C until analysis.  
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Table 2.4: Information on the probe mixes, colours of the fluorescent probes and conditions used during FISH. Each probe name is presented, its 
chromosomal location, the type, the volume used in a total of 5l of probe mix, the type of buffer used, denaturation (sep: separate slide and probe denaturation, 
co: simultaneous slide and probe denaturation) and post-hybridisation washes. Probes for chromosomes 13, 21, X, Y and 18 were part of the AneuVision kit. LSI: 
Locus specific identifier probe, CEP: chromosome enumeration probe, SG: spectrum green, SO: spectrum orange, SA: spectrum aqua.
Table 2.4: Fluorescent probes used in this thesis for FISH 
Probe mix Chromosome Type of probe Volume of each 
probe (l) 
Buffer Denaturation Post-hybridisation washes 
LSI 13/LSI 21 13 and 21 Locus specific 0.6 LSI Sep 50% formamide/2xSSC, 40C 
CEP X/CEP Y/ CEP 18 X, Y and 18 Centromeric 2.5 CEP Co 60% formamide/2xSSC, 40C 
CEP 10 (SA) 10 Centromeric 0.5 CEP Co 40% formamide/2xSSC, 41C 
CEP 12 (SG) 12 Centromeric 0.1 CEP Co 50% formamide/2xSSC, 40C 
TelVysion 14q (SO) 14 Telomeric 0.6 LSI Co 40% formamide/2xSSC, 40C 
TelVysion 1q (SO) 
CEP4 (SA) 
TelVysion 5p (SG) 
1 
4 
5 
Telomeric 
Centromeric  
Telomeric 
0.6 
0.5 
0.6 
CEP Co 50% formamide/2xSSC, 41C 
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2.4.3 Fluorescence polymerase reaction 
 
Fluorescence polymerase chain reaction (FPCR) was used to amplify polymorphic 
loci in genomic DNA from couples as well as WGA products from embryos (aim 3). 
Haplotyping was then performed in order to detect cross over events and determine 
the recombination rate in embryos from PGD and PGS couples. In total, 14 loci 
were amplified corresponding to 14 different short tandem repeat (STR) polymorphic 
markers on five different chromosomes.  
2.4.3.1 Polymorphic marker selection 
Selection of markers was performed by Dr Nick Maniatis and Dr Winston Lau of the 
Department of Genetics, Evolution and Environment at UCL. Four genomic regions 
of high recombination on chromosomes 1, 5, 16 and 19 and one region of no 
recombination on chromosome 17 were selected on the basis of genetic maps. 
Information from two types of genetic maps was used in order to identify the five 
selected regions. These were the high-resolution linkage disequilibrium (LD) maps 
based on the SNP data from the International HapMap project (Maniatis et al, 2002) 
and the most recent recombination map (cM) based on family data (Kong et al, 
2010). 
 
High-density LDU maps for the whole genome were constructed using four different 
populations from the PHASE II data of the HapMap project (International HapMap 
Consortium, 2007). On LDU maps, recombination hotspots were represented as 
“steps” and recombination silent spots as “blocks”. Figure 2.7 shows the LDU map 
from the CEU (Utah residents with Northern and Western European ancestry) 
HapMap II data for the recombination silent spot on chromosome 17. All maps were 
very similar across all four populations (CEU, Chinese, Japanese, Yoruba) for all 
five selected regions.  
 
The LDU map provided information about current and historic recombination at a 
very fine resolution. However, the most recent recombination map in cM (Kong et al, 
2010) was also used in this study. Although the cM map was of lower marker 
resolution, compared to LDU maps, it was based on family data and hence provided 
evidence of current recombination that could be directly compared to our embryo 
recombination data. This cM map was based on CEU families and, as seen in figure 
2.7, a very close relationship with the LDU map was shown.  
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Figure 2.7: The LD structure of the NF1 region 
Figure 2.7: The LD map of the region is shown by plotting HapMap LDUs (Y axis) against kb 
(X axis). The family based recombination map for the same region is shown by plotting sex-
averaged cM (secondary Y axis) against kb (X axis). The vertical lines show the start and 
end of the gene and the red points within the gene are two of the five STR on that region 
markers that were used to estimate recombination frequency using embryo data. 
 
2.4.3.2 Primer design 
For the purpose of primer design information on markers was retrieved in Ensembl 
(Ensembl release 60, www.ensembl.org, NCBI build 37). The sequence of each 
marker was identified through BLASTN, of the marker primers provided by Ensembl, 
in the Basic Local Alignment Search Tool (BLAST) programme 
(http://www.ensembl.org/Homo_sapiens/blastview). Primers were then designed 
with the aid of Primer3 software via a web interface (http://frodo.wi.mit.edu/). All 
primers were 20-28 bases long with similar melting temperatures of around 60C, 
low self-complementarity. Primer product size ranged from  Sets of forward and 
reverse primers were designed specific for each locus, with the forward primer 
labelled with a fluorescent dye an at the 5’- end to allow fragment analysis post 
FPCR. Each set of primers was initially tested on genomic DNA in a singleplex 
reaction using either High Fidelity (HiFi) polymerase (Roche Diagnostics, UK), or 
Taq polymerase (Qiagen, UK). Optimisation was achieved by performing a gradient 
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PCR in a thermocycler (Mastercycler gradient, Eppendorf, UK) and testing different 
annealing temperatures, ranging +/-4C of the determined melting temperature 
provided by the supplier company. Once optimisation for each primer set was 
achieved markers were amplified, if possible, in multiplex reactions, using the 
Qiagen Multiplex PCR kit (Qiagen, UK) or in singleplexes.  
 
All PCR reactions were performed in 0.2ml microfuge tubes. All mastermixes were 
prepared in 0.5ml PCR or 1.5ml individually packed, sterile microfuge tubes (VWR, 
UK).  
 
All primers arrived in lyophilised pellets, in 40nm quantities. Each primer was 
reconstituted by adding the required volume of nuclease-free water (Promega, UK) 
or 1xTE [Tris(hydroxymethyl)aminomethane (Tris)/EDTA] buffer (Promega, UK) to 
make up to 50, 100 or 200 micromolar (M) concentration. Stock aliquots of the 
primers were kept at -80C. Working aliquots of each primer were prepared at 50M 
concentration and kept at -20C, in order to minimise the number of freeze/thaws of 
the stock aliquots. Details of each primer sequence and fluorescent dye are found in 
table 2.5. 
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Table 2.5: Details of primers used for the detection of cross-over events. The 
sequences (from the 5’- to the 3’- ends) and the fluorescent labels at the 5’- end of each 
forward primer (FAM – 6-Carboxyfluorescein, YY – Yakima Yellow, DO – Dragonfly Orange) 
are shown.  
 
 
 
 
 
 
 
 
 
Table 2.5: Primer sets used in this thesis 
Marker Primer sequence (5’- to 3’- end) 
Fluorescent 
label 
D1S495 
Forward CTGCAGAGAAAGGGAACCTG 
FAM 
Reverse CTTTGCAGAGGAGGCAAACT 
D1S486 
Forward GTTGCAGTGAGCTGAGATCG 
DO 
Reverse GTCTCCTCCTTGGTGCATGT 
D5S1991 
Forward GAAAAGCAAGGTGCCAAATC 
FAM 
Reverse TCTTCCATCCCAACTCCAAC 
D5S2081 
Forward ATCTCCGGAAGGAAAAGGAA 
FAM 
Reverse AATTTCATCCTGGCATCCTG 
D16S492 
Forward GCTGTGAGTAGCGACAGTGC 
FAM 
Reverse GTCCCAGCCTCTCTGCTCTA 
D16S3053 
Forward AGCTGATAGCGTCCACAGGT 
FAM 
Reverse ATGGAGCAGGGTATCACCAA 
NF1int1 
Forward CAAAGTGCTGGGATTACAGCATGAG 
FAM 
Reverse TATACATTCTGAAATGATTACCACG 
D17S1307 
Forward ATAGGAGACCTGCTGCCTTT 
YY 
Reverse AGGGCAGAGAAACCTAAGGA 
NF1int17 
Forward CTCTTGTGAGTTATTGTATGCGG 
FAM 
Reverse CTGAGAGTCAAGGGTGGAAGAC 
NF1int29 
Forward CTTTCCTCTAAACAAACAGAGTCAG 
YY 
Reverse CAGTGCACTCCCAGTGCTGGTG 
D17S1166 
Forward TAACAATTGTGGAACTGCAGCAATTATT 
YY 
Reverse CCCATACCTAGTTCTTAAAGTCTGT 
D19S219 
Forward TTGCTGGGTCATTCAGTTTG 
FAM 
Reverse AGCGAGAATCCGTCTCAAAA 
D19S207 
Forward GAGGGGAACTATAGCCACCA 
DO 
Reverse AGGCAGAGGTTGCAGTGAGT 
D19S412 
Forward GTTGCAGTGAGCTGAGATCG 
FAM 
Reverse GTCTCCTCCTTGGTGCATGT 
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2.4.3.3 PCR using High Fidelity polymerase 
Singleplex PCR reactions were prepared using the Expand High Fidelity (HiFi) PCR 
system (Roche Diagnostics, UK). Each PCR reaction contained 0.2M of each 
primer (forward and reverse), 0.4mM deoxyribonucleotide triphospathes (dNTPs, 
Promega, UK), 2.5l of Expand High Fidelity buffer [containing 1.5mM magnesium 
chloride (MgCl2)] and 1.5 units of Expand High Fidelity polymerase. All PCR reaction 
volumes for amplification of either genomic DNA or WGA products were made up to 
24l with nuclease-free water (Promega, UK) and 1l of DNA or WGA product was 
added. The program followed is found in table 2.6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.6: PCR amplification by the Expand High Fidelity PCR system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.6: Singleplex PCR program using High Fidelity polymerase 
Step Temperature Time Cycles 
Initial denaturation 95C 2 min 1 cycle 
Denaturation 96C 15 sec 
10 cycles Annealing 58 or 60C 45 sec 
Elongation 72C 1 min 
Denaturation 94C 15 sec 
30 cycles Annealing 60C 45 sec 
Elongation 72C 1 min 
Final elongation 72C 7 min 1 cycle 
Hold 4C Hold 1 cycle 
 73 
2.4.3.4 PCR using the Taq PCR master mix 
The Qiagen Taq PCR master mix was used to prepare some of the singleplex PCR 
reactions (Qiagen, UK). The kit included a ready-made mix, the 2x Taq PCR master 
mix that contained the Taq DNA polymerase, Qiagen PCR buffer [20mM Tris-HCl, 
100mM potassium chloride (KCl), 1mM DL-Dithiothreitol (DTT), 0.1 mM EDTA, 0.5% 
(v/v) Nonidet P-40, 0.5% (v/v) Tween 20, 50% (v/v) glycerol; pH 8.0] with 3mM 
Magnesium chloride (MgCl2) and 400mM of each dNTP. Each PCR reaction was 
prepared in a final volume of 25l, containing 12.5l of 2x Taq PCR master mix, 
resulting in a final concentration of 2.5 units of Taq, 1x Qiagen PCR buffer and 
200mM of each dNTP, 0.2M of each of the primers (forward and reverse), 1l of 
genomic DNA or WGA product and sufficient volume of nuclease-free dH2O to make 
up to 25l. The program followed for each reaction is found in table 2.7.  
 
 
Table 2.7: Singleplex PCR program using Taq polymerase 
Step Temperature Time Cycles 
Initial denaturation 94C 3 min 1 cycle 
Denaturation 96C 30 sec 
10 cycles Annealing 60C 45 sec 
Elongation 72C 1 min 
Denaturation 94C 30 sec 
30 cycles Annealing 60C 45 sec 
Elongation 72C 1 min 
Final elongation 72C 10 min 1 cycle 
Hold 4C Hold 1 cycle 
Table 2.7: DNA amplification using the Taq PCR master mix 
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2.4.3.5 Multiplex PCR using the Qiagen multiplex kit 
If possible, different sets of primers were combined in a single, multiplex PCR 
reaction, for the simultaneous amplification of multiple loci. The Qiagen Multiplex 
kit was used for that purpose (Qiagen, UK). The kit included the 2x Qiagen Multiplex 
PCR Master Mix (HotStarTaq DNA polymerase, Multiplex PCR buffer and dNTP 
mix) and 5x Q-Solution, a PCR additive to make the reaction more stringent, which 
changed the melting behaviour of DNA and improved reactions, where primers used 
were of high GC content. A suitable 10x primer mix was prepared for each reaction 
containing each primer in equal concentration of 2M. Each reaction was of a final 
volume of 25l and included, 12.5l of Qiagen Multiplex PCR Master Mix, 2.5l of Q 
solution, 2.5l of 10x primer mix, 1l of genomic DNA or WGA product and 6.5l of 
nuclease-free dH2O. The program followed for all multiplex reactions using this kit is 
shown in table 2.8.  
 
 
Table 2.8: Multiplex PCR program using the Qiagen multiplex kit 
Step Temperature Time  Cycles 
Initial denaturation 95C 15 min 1 cycle 
Denaturation 96C 30 sec 10 cycles 
Annealing 60C 90 sec 
Elongation 72C 90 sec 
Denaturation 94C 30 sec 30 cycles 
Annealing 60C 90 sec 
Elongation 72C 90 sec 
Final elongation 72C 10 min 1 cycle 
Hold 4C Hold 1 cycle 
Table 2.8: DNA amplification with the Qiagen multiplex kit. 
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2.5 Sample analysis 
2.5.1 Agarose gel electrophoresis 
WGA products were run on 2% agarose gels to confirm amplification. The gel was 
prepared by melting 1g agarose (Sigma-Aldrich, UK) in 50ml of 1xTBE buffer 
(10xTBE: 3.7gr EDTA, 108gr Tris, 45g boric acid, in 1L of dH2O). 1.5µl of ethidium 
bromide (10mg/ml, Sigma-Aldrich, UK) were added in order to visualise the bands 
under UV light. The gel was poured onto a mini-gel mould and was left to set at 
room temperature. The set gel was transferred to a tank containing 50ml of 1xTBE. 
Five µl of each product were mixed with 0.8µl of loading buffer (40% w/v sucrose, 
4mM bromophenol blue, 4mM xylene cyanol) and were loaded on the gel wells. The 
Hypeladder IV (1.5µl, Bioline, UK, figure 2.8), 100 base pair (bp) molecular weight 
marker was used to confirm the presence of the WGA smears at the right size. The 
gel was left to run at 80V for 15 minutes in 50ml of 1xTBE. After electrophoresis the 
gel was visualised under UV light using the MultiImage Light Cabinet (Flowgen, UK). 
 
 
Figure 2.8: Hyperladder  IV (Bioline, UK) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8: Molecular weight marker used for the sizing of WGA products on 2% agarose 
gels.  
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2.5.2 Array comparative genomic hybridisation using the 24sure 
microarray platform  
aCGH was performed to achieve complete enumeration of the chromosomes in 
various samples. Tests were undertaken to validate aCGH for clinical application in 
PGS and for research purposes in PGD embryos. All aCGH experiments were 
performed using the 24sure V2 array platform (BlueGnome Ltd, UK) with various 
changes in the conditions to optimise the result in our laboratory setting. 24sure V2 
arrays consisted of 2674 Roswell Park BAC clones, DOP-PCR amplified and 
random spotted in duplicates onto Surmodics glass sides, in two hybridisation areas. 
The performance of each BAC clone had been highly validated by whole 
chromosome reverse painting on arrays, end sequencing, FISH and over aCGH 
experiments. The 2674 clones had been chosen to have low noise (control 
experiment hybridisation to hybridisation variation) and to be outside any regions of 
known number polymorphisms (data from Database of Genomic variants and 
BlueGnome customer post-natal aCGH database, provided by BlueGnome, UK).  
 
The 24sure kit included the control DNA and reagents needed for the labelling of the 
WGA products and controls and for the hybridisation on the array slides. In 
summary, the test DNA (our samples) and the control DNA were differentially 
labelled, co-precipitated and resuspended and finally applied on the array slide for 
hybridisation. The slides were then washed, dried and scanned to produce an image, 
which was analysed using the BlueFuse Multi software v2.2 (BlueGnome, Ltd, UK). 
Details of each step are outlined below.   
2.5.2.1 Labelling 
The labelling reactions were all prepared in 0.5ml, autoclaved microfuge tubes. All 
steps were performed on ice. All the reagents were thawed, briefly vortexed and 
pulse centrifuged. For each labelling reaction the following reagents were added: 
 5l of reaction buffer 
 5l of primer solution 
 5l of dCTP-labelling mix 
 1l of Cyanine 3 (Cy3) for sample DNA (blue) or 1l of Cyanine 5 (Cy5) for 
control DNA (red) 
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In each sample DNA tube, 8l of the amplified product were aliquoted and in each 
control DNA tube 8l of SureRef DNA (BlueGnome Ltd, UK) were added (figure 
2.9a). 
 
The samples were then denatured in a prewarmed thermal cycler for 5 min at 94C 
and transferred immediately on ice, where they were further incubated for 5 min. In 
all the tubes 1l of Klenow enzyme (BlueGnome Ltd, UK) was added and the tubes 
were then vortexed and spun to collect all components in the bottom of each tube.  
The labelling reaction was performed for 3 to 18 hours in a thermal cycler at 37C. 
 
2.5.2.2 Combination and ethanol precipitation 
The labelled control and sample DNAs were combined into labelled 1.5ml, 
autoclaved microfuge tubes (figure 2.9b). Human COT DNA (0.4mg, BlueGnome 
Ltd, UK) was added in all the combined samples at a volume of 25l in order to 
block repetitive sequences in the genome, mainly found around the centromeres 
and in the telomeres of each chromosome and prevent non-specific hybridisation. In 
the combined samples, 7.5l of sodium acetate (Sigma-Aldrich, UK) were added in 
each sample to aid DNA precipitation. Finally, 187.5l of absolute ethanol (Analar, 
VWR, UK) were added and the tubes were inverted twice to mix and placed in -80C 
for 10 min.  
 
2.5.2.3 Hybridisation 
The combined labelled DNAs were centrifuged for 10 min at full speed (13000 rpm). 
After centrifugation the pellets should have had a strong purple colour (figure 2.9c). 
The supernatant was discarded and 500l of 70% ethanol were added to wash the 
pellets. The tubes were inverted to mix and centrifuged for 5 min at full speed. The 
supernatant was again discarded and the tubes were inverted gently on a tissue to 
remove more ethanol. As it was essential to remove as much of the ethanol as 
possible, the tubes were again pulse centrifuged and the remaining ethanol was 
removed with a small pipette, carefully not to touch or move the pellet. The pellets 
were air dried for exactly 2 min at room temperature, as over-drying the pellets 
made resuspension more difficult. Resuspension was performed by adding 21l of 
prewarmed hybridisation buffer in a heating block set at 75C. The pellets were 
vigorously agitated in order for them to be completely dissolved. Once the solution 
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was clear of the pellets, the tubes were incubated for 10 min at 75C for 
denaturation.  
 
Figure 2.9: Labelling, combination and precipitation of WGA products for 
aCGH 
 
Figure 2.9: a) Differentially labelled sample (blue, left) and control (red, right) DNAs prior to 
combination. b) Combined labelled and control DNA prior to co-precipitation. c) Precipitated 
labelled and control DNAs prior to resuspension. A strong purple pellet is seen on the left 
and a blue pellet on the right indicating poor labelling or precipitation. 
 
 
In order to make sure that the samples were correctly placed on the slide, the 
hybridisation template provided with the kit was used (figure 2.10a). Each array slide 
had two array areas and therefore two samples were applied on each slide. The 
22x22mm hybri-slips (Sigma, UK) were placed on each hybridisation area. Eighteen 
l of the labelled DNA were carefully applied on each hybri-slip and the array was 
lowered with the barcode facing down. The DNA was pipetted slowly on the cover 
slip in order to avoid the formation of bubbles. If any bubbles were formed the 
solution was aspirated back and returned to the tube, which was pulse centrifuged 
to remove the bubbles and the DNA was applied again on the hybri-slip. The 
position of each sample on the slide as well as the slide’s barcode was reported, as 
they were the only indicators of each sample.  
 
The 24sure array slides with the labelled DNAs were placed in a hybridisation 
chamber (figure 2.10b), which was prepared with a tissue saturated with 6ml of 
2xSSC/50% formamide (7.5ml formamide, 1.5ml 20xSSC and 6ml of dH2O). The 
chambers were tightly closed and sealed with parafilm and incubated at a 47C 
water bath for 3 to 16 hours.    
 
 
 
 
 
 
 
c) a) b) 
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Figure 2.10: aCGH with 24sure microarray slides 
 
 
Figure 2.10: a) Hybridisation template with the labelled DNA (purple drop) aliquoted on the 
cover slip before application on the array slide. b) Hybridisation chamber with the saturated 
tissue. Two ordinary microscope slides were used for the image, which were of the same 
size as a microarray slide.  
 
 
2.5.2.4 Post-hybridisation washes 
Once hybridisation was completed the slides were washed to remove any un-
hybridised DNA and dried. Two different types of washing were used. Initially, the 
slides were washed using more stringent conditions, with a formamide wash step. 
Quicker and easier steps of washes with no formamide and a high-temperature step 
were followed later on. Both methods are described in the next sections.  
2.5.2.4.1 Method 1: Formamide washes 
The solutions used for the formamide washes were: 
 1xPBS/0.05% Tween20: 1800ml dH2O, 200ml 10xPBS, 1ml Tween20 (final 
volume 2000ml) 
 2xSSC/50% formamide: 40ml 20xSSC (pH 7.0), 200ml formamide, 160ml 
dH2O (final volume 400ml) 
 1xPBS: 900ml dH2O, 100ml 10xPBS (final volume 1000ml) 
Following hybridisation the slides were moved to a 100ml Coplin jar filled with 
1xPBS/0.05% Tween20 to remove the cover slips, at room temperature (RT). They 
were removed by holding the slides at the barcode and with gentle agitation in the 
jar. With the cover slips removed the slides were then transferred to a 25-position 
steel staining rack and into a 500ml glass staining dish, containing 400ml of 
1xPBS/0.05% Tween20 and a 2.5cm magnetic stir bar. The dish was placed on a 
a) b) 
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stirrer with the lid replaced and was covered with aluminium foil to keep in the dark. 
The steps of the washes are summarised in table 2.9. 
 
 
Table 2.9: Formamide washes of hybridised array slides 
Wash Volume Temperature Time Agitation Buffer 
1 500ml RT 10min Stirrer 1xPBS/0.05% Tween20 
2 500ml RT 10min Stirrer 1xPBS/0.05% Tween20 
3 500ml RT 10min Stirrer 1xPBS/0.05% Tween20 
4 100ml 42C 30min Hand stirring 2xSSC/50% formamide 
5 500ml RT 10min Stirrer 1xPBS/0.05% Tween20 
6 500ml RT 5 min Stirrer 1xPBS 
7 500ml RT 5 min Stirrer 1xPBS 
Table 2.9: Stringent conditions of washing aCGH slides. 
 
 
The rack with the slides remained in a buffer at all times and transfer to the 
consecutive wash steps was done immediately upon completion of each wash. The 
slides on the rack were facing away from the stir bar to avoid contact of the bar with 
the arrays. Wash 4 was performed in a water bath and the Coplin jar was gently 
swirled by hand every 10 minutes. 
 
2.5.2.4.2 Method 2: Formamide-free washes 
Prior to washing the slides, the solutions were warmed to the appropriate 
temperature. These solutions were: 
 2x SSC/0.05% Tween 20: 100ml 20x SSC (pH 7.0), 899.5ml dH2O, 0.5ml 
Tween 20 (final volume: 1000ml) 
 1x SSC: 25ml 20x SSC (pH 7.0), 475ml dH2O (final volume: 500ml) 
 0.1x SSC: 5ml 20x SSC (pH 7.0), 995ml dH2O (final volume: 1000ml) 
The 0.1xSSC solution was poured in the ClearHyb (BlueGnome, UK) washing 
chamber, which was set at 60C. The temperature of the solution was checked with 
a thermometer before the start of the washes. At room temperature, 100ml of 2x 
SSC/0.05% Tween 20 were added to a 100ml Coplin jar, in which the slides were 
positioned and the cover slips were removed as described above. The washing 
steps are summarised in table 2.10.  
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Table 2.10: Formamide-free washes of hybridised array slides 
Wash Volume Temperature Time Agitation Buffer 
1 400ml RT 10 min Stirrer 
2x SSC/0.05% 
Tween 20 
2 400ml RT 10 min Stirrer 1x SSC 
3 500ml 60C 5 min 
None 
(ClearHyb) 
0.1x SSC 
4 100ml RT 1 min Stirrer 0.1x SSC 
Table 2.10:  Less stringent washing conditions of aCGH slides using the ClearHyb. 
 
Once the washes were completed the slides were dried by centrifugation. They 
were placed in 50ml Falcon tubes with the barcode at the bottom of the tube and 
spun at 1200rpm for 3 min in a benchtop centrifuge (Heraus, Labofuge 300, Thermo 
Scientific, USA). The slides were finally removed from the tubes using forceps and 
placed in a dark slide box until scanning.  
 
2.5.2.5 Scanning 
Three different scanners were used in this project for the arrays slides. The 
ScanArray Express (Perkin Elmer, UK), the InnoScan 700 (Innopsys SA, France) 
and the Agilent, High-Resolution Microarray Scanner (Agilent Technologies, UK). All 
slides were scanned at a resolution of 10m. All scanners were equipped with 
suitable lasers to excite the two different fluorescent dyes Cy3 and Cy5 at 
appropriate wavelengths 532nm and 635nm respectively. When the ScanArray 
Express scanner was used the voltage value of the photomultiplier tube (PMT) was 
adjusted manually after a quick scan of each slide. For the other two scanners the 
PMT value was adjusted automatically. Scanning produced TIFF (Tagged Image 
File Format) images of all the arrays, which were stored until the analysis. 
 
2.5.2.6 Analysis 
The scanned images of the 24sure array slides were analysed and interpreted using 
the BlueFuse Multi v2.2 (BlueGnome, UK). aCGH images of each result were 
available from this software showing the log2 ratio of the test over the control DNA 
for each chromosome. The cut-off value (threshold) of the log2 ratio for chromosome 
gains was set at 0.3 and for losses at -0.3. For the majority of the analyses 
chromosome gains and losses were considered but for the analysis of the mosaic 
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models, the average log2ratio and the standard deviation (SD) of all the clones for 
chromosome 10 were calculated. 
The software that produced the aCGH result also provided a list of values indicating 
the quality of each experiment. These indicators were checked for every experiment 
to assess its efficacy. The indicators were: 
 % of clones included: This was the percentage of clones that were 
analysable by the software. The higher the percentage the better the quality 
of the experiment. Ideally, it should have been >90%. 
 Signal to background ratio (SBR) channel 1/channel 2 (Ch1/Ch2): The signal 
to background ratio for channels 1 and 2, which represented the two 
fluorescently labelled DNAs. Channel 1, was the test DNA labelled with Cy3 
and channel 2 was the reference DNA, labelled with Cy5. An experiment 
with a signal to background ratio of one indicated similar intensities of the 
clones and the background, which resulted to poor analysis. A good 
experiment should have had a ratio over two.  
 Mean spot amplitude (MSA) Ch1/Ch2: This value gave an indication of how 
bright the clones were for each of the two channels. For an analysis to be 
successful this value should have been over 1000.  
2.5.2.7 Chromosomal classification of embryos analysed by aCGH 
Embryos from couples that had undergone PGD that were used in the aneuploidy 
study, to determine the aneuploidy level and were tested by aCGH, were 
characterised as: 
- Euploid: There was no change detected on the log2 ratio for any of the 
chromosomes. 
- Aneuploid: A gain or loss in up to two chromosomes was detected. 
- Complex aneuploid: A gain or loss in three or more chromosomes was 
detected. 
Mosaicism was not scored by aCGH, since all embryos were tubed as whole and 
therefore no individual cell assessment was performed as in FISH. 
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2.5.3 Fluorescence microscope analysis 
Analysis of chromosomes in human embryos was performed using an 
epifluorescence microscope: Olympus BX 40 (Olympus, UK). The microscope was 
equipped with a Sensys Photometrics camera for capturing of images and was 
connected with a computer running the Smartcapture software for image acquisition 
(both Digital Scientific, UK).  Nuclei were first located under the blue filter, as they 
were stained with DAPI, using the coordinates taken immediately after spreading. 
The colour of the filters was changed depending on the probes that were used and 
each nucleus was scored.  
 
The criteria used for the signal scoring where those suggested by Hopman et al 
(1988). Signals that appeared to be split were considered to be one. For signals to 
be scored as two distinct signals, the distance between them should have been at 
least the width of one. Nuclei that seemed to be covered with cytoplasm and did not 
produce clear bright signals were not considered.  
 
2.5.3.1 Chromosomal classification of embryos analysed by FISH 
The criteria that were used for the classification of the embryos from couples that 
had undergone PGD in the aneuploidy study were similar to those used by 
Mantzouratou et al (2007). Embryos were classified as: 
- Diploid: When more than 90% of cells showed no aneuploidies. 
- Aneuploid: When more than 90% of cells showed the same abnormality due 
to a meiotic error.  
- Diploid mosaic: When embryos consisted of a distinct diploid cell line, and a 
proportion of cells with one or more abnormalities (aneuploid and/or chaotic). 
- Aneuploid mosaic: When embryos had an aneuploid cell line and cell lines 
with one or more different abnormalities. 
- Chaotic: When all the nuclei examined were abnormal, carrying a variety of 
abnormalities.  
- Haploid: When all nuclei had one copy for all the chromosomes tested. 
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2.5.4 Fragment analysis of fluorescent PCR products 
FPCR products were analysed by capillary electrophoresis using the ABI Prism 310, 
3100 and 3730 genetic analysers (Applied Biosystems, UK). All reagents and 
software used for these procedures were from Applied Biosystems, UK.  
 
All genomic DNA FPCR products were diluted with nuclease free water before the 
analysis in a 1:10 dilution due to their high concentration; FPCR products amplified 
from WGA products were not diluted. The products were mixed with formamide and 
a molecular size standard to allow sizing of the peaks. Genescan-500 ROXTM size 
standard was used for the analysis in the 310 and 3100 prisms, whereas Genescan-
500 LIZTM was used for the 3730. 
 
Preparation of the products for the analysis was similar and according to the 
analyser that was used. One microliter of FPCR product was mixed with 12l of Hi-
Di formamide and 0.3l of the appropriate size standard, depending on the analyser 
used. The samples were then denatured at 95C for five minutes in a thermal cycler.  
 
Products analysed in the 310 Prism were subjected to single capillary 
electrophoresis. The conditions followed during electrophoresis were five seconds of 
injection time at 15000V in the single capillary. Separation of the fragments was 
performed at 60C for 30 minutes using the Performance Optimised Polymer 4 
(POP-6TM) and 1x Genetic Analyser Buffer with EDTA. The data were analysed 
using the Genescan software.  
 
Products analysed in the 3100 or 3730 prisms were subjected to a 16- or 96- 
capillary injection for five seconds at 1000V or five seconds at 2000V respectively. 
Separation was performed at 15000V for 24 minutes at 60C using POP-6 TM 
polymer if the 3100 was used and POP-7TM when the 3730 genetic analysed was 
used. The data from both were analysed by the Genemapper analysis software, 
version 3.5 (Applied Biosystems, UK). 
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2.5.4.1 Haplotype analysis of parental and embryo DNA for detection of 
recombination  
FPCR was used to amplify microsatellite markers on five different chromosomes to 
detect recombination on parental DNA and WGA amplified products from embryonic 
DNA. For each family (mother, father and embryos) it was essential to determine the 
segregation of the markers on the parental chromosomes correctly. Haplotype 
analysis was not possible in cases where the parents were not informative for the 
markers and heterozygosity of at least one of the markers on each locus for both 
parents was essential. The marker alleles in phase with each other were determined 
by the combination of parental alleles that resulted in the smallest recombination 
fraction in the embryos for that family. Allele drop out (ADO) was observed in some 
embryonic samples. Cases that produced a haplotype that could have been a result 
of either recombination or ADO were excluded from the analysis.  
 
2.6 Statistical analysis 
Distribution of embryos among different groups was compared using the Fisher’s 
exact test. Means were compared by t-test. StatPlus:mac LE.2009 software for 
Microsoft Excel was used for statistical analysis. When p was found to be less than 
0.05 the finding was considered to be of statistical significance. 
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3 Results 
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3.1 Validation of aCGH for clinical application 
Array comparative genomic hybridisation (aCGH) was validated as a technique to 
detect aneuploidy in embryos during preimplantation genetic screening (PGS). The 
steps that were followed for the validation were, testing aCGH primarily on single 
cells from aneuploid and euploid cell lines, for PGS after cleavage stage embryo 
biopsy of single blastomeres. This was followed by examining the effect of 
mosaicism on aCGH post biopsy of a trophectoderm (TE) sample from a blastocyst. 
This was achieved by mixing euploid and aneuploid cells in different ratios to 
produce TE and blastocyst mosaic models, which were analysed by aCGH. Prior to 
clinical application the optimum conditions to get a quick and efficient aCGH result 
were determined through a series of tests. A clinical “dry-run” of aCGH post TE 
biopsy was performed by analysing biopsied TE samples from frozen-thawed 
blastocysts from routine IVF patients and confirming the result on the remainder of 
the blastocysts. Following the application of aCGH in PGS, confirmation of the 
clinical result on cleavage stage embryos or blastocysts was carried out by FISH as 
follow up analysis on untrasferred embryos using probes for the abnormalities 
detected by aCGH.  
 
3.1.1 Analysis by aCGH 
In this section, two examples of aCGH profiles, using the 24sure by BlueGnome, UK, 
which was the platform used in this project, are provided (figure 3.1) in order to 
describe the aCGH result. The profile was provided as a graph with the X-axis 
indicating all 22 autosomes, with the sex chromosomes at the end of the axis. The 
Y-axis represented the log2 ratio of the clone fluorescence of the test over the 
reference DNA, a diploid male. Each green spot represented a clone. Spots along 
zero log2 ratio indicated that the fluorescence of the two DNA samples was the same 
and therefore there was no gain or loss of genetic material in the test. Chromosomal 
gain was detected when the log2 ratio of the clones for the chromosome was over 
the 0.3 threshold (green line) as seen for chromosome X in figure 3.1A and 
chromosome 4 in 3.1B. Chromosomal loss was detected when the ratio was below 
the -0.3 threshold (red line), shown in figure 3.1A for chromosome 18. For female 
samples, apart from the gain of chromosome X, a loss of chromosome Y needed to 
be seen as well. Since this was a nullisomy the ratio was expected to be well below 
-0.3, at around -0.8. In males the log2 ratio for both sex chromosomes was expected 
to be zero since there was no difference from the normal diploid male reference 
DNA (figure 3.1B).  
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Figure 3.1: Analysis by aCGH 
 
Figure 3.1: A: Female with loss of chromosome 18. Gain of chromosome X and loss of 
chromosome Y indicated the sex. B: Male with gain of chromosome 4. No change in the ratio 
of the sex chromosomes indicated the sex. In both profiles the thresholds for chromosomal 
gains and losses were indicated on the Y-axis. The X-axis represented all the autosomes 
and the sex chromosomes.  
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3.1.2 Description of cell lines 
Cells from ovarian epithelial cell lines were used for the validation of aCGH in PGS. 
These were the aneuploid SKOV3 and TOV-21G and euploid IOSE-1 and IOSE-19. 
Cells in all experiments were retrieved from a single passage of each of the lines in 
order to minimise cell-to-cell variation. Prior to the aCGH experiments, FISH was 
performed in order to verify the karyotype of each of the cell lines.  
 
3.1.3 FISH on cell lines to verify the karyotype 
Probes for chromosomes 13, 18, 21, X and Y were used for all the cell lines in two 
consecutive FISH rounds as described in the Materials and Methods section 2.4.2. 
An additional probe of the known aneuploidies was used in a third FISH round for 
the two aneuploid cell lines; chromosome 10 for TOV-21G and chromosome 12 for 
SKOV3. Analysis on a minimum of 50 nuclei was performed for each cell line. As 
these were all ovarian epithelial cell lines, a female sex was expected and that was 
confirmed in lines IOSE11, IOSE19 and TOV-21G on an average of 96% of cells. In 
the aneuploid cell line TOV-21G trisomy for chromosome 10 was detected in 97% of 
the nuclei. Only one copy for chromosome X was detected in 90% of the nuclei 
analysed from cell line SKOV3. This cell line carried a segmental deletion that 
included the centromere and as the probe for chromosome X was centromeric, only 
one signal was seen. A euploid result was observed for chromosomes 13, 18 and 
21 for all cell lines in an average of 98% of analysed cells. Figure 3.2 presents the 
FISH result of nuclei from the two aneuploid cell lines.  
 
Figure 3.2: FISH result of the two aneuploid cell lines, TOV21G and SKOV3 
 
Figure 3.2: TOV-21G (A): A nucleus with three copies of chromosome 10 in spectrum aqua. 
TOV-21G (B): A female nucleus diploid for chromosome 18 (spectrum green and spectrum 
aqua respectively). SKOV3 (A): Trisomy for chromosome 12 (spectrum green). SKOV3 (B): 
A nucleus with monosomy X due to a segmental deletion and diploid for chromosome 18. 
[Reprinted from Fertility and Sterility, 97 (4), Mamas et al, Detection of aneuploidy by array 
comparative genomic hybridization using cell lines to mimic a mosaic trophectoderm biopsy, 
943-947, Copyright (2012), with permission from Elsevier] 
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3.1.4 aCGH on single cells 
Isolation of single cells from the four cell lines was performed at the UCL Centre for 
PGD. WGA by GenomePlex and aCGH by 24sure was performed by BlueGnome. 
Immediately after isolation the cells were coded using random numbers. Analysis 
was done blind without prior knowledge of the origin of each cell. In total 40 single 
cells were isolated. Five cells were isolated from each of the euploid cell lines, 
IOSE-1 and IOSE-19, 18 cells from TOV-21G and 12 from SKOV-3.  
 
To assess the efficacy of WGA, all amplified samples were run on a 2% agarose gel 
prior to hybridisation on the array. Good quality amplified products were expected to 
produce a bright smear with maximum intensity at around 400 base pairs, 
corresponding to the average size of the fragments produced. WGA was successful 
for 95% (38/40) of single cells analysed (Table 3.1), as measured by the presence 
of a WGA product by electrophoresis on a 2% agarose gel. The two cells that failed 
to amplify were not analysed further. Of the 38 successful amplifications, four 
products were observed as weak by comparison of ethidium bromide staining 
intensities with other single cells after electrophoresis (Figure 3.3). These were 
included in the analysis to maximise the data.  
 
 
Figure 3.3: 2% agarose gel electrophoresis of some WGA single cell products 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: M: 100bp ladder. 1 to 10: coded WGA products from single cell samples. 
Product present in wells 1, 5, 9 and 10 were observed as weak. 
 
 
500bp 
 91 
Of the 38 successful amplification products, 92% (35/38) produced a result when 
analysed by aCGH using the 24sure platform (Table 3.1). A successful analysis was 
determined by the presence of an appropriate X and Y chromosome log2 ratio after 
cohybridisation of the WGA products of cells from the female cell lines with a male 
genomic control DNA (Figure 3.4). As described in the Results section 3.1.1, a 
female sample should have produced an X chromosome log2 ratio over the 0.3 
threshold, representing a gain and a Y chromosome log2 ratio at around -0.8, 
representing a nullisomy. The three cells that could not be analysed by aCGH had 
produced a weak smear on the agarose gel. Upon decoding of the cells, it was 
revealed that the expected result was attributed to 100% (9/9) of the normal cells, 
scored as euploid female and 100% (30/30) of abnormal cells as aneuploid. 
Examples of single cell analysis by aCGH are found in figure 3.4. Strong 
concordance of the observed abnormalities was seen amongst the aCGH results of 
each abnormal cell line. Cells from TOV-21G showed no variability and all showed 
the expected gain of chromosome 10. Each SKOV-3 cell displayed the gain of 
chromosome 12, whilst 91% (10/11) also carried the large segmental loss of 
material between the terminus of the short arm of chromosome X and Xq21.3. 
 
 
 
Table 3.1: aCGH result of the single cell analysis. The number of cells that did not 
produce a WGA or an aCGH result is indicated.  
 
 
 
 
 
 
 
Table 3.1: Single cells used for the validation of aCGH 
CELL LINE EUPLOID ANEUPLOID NO AMPLIFICATION NO Y 
CHROMOSOME 
RATIO 
SUM 
IOSE-11  4 0 0 1 5 
IOSE-19  5 0 0 0 5 
TOV-21G 
 
0 15 2 1 18 
SKOV-3  0 11 0 1 12 
TOTAL 9 26 2 3 40 
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Figure 3.4: Examples of aCGH outcome on single cells 
 
 
Figure 3.4: A+F: Example of cells from each of the euploid cell lines IOSE-11 and IOSE-19. 
B: SKOV-3 cell line (aneuploid, gain of chromosome 12 and loss of Xpter to Xq21.3). C: 
TOV-21G cell line (aneuploid, gain of chromosome 10). G: Zoom in for X chromosome of an 
SKOV-3 cell, displaying the segmental deletion between the terminus of Xq to Xq21.3. H: 
Zoom in for X chromosome of a euploid IOSE-11 cell where no segmental changes were 
seen.  
 
3.1.5 aCGH on mosaic trophectoderm and blastocyst models 
From the FISH and aCGH results on single cells from each cell line it was shown 
that TOV-21G was the most stable amongst the two aneuploid lines. For this reason 
it was selected to prepare the mosaic models along with the IOSE-19 euploid line. 
As described in the Material and Methods section 2.3.1.3, 24 mixed cell samples 
were prepared, 14 representing mosaic TE models with a total of eight cells each 
and 10 blastocyst models with a total of 100 cells each. Seven TE samples were 
prepared containing different ratios of aneuploid cells ranging from 0 to 100% in 
duplicates (TE group A and TE group B). Similarly, five blastocysts samples were 
prepared again in duplicates (Blastocyst group A and Blastocyst group B). All 
samples were amplified using the Sureplex WGA kit (BlueGnome, UK) and showed 
a bright smear on the agarose gel and all produced an interpretable aCGH result. In 
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order to determine the effect of mosaicism on aCGH the average log2 ratios of the 
sample to control DNA of the clones for chromosome 10 were calculated.  
 
Theoretically, the log2 ratio should have increased as the proportion of aneuploid 
cells in the sample increased. Variation in the ratios among the clones for 
chromosomes 10 was represented by the SD. Low SD values indicated that the 
values of the clones were similar. SD also indicated the quality of the array. Low SD 
indicated a good quality result with low experimental noise. The percentage of the 
clones included was also noted as a quality indicator of the array experiments. This 
also acted as a means of comparison between the analysis of a small (eight) and 
large (100) number of cells in the starting material. The values of the average ratios 
for all samples are found in table 3.2 and figure 3.5 presents graphs with the log2 
ratio of all the samples.  
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Table 3.2: The log2 ratios of the mosaic samples prepared for aCGH analysis. The 
average log2 ratios along with the standard deviation (SD) for the clones on chromosome 10 
as well as the clones included in the analysis of each aCGH experiment for all the TE and 
blastocyst models are shown.  
Table 3.2: Log2 ratios for chromosome 10 of the mixed samples 
8-cell samples (TE) 
Sample: 
euploid/aneuploid 
(% aneuploid cells) 
 Average log2 
ratio 
±SD Clones 
included (%) 
1: 8/0 
(0) 
A -0.13 0.11 91.64 
B -0.21 0.15 88.63 
2: 6/2 
(25) 
A 0.03 0.09 90.46 
B 0.15 0.12 64.38 
3: 5/3 
(37.5) 
A 0.10 0.11 89.48 
B 0.22 0.10 90.89 
4: 4/4 
(50) 
A 0.28 0.09 89.14 
B 0.29 0.08 68.47 
5: 3/5 
(62.5) 
A 0.25 0.08 96.66 
B 0.33 0.12 73.19 
6: 2/6 
(75) 
 
 
 
( 
A 0.28 0.14 79.09 
B 0.37 0.12 69.34 
7: 0/8 
(100) 
A 0.34 0.09 88.30 
B 0.38 0.12 64.72 
100-cell samples (Blastocyst) 
8: 100/0 
(0) 
A -0.10 0.11 94.30 
B -0.02 0.07 74.97 
9: 75/25 
(25) 
A 0.11 0.08 72.58 
B 0.32 0.08 79.80 
10: 50/50 
(50) 
A 0.34 0.10 63.98 
B 0.40 0.08 75.89 
11: 25/75 
(75) 
A 0.32 0.10 87.69 
B 0.40 0.13 63.54 
12: 0/100 
(100) 
A 0.42 0.10 96.63 
B 0.32 0.09 67.69 
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Figure 3.5: Shift of the log2 ratio in mosaic samples of clones on chromosome 
10 
 
Figure 3.5: For the 8-cell samples (A) a shift from normality was detected even when the 
proportion of aneuploid cells was 25%. A gain was detected when the proportion of 
aneuploid cells were over 50%. For the 100-cell samples (B) a clear increase of the ratio 
was observed even at a proportion of 25% with clear gain detected at and above 50% of 
aneuploid cells [Reprinted from Fertility and Sterility, 97 (4), Mamas et al, Detection of 
aneuploidy by array comparative genomic hybridization using cell lines to mimic a mosaic 
trophectoderm biopsy, 943-947, Copyright (2012), with permission from Elsevier]. 
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An increasing trend of the ratio was observed for all samples when the number of 
aneuploid cells increased. The cut-off value for a chromosomal gain was determined 
by the BlueFuse Multi software at 0.3 ratio. For the TE models, the log2 ratio ranged 
from -0.21 for 0% aneuploid cell to 0.38 for 100% aneuploid cells. Although an 
increase was observed in both groups, there were some differences between them. 
All samples of the TE group B showed a higher value than the samples of TE group 
A apart from the 0% aneuploid cells samples. This could be attributed to variation 
within the cells and/or inclusion of anucleate cells. The ±SD of the samples also 
varied and reached up to 0.15 for one of the samples including 0% of aneuploid 
cells probably due to experimental noise of the aCGH. Both samples with 50% 
aneuploid cells had log2 ratios close to the 0.3 threshold (0.28 and 0.29). All 
samples with more than 50% aneuploid cells were over the threshold with the 
exception of one of the two samples with 62.5% and 75% aneuploid cells. Figure 3.6 
presents examples of four mosaic TE models with 0, 25, 50 and 100% aneuploid 
cells.  
 
Figure 3.6: Examples of aCGH outcome of TE mosaic models 
 
Figure 3.6: A: Sample containing no aneuploid cells, showing a euploid 46,XX result. B: 
Sample containing 25% aneuploid cells, in which a small shift in the ratio towards a gain is 
observed. C: 50% aneuploid cells and the ratio is on the 0.3 threshold. D: Cells containing 
only aneuploid cells. The ratio is higher than the threshold. [Reprinted from Fertility and 
Sterility, 97 (4), Mamas et al, Detection of aneuploidy by array comparative genomic 
hybridization using cell lines to mimic a mosaic trophectoderm biopsy, 943-947, Copyright 
(2012), with permission from Elsevier] 
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For the blastocyst model, both samples containing no aneuploid cells were below 
the threshold. For the two samples containing 25% cells one was below the 
threshold, whereas the repeat showed a high value of 0.32. All samples containing 
50%, 75% and 100% aneuploid cells had log2 ratios ranging from 0.32 to 0.40. The 
standard deviation for this set was lower than the TE models ranging from 0.08 to 
0.1, representing lower experimental noise in the aCGH result. Generally, an 
increasing trend was seen in the samples of the Blastocyst group A, with, however, 
the log2 ratio of the sample with 50% aneuploid cells being higher than the sample 
containing 75%. A rapid increase was observed in the samples of the Blastocyst 
group B between the completely normal sample and that containing 25% of 
aneuploid cells and finally a small decrease in the log2 ratio of the completely 
abnormal sample when compared to that containing 75% of aneuploid cells.  
 
When observing the clones included for each aCGH experiment it was noted that 
that the average of clones included for the 8-cell sample groups was 81.74 (range: 
64.38 – 96.66) and for the 100-cell sample groups, 77.71 (range: 63.54 – 96.63). 
Although not statistically significant (t-test, p=0.40) the clones included in the 
analysis of 100 cells was lower. This might be due to poor amplification resulting 
from the high volume of PBS in the starting material following the isolation of 100 
cells in the same tube. 
 
3.1.6 aCGH experimental quality 
As described in the Materials and Methods section 2.5.2.6 during the analysis of the 
aCGH result, the software provided indicators for the quality of each experiment. 
These were the percentage of the clones included, the signal to background ratio 
(SBR) and the mean spot amplitude (MSA). The ideal values of these indicators in 
an efficient experiment were >90% clone inclusion, an SBR of over two and an MSA 
of over 1000. In the following sections a series of tests to decrease the experimental 
time and increase the efficacy of aCGH are described. Comparison of the tests was 
performed using these indicators. 
 
As described by the manufacturer, the labelling and hybridisation times could vary 
between two to 18 and three to 16 hours respectively. In a clinical PGS setting the 
time of diagnosis is critical and ideally a result should be reached as soon as 
possible. A series of tests were performed to identify the quickest and most efficient 
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combination of labelling and hybridisation. This was done first by labelling the same 
whole genome amplified sample twice, for three hours and then hybridising one 
labelled product for three hours and the other for 16 hours. The sample that was run 
was a whole untransferred embryo, which was found to be aneuploid post PGS. 
Reanalysis of the embryo showed a loss of chromosome 10. The aCGH profiles as 
well as the values of the indicators for both samples are found in figure 3.7 (A+B). 
The MSA and SBR for both experiments were at acceptable levels and showed 
small differences. The percentage of the clones analysed, however, was much 
lower after hybridisation for three hours (56%) when compared to the 16-hour 
hybridisation (75%).  
 
Figure 3.7: Long and short hybridisation 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: The same whole genome amplified sample was labelled twice. One labelled 
product was hybridised for three hours (A) and the other for 16 hours (B).  
 
The next set of experiments tested short and long labelling times and their effects 
on the aCGH result. Again the same whole genome amplified sample, this time a 
single blastomere, was labelled for three and 18 hours. The two samples were then 
hybridised for three hours. A short hybridisation time was preferred over the long 16-
hour one in order to reduce the overall time of the experiment. The single cell was 
found to be highly aneuploid, showing a shift in almost all the chromosomes (figure 
3.8A+B). The values of the indicators of the sample labelled and hybridised for three 
hours were comparable to the whole embryo, which was subjected to the same 
labelling and hybridisation times described above. On the other hand, the sample 
that was labelled for 18 hours showed very satisfactory values. The percentage of 
A 
B 
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the clones analysed was ideal, 95%. Similarly, the MSA and SBR values were both 
very high. The combination of a long labelling with a short hybridisation was shown 
to be the most appropriate to use during a PGS case when time for achieving a 
good result is critical.  
 
Figure 3.8: Long and short labelling 
Figure 3.8: The same whole genome amplified sample was labelled once for three hours (A) 
and once for 18 hours (B). Both samples were hybridised for three hours.  
 
3.1.7 aCGH on trophectoderm samples biopsied from frozen-
thawed blastocysts 
Trophectoderm (TE) was biopsied from four thawed blastocysts, to further validate 
the ability to detect chromosomal imbalance by aCGH post blastocyst biopsy. This 
also acted as a “dry-run” of a clinical PGS case, in which aCGH was going to be 
used for the analysis. Four blastocysts, which were donated to research, from 
routine IVF patients, were thawed and TE biopsy was performed by the 
embryologists. The biopsied TE cells and their corresponding blastocysts were run 
on 24sure arrays. aCGH was successful in all samples, confirmed by smears on an 
agarose gel. As seen in figure 3.9 smears for all the samples were more intense at 
around 400bp, the average size of fragments produced by SurePlex. The TE 
A 
B 
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samples (wells 1 to 4) were not as bright as the remainder of the blastocyst (wells 5 
to 8) since the starting material was less.  
 
Figure 3.9: Agarose gel electrophoresis of biopsied TE and remainder of 
blastocysts 
 
Figure 3.9: M: 100bp molecular weight marker, indicating the 500bp band used for 
comparison with the bright intensities of the smears at around 400bp. Wells 1-4: Amplified 
biopsied TE samples. Wells 5-8: Amplified blastocysts.  
 
 
Validation was performed by first confirming the sex of the embryo seen in TE cells 
in the remainder of the blastocysts and then by any aneuploidies that were detected. 
Embryos A and B were found to be euploid female and male, respectively, after TE 
analysis, which was confirmed in the blastocysts. Embryo C was a male showing a 
loss for chromosome 21 in both samples. Finally, embryo D showed a shift in the 
log2 ratio for both the sex chromosomes away from zero indicating a possible female 
sample. However, this was not comparable to the dynamic change in ratio between 
the sex chromosomes that was expected in a female sample (around 0.3 for 
chromosome X and -0.8 for Y) but was equally reduced, thus indicating a possible 
69,XXY triploid sample. Figure 3.10 presents the TE and blastocyst results of the 
embryos analysed. 
 
 
 
M 1 6 5 2 4 7 3 8 
500 bp 
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Figure 3.10: Trophectoderm and blastocysts aCGH profiles 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: Trophectoderm samples are presented on the left and blastocyst samples on 
the right of the figure. Embryos A and B were shown to be euploid female and male 
respectively. Embryo C was male with a loss of chromosome 21. Embryo D was 69,XXY as 
determined by the smaller ratio change between the sex chromosomes.  
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3.1.8 FISH confirmation of abnormalities detected by aCGH in 
PGS  
In order to complete the validation of aCGH, FISH was performed as follow up 
analysis of embryos that were first clinically analysed by aCGH during PGS. Probes 
were selected according to the abnormalities detected during the case to confirm 
their presence in the whole embryo. Follow-up was performed on two embryos from 
two cases of PGS on TE biopsied samples and six embryos from three cases of 
PGS after biopsy of single blastomeres from cleavage stage embryos. Table 3.3 
presents the results of the FISH follow-up for all embryos.    
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Table 3.3: Results of the follow-up by FISH after PGS using aCGH. The type of biopsy used for each embryo, the aCGH result, morphology on 
day five, the number of nuclei analysed by FISH as well as the FISH result are indicated. 
Table 3.3: FISH follow-up analysis of embryos analysed by aCGH for PGS 
Couple Embryo Biopsy aCGH result 
Day 5 
morphology 
No of 
nuclei 
analysed 
FISH result 
A1 A1.1 Blastocyst 45,XY,-14 Blastocyst 51 
67% nuclei disomy 14 
33% nuclei monosomy 14 
A2 A2.1 Blastocyst 48,XY,+1q22-qter,+4,+5 Blastocyst 34 
85% nuclei trisomy 5 
57% nuclei trisomy 4 
88% nuclei trisomy 1q 
Remaining nuclei disomy for all chromosomes 
A3 
A3.1 Cleavage 44,XY,-6,-18 Morula 36 
88% nuclei monosomy 18 
12% nuclei disomy 18 
A3.2 Cleavage 51,XX,+2,+8,+12,+15,+18 Morula 7 Chromosome 18: 57% trisomy, 43% disomy 
A4 
A4.1 Cleavage 46,XY Morula 58 
57.4% nuclei disomy for chromosomes 13, 15, 
18, 21 and 22 
Remaining nuclei chaotic 
A4.2 Cleavage 44,XY,-15,-21 Morula 35 
Chromosome 21: 33% monosomy, 54% disomy 
Chromosome 15: 24% monosomy, 29% disomy, 
35% trisomy 
A5 
A5.1 Cleavage 45,XX,-21 Morula 43 Chromosome 21: 76% monosomy, rest disomy 
A5.2 Cleavage 45,XY,-17 Arrested 5 All nuclei showed monosomy 17 
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Embryos from couples A1 and A2 were biopsied at the blastocyst stage, during 
which six to ten cells were removed from the trophectoderm. For embryo A1.1 
(figure 3.11 A) a shift was observed in the ratio of chromosome 14 towards a loss. 
The average log2 ratio for that chromosome was -0.20 (±0.06), indicating mosaicism. 
Indeed, FISH with a telomeric probe on the q arm of chromosome 14 revealed that 
in the whole of the embryo only 33% of the nuclei showed monosomy with the rest 
(67%) being diploid for that chromosome.  
 
Embryo A2.1 (figure 3.11 B) presented a shift in the ratio in the long arm from 
chromosome 1, from 1q22 to the terminus. The average ratio observed was 0.24 
(±0.05) showing a mosaic gain. FISH, however, showed that 88% of the nuclei in 
the whole embryo carried that aneuploidy, a high percentage of cells, which if that 
was the same in the TE sample, it should have resulted in a higher shift of the log2 
ratio. In the same embryo chromosome 4 had an average ratio of 0.18 (±0.07) and 
only 57% of the analysed nuclei by FISH showed trisomy for that chromosome. The 
third abnormality detected in this embryo was a gain of chromosome 5 with the 
highest ratio amongst the affected chromosomes of 0.28 (±0.05). Trisomy for 
chromosome 5 was seen in 85% of the nuclei in the whole embryo.   
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Figure 3.11: FISH follow-up of PGS after blastocyst biopsy 
Figure 3.11: A: Embryo A1.1. aCGH showed a shift towards a loss for chromosome 14. 
FISH showed 67% of the nuclei being diploid and the rest carrying monosomy 14. B: Embryo 
2.1. aCGH showed a segmental gain of 1q22 to the q terminus, 4 and 5. The nucleus on the 
right showed trisomy for chromosome 5. 
 
PGS on single blastomeres biopsied from cleavage stage embryos was performed 
for couples A3, A4 and A5. Mosaicism in the biopsied sample was not an issue for 
these diagnoses, since only one cell was analysed. Mosaicism in the embryo 
however was very critical since the biopsied cell might have not represented the 
chromosomal status of the whole embryo.  FISH to check only chromosome 18 was 
performed in the embryos of couple A3, which were both morulae on day five, due 
to unavailability of the rest of the probes. Embryo A3.1 showed loss for that 
chromosome and it was confirmed in 88% of the nuclei. Embryo A3.2 showed gain 
for 18, detected upon follow-up in 57% of the nuclei.  
 
Embryo A4.1 was found to be euploid by aCGH but was not transferred as the 
couple had a surplus of normal embryos and was not of good quality. It reached the 
blastocyst stage on day five and FISH with probes for five chromosomes revealed 
that 57.4% of the nuclei were diploid for these chromosomes, whereas the rest 
showed a chaotic chromosomal complement. The second embryo of this couple 
showed loss for chromosomes 15 and 21. FISH revealed 24% monosomic, 35% 
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trisomic and 29% diploid nuclei for chromosome 15 with the rest showed a low level 
of chaoticism. The presence of both monosomic and trisomic nuclei revealed that 
mitotic non-disjunction occurred in the embryo for that chromosome. The loss of 
chromosome 21 was confirmed in only 33% of the nuclei, 54% were diploid and the 
rest showed different abnormalities.  
 
Loss of the same chromosome was also confirmed in 76% of the nuclei of embryo 
A5.1 (figure 3.12 A). All the nuclei analysed from embryo A5.2 (figure 3.12 B) 
showed a loss for chromosome 17, which was detected by aCGH. However, this 
was an arrested at cleavage stage embryo and only five nuclei were analysed.  
 
Figure 3.12: FISH follow-up of PGS after cleavage stage biopsy 
Figure 3.12: A: Embryo A5.1. aCGH showed a loss for chromosome 21. Probes for 
chromosomes 13, 17 and 21 were used. Monosomy 21 is seen in spectrum orange. 
B: A5.2. The loss of chromosome 17 was confirmed by FISH in spectrum aqua in all 
nuclei analysed from that arrested embryo. 
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3.1.9 Summary of results for section 3.1: aCGH validation for 
clinical application 
 
 The chromosomal status of single cells was successfully analysed by aCGH. 
Euploidy and known aneuploidies were identified in cells from euploid and 
aneuploid cell lines with a 100% concordance. 
 The effect of mosaicism in the aCGH result was made apparent with the 
analysis of mosaic TE and blastocyst models. A shift from normality was 
observed when 25% of aneuploid cells were present in a sample and at 50% 
of aneuploid cells the ratio reached the abnormality threshold. 
 A series of tests showed that long labelling for 18 hours with a short, three-
hour hybridisation provided the best and quickest aCGH result.  
 Concordance in the chromosomal analysis by aCGH was also observed 
between biopsied TE samples and the remainder of their corresponding 
blastocysts. 
 Confirmation on whole embryos of the aCGH result after PGS on cleavage 
stage embryos and blastocysts by FISH revealed that abnormalities detected 
by aCGH did not always represent the chromosomal status of the embryo 
mainly due to mosaicism. 
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3.2 Aneuploidy in embryos from couples undergoing PGD 
The level of aneuploidy was examined in embryos from couples undergoing PGD by 
FISH and aCGH. These were couples of young age with no known fertility problems, 
seeking IVF only for the purpose to perform PGD. This analysis highlighted 
differences in the limitations between the two techniques when applied to 
investigate the chromosome number. Mechanisms that lead to aneuploidy were also 
considered, especially after FISH analysis. Finally, the level of aneuploidy in 
embryos from couples undergoing PGD that were considered fertile, was compared 
with that in embryos from couples undergoing PGS. Couples performing PGS cycles 
were infertile with increased chances of aneuploidy in their embryos.  
 
3.2.1 Patient description 
FISH analysis was performed on 86 embryos (PGD-FISH group) from 19 couples 
that went though 24 cycles of PGD. The average female age was 32.5 (4.2) and 
the average male age was 34.9 (5.4). aCGH was used to analyse 53 embryos 
(PGD-aCGH group) from six couples that underwent nine PGD cycles. The average 
female age for this group of couples was 31.5 (4), whereas the male age was 33.3 
(4.3). The indication for PGD in both groups were mutations in genes causing a 
variety of monogenic disorders, namely Myotonic Dystrophy type 1 (DM1, gene: 
DMPK), Familial Adenomatous Polyposis (FAP, gene: APC), breast-ovarian cancer-
1 (BROVCA1, gene: BRCA1), Neurofibromatosis type 1 (NF1, gene: NF1), Crouzon 
syndrome (gene: FGFR2) and non-syndromic deafness (gene: Cx26). Of all couples 
analysed, only one presented fertility issues, through a poor ovarian reserve test 
(ORT) probably due to advanced maternal age. Five had previous pregnancies that 
were either terminated due to the presence of the mutation in prenatal diagnosis, or 
resulted in the birth of unaffected children. The rest had no children. Tables 3.4, 
provides the couple information for the PGD-FISH and PGD-aCGH groups.  
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Table 3.4: Information on couples from PGD cycles with embryo chromosomal analyses 
 
PGD-FISH group 
Couple 
ID 
FA MA Reproductive 
history 
Disease No of 
cycles 
No of 
embryos 
B1 33 41 No children Crouzon 1 1 
B2 31 34 No children NF1 2 9 
B3 32 29 No children FAP 1 4 
B4 34 36 1 TOP DM1 1 2 
B5 35 36 1 child          
+2 TOP 
DM1 1 1 
B6 31 38 No children DM1 1 3 
B7 38 36 Poor ORT DM1 3 5 
B8 39 42 1 m/c DM1 1 6 
B9 30 31 No children DM1 2 3 
B10 27 28 No children BROVCA1 1 5 
B11 30 31 1 child          
+1 TOP 
FAP 1 6 
B12 35 38 No children DM1 1 1 
B13 27 25 No children BROVCA1 2 11 
B14 30 38 1 child FAP 1 4 
B15 40 47 1 child Deafness 1 3 
B16 29 37 1 m/c FAP 1 1 
B17 36 32 No children DM1 1 3 
B18 35 36 No children Crouzon 1 9 
B19 25 29 No children DM1 1 9 
Average 32.5 (4.2) 34.9 (5.4)  Total 24 86 
PGD-aCGH group 
Couple 
ID 
FA MA Reproductive 
history 
Disease No of 
cycles 
No of 
embryos 
B20 28 29 No children FAP 1 8 
B21 27 27 No children NF1 1 8 
B22 33 34 No children DM1 3 11 
B23 36 36 No children NF1 1 2 
B24 29 37 No children FAP 1 2 
B25 36 37 No children NF1 2 22 
Average 31.5 (4) 33.3 (4.3)  Total 9 53 
Table 3.4: Couples of the PGD-FISH and –aCGH groups. For each couple the female and 
male age, reproductive history, the genetic disorder diagnosed by PGD, the number of PGD 
cycles after which FISH or aCGH follow up analysis was performed as well the number of 
embryos analysed are indicated. FA: Female Age, MA: male age. TOP: Termination of 
pregnancy. ORT: Ovarian reserve test. m/c: miscarriage 
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3.2.2 Results from embryos analysed by FISH 
The Aneuvision kit was used for all the embryos, for the analysis of chromosomes 
13, 18, 21, X and Y in two FISH rounds. An interpretable result was obtained from 
66 (82.5%) of the 86 embryos. Figure 3.13 shows an example of two nuclei that 
were found to be diploid for all chromosomes on both rounds (A+C), one example of 
a nucleus that showed monosomy for chromosome 13 (B) and finally a male 
nucleus with monosomy 18 (D). 
 
 
Figure 3.13: Blastomere nuclei hubridised with fluorescent probes 
 
Figure 3.13: A) Nucleus diploid for chromosome 13 (green) and 21 (orange). B) Nucleus 
with monosomy for chromosome 13. C) Female nucleus (X chromosome is hybridised with a 
green fluorescent probe) diploid for chromosome 18 (aqua). D) Male nucleus (one green 
signal for X and one orange for chromosome Y) with monosomy 18.   
 
 
 
 
 111 
A detailed classification of the embryos is described in the Material and Methods 
section 2.5.3.1. Briefly, embryos consisting of uniform cell lines were diploid, 
aneuploid or haploid, when 90% of cells were normal, carried the same 
chromosomal aneuploidies or had one copy of all the chromosomes tested 
respectively. Mosaic embryos consisted of different cell lines. Chaotic were those 
embryos in which each cell had a different chromosomal complement. Table 3.5 and 
figure 3.14 present the overall FISH results of all the embryos analysed. The most 
predominant classification amongst the embryos was diploid/chaotic mosaic (41%). 
Of these only two had less than 50% diploid cells. All the diploid/aneuploid/chaotic 
mosaic embryos had more than 50% cells that were diploid. The detailed results for 
each embryo chromosomal classification, along with the developmental stage, 
number of pronuclei, the number of nuclei analysed in each round and the number 
of diploid nuclei seen are found in table 6.1 of Appendix A.  
 
 
Table 3.5: Chromosomal status of embryos in the PGD-FISH group. The number and 
percentages of embryos with each chromosomal complement are indicated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.5: Chromosomal classification of embryos analysed by FISH 
Number of embryos with a result 66/86 (82.5%) 
Diploid 12 (18%) 
Haploid 3 (5%) 
Aneuploid 4 (6%) 
Diploid/chaotic mosaic 27 (41%) 
Diploid/aneuploid/chaotic mosaic 6 (9%) 
Aneuploid/chaotic mosaic 8 (12%) 
Chaotic 6 (9%) 
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Figure 3.14: Percentages of the different chromosomal classifications 
identified by FISH in embryos from PGD cycles 
 
 
Figure 3.14: Diploid/chaotic and diploid/aneuploid/chaotic mosaic embryos were grouped as 
diploid mosaics representing 50% of the embryos analysed.  
 
3.2.2.1 Chromosomal status of abnormally fertilised embryos 
 
Among the 86 embryos analysed, 13 were scored as abnormally fertilised 16 to 20 
hours post insemination due to abnormal number of pronuclei (PN). No pronuclei 
were seen in nine embryos (0PN) and three in four embryos (3PN). Table 3.6 
presents the results of the FISH analysis for this small group of embryos. Both 
embryos with 3PN that produced a result had a diploid cell line. Of the seven 0PN 
embryos that gave a result, 3 were diploid/chaotic mosaic, one was haploid, two 
were chaotic and one was aneuploid/chaotic mosaic, which showed chromosome 
gain for chromosome 13. A deviation from the expected number of pronuclei post 
insemination might have been due to abnormal fertilisation but also due to the fact 
that embryologists had missed the normal two-pronuclei status. The absence of 
pronuclei might also have been due to delay of pronuclei appearance and the 
presence of three pronuclei might have been due to accelerated development of the 
embryo. For this reason, results of abnormally fertilised embryos are reported here 
separately, but they were included in the overall results of all embryos.  
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Table 3.6: Chromosomal classification of abnormally fertilised embryos 
Number of abnormally fertilised 
embryos with a result 
9/13 (69%)  
0PN embryos with a result 7 
Haploid 1 
Chaotic 2 
Diploid/chaotic mosaic 3 
Aneuploid/chaotic mosaic 1 
3PN embryos with a result 2 
Diploid 1 
Diploid/chaotic mosaic  1 
Table 3.6: Chromosomal status of abnormally fertilised embryos in the PGD-FISH 
group.  
 
3.2.3 Results of embryos analysed by aCGH 
aCGH was used to analyse the total chromosomal complement of 53 embryos. The 
24sure microarray platform (BlueGnome, UK) was used. A result was obtained from 
52 embryos (98%). The classification of the embryos according to their chromosome 
status was different to that of embryos analysed by FISH due to the differences 
between the two techniques. Contrary to FISH, where each cell was scored 
individually, in aCGH a cumulative result of all the cells in each embryo was 
obtained. Therefore, it was not possible to score mosaicism with the level of detail 
that is possible in FISH.  
 
The log2 ratio of the fluorescence of the male reference DNA over the sample DNA 
for each chromosome was given after analysis of the array by the BlueFuse Multi 
software. Clear gains and losses should have resulted in log2 ratios that were above 
the 0.3 and below the -0.3 thresholds respectively. However, mosaicism in the form 
of diploid and aneuploid cells in the same sample could have altered these ratios. 
As shown in the Results section 3.1.5 that describes the mixing of euploid and 
aneuploid cells to mimic trophectoderm samples and whole blastocysts, a mosaic 
sample that consisted >50% of aneuploid cells, was represented by a log2 ratio 
above the threshold. Representation of mosaicism in aCGH was also confirmed 
when FISH follow-up was used to confirm the aCGH as described in section 3.1.8. 
On the other hand, errors that were caused by mitotic non-disjunction in a mosaic 
sample could not be detected by aCGH as the presence of reciprocal gains and 
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losses would not alter the log2 ratio. Moreover, one of the consequences of bad 
experimental quality is the reduction of the shift of the log2 ratio of an aneuploidy. 
Detailed analysis of mosaicism by aCGH is only possible after embryo 
disaggregation and separate analysis of each individual blastomere. Since all 
embryos, in this study were tubed whole, no attempt was made to score mosaicism. 
Chromosomal gains and losses were considered when there was a deviation from 
zero for the majority of the clones for each chromosome.  
 
Embryos were characterised as euploid when there was no deviation from zero for 
any of the chromosomes. Aneuploid were those with a gain or loss for up to two 
chromosomes and complex aneuploid were those where three or more 
chromosomes were affected. Figure 3.15 shows four examples of aCGH profiles of 
euploid, aneuploid and complex aneuploid embryos.  
 
Figure 3.15: aCGH profiles of embryos 
 
Figure 3.15: A) A euploid male embryo, B) an aneuploid embryo with a gain of chromosome 
X, C) an aneuploid embryo with gain of chromosome 4 and loss of chromosome 16 and D) a 
complex aneuploid embryo with gain of chromosomes 7, 9, 13, loss of chromosomes 2, 3, 
11, 16, 17, 18, 19 and 20, partial gain of 5q arm and partial loss of 6q and 12p arms.  
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The detailed results for each embryo, the number of pronuclei, developmental stage, 
chromosomal classification and complement are found in table 7.1 of Appendix B. 
As seen in table 3.7 and figure 3.16, 38% of embryos analysed by aCGH were 
found to be euploid, whereas 37% were aneuploid. Twenty five per cent of embryos 
carried abnormalities affecting more than three chromosomes and were 
characterised as complex aneuploid.  
 
 
Table 3.7: Chromosomal classification of embryos analysed by aCGH 
Number of embryos with a result 52/53 
Euploid 20 (38%) 
Aneuploid 19 (37%) 
Complex aneuploid 13 (25%) 
Table 3.7: Chromosomal status of embryos in the PGD-aCGH group. The number and 
percentages of embryos with each chromosomal complement are indicated.  
 
Figure 3.16: Percentage of the different chromosomal classifications in 
embryos from PGD cycles analysed by aCGH 
 
 
Figure 3.16: Euploid embryos showed no abnormalities, aneuploid embryos carried 
abnormalities affecting one or two chromosomes and complex aneuploid embryos carried 
three or more affected chromosomes.  
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3.2.4 Chromosomal status and development 
All embryos with chromosomal analysis in this section were untrasferred embryos 
from PGD cycles on day five or six of development. They were arrested at cleavage 
stage, morulae or blastocysts. Of the 86 embryos analysed by FISH, 36 were 
arrested at cleavage stage, 33 were morulae and 17 were blastocysts. Of the 53 
embryos analysed by aCGH, 18 were arrested, 20 morulae and 15 blastocysts. 
Figure 3.17 presents the chromosomal status of embryos at different developmental 
stages analysed by FISH (3.17A) or aCGH (3.17.B). All blastocysts analysed by 
FISH were found to be diploid mosaic. Diploid, aneuploid, diploid mosaic and 
aneuploid mosaic morulae were seen, however the distribution of diploid mosaic 
morulae was significantly higher than any other chromosomal type within that group 
of embryos (p<0.05, Fisher’s exact test). All chromosomal classifications were seen 
within the arrested embryos, apart from diploid mosaic. It is important to note that all 
chaotic and haploid embryos had arrested at the cleavage stage.  
 
All three different chromosomal classifications were seen among all embryos 
analysed by aCGH. Some differences were noted among the distribution of embryos 
in the chromosomal classifications. Euploid blastocysts were significantly more than 
complex aneuploid, aneuploid morulae were significantly more than aneuploid 
arrested and blastocysts and finally, complex aneuploid arrested embryos were 
significantly more than complex aneuploid blastocysts (all p<0.05, Fisher’s exact 
test).  
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Figure 3.17: Grouping of embryos from PGD cycles according to 
chromosomal status and developmental stage 
Figure 3.17: A) Distribution of embryos analysed by FISH, B) distribution of embryos 
analysed by aCGH.   
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3.2.5 Chromosomal status and female age 
Despite the fact that the average female age in both groups was relatively low (32.5 
and 31.5 for the PGD-FISH and -aCGH groups respectively) the age among the 
females ranged from 27 to 40 in the PGD-FISH group and 27 to 36 in PGD-aCGH 
group. In order to investigate any possible effect of maternal age in the embryonic 
chromosomal status, the embryos were categorised in two sub-groups. The first was 
of women who were 27 to 34 years old and the second was of women who were 35 
years or above. Tables 3.8 and 3.9 show the distribution of embryos according to 
their chromosomal status in the two age sub-groups in the PGD-FISH and PGD-
aCGH groups respectively. When comparing the two age groups the only significant 
difference was noted in the number of diploid embryos, which was higher in the 
older age sub-group of the PGD-FISH group. On the other hand, the percentage of 
diploid and aneuploid mosaic embryos was higher in younger women, haploid 
embryos were only seen in this group and the rest of the classifications occurred in 
similar numbers in both age groups. In the PGD-aCGH group no significant 
differences were noted, nevertheless, euploid and aneuploid embryos were more 
common in the younger group but complex aneuploid embryos occured at a higher 
percentage in the older group. 
 
When examining the developmental stage of the embryos in addition to the age and 
the chromosomal status no significant differences were observed. As seen in the 
graphs of figure 3.18, in the PGD-FISH group arrested embryos were more evenly 
distributed in all chromosomal classifications in younger women, whereas in older 
the majority of arrested embryos were diploid. Similarly in the PGD-aCGH group no 
significant differences were seen, however in the younger group among the euploid 
embryos none of them were arrested, whereas in the older group the total number 
of euploid arrested embryos was higher than the sum of the euploid morulae and 
the blastocysts.  
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Table 3.8: Distribution of embryos analysed by FISH according to chromosomal status 
in young and older women. The p value was calculated by the Fisher’s exact test. *The 
only significance was seen for the diploid embryos, which were more in the older age group.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.9: Distribution of embryos analysed by aCGH according to chromosomal 
status in young and older women. No statistical significance was observed between the 
two age groups.  
Table 3.8: Chromosomal status and age in the PGD-
FISH group 
 27-34 years ≥35 years p value 
Diploid 3/44 (7%) 9/22 (41%) 0.0015* 
Haploid 3/44 (7%) 0 0.5452 
Aneuploid 3/44 (7%) 1/22 (4.5%) 1.000 
Diploid 
mosaic 
24/44 (54%) 9/22 (41%) 0.4339 
Aneuploid 
mosaic 
7/44 (16%) 1/22 (4.5%) 0.2520 
Chaotic 4/44 (9%) 2/22 (9%) 1.000 
Table 3.9: Chromosomal status and age in the PGD-aCGH 
group  27-34 years ≥35 years p value 
Euploid 11/28 (39%) 9/24 (33%) 1.0000 
Aneuploid 12/28 (43%) 7/24 (33%) 0.3911 
Complex 
aneuploid 
5/28 (18%) 8/24 (33%) 0.2201 
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Figure 3.18: Chromosomal status, morphology and maternal age in embryos from PGD cycles 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18: The distribution of embryos according to their chromosomal status in women of 27 to 34 years and women over 35 years analysed by FISH (A) 
or aCGH (B).  
A 
B 
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3.2.6 Analysis of chromosomal errors 
Depending on the technique used to analyse the chromosomes different 
conclusions could be drawn about the mechanisms leading to the errors in 
preimplantation embryos. With FISH due to the detailed examination of each cell, 
the mechanisms that lead to aneuploidy and mosaicism could be uncovered, but 
only for the chromosomes examined. On the other hand, aCGH gave an important 
insight on the fact that almost all the chromosomes could be affected by aneuploidy 
in the embryos.  
 
3.2.6.1 Chromosomal analysis by FISH 
Of the total of 66 embryos that produced a result, chromosomal errors could be 
analysed in detail in those that were aneuploid and those that were chaotic and 
mosaic and mechanisms that led to their chromosomal status could be determined. 
Monosomies and trisomies of the chromosomes tested were detected in aneuploid 
embryos and were errors that occurred in meiosis leading to uniform abnormalities. 
A variety of mechanisms led to mitotic errors in mosaic and chaotic embryos, 
namely mitotic non-disjunction, chromosome loss or chromosome gain. A 
mechanism was attributed to an abnormality only when it affected more than 20% of 
the nuclei analysed. Table 3.10 presents the meiotic and mitotic errors identified for 
the chromosomes tested by FISH. In total, thirteen meiotic errors were identified and 
none of them involved the Y chromosome. Most meiotic errors were seen for 
chromosome 21. Monosomy was observed at least once for all the chromosomes 
tested, apart from Y, whereas a trisomy was only seen three times for chromosome 
21 and once for 13, 18 and X. Amongst the mechanisms leading to a mitotic error, 
chromosome loss was observed more frequently whereas chromosome 13 showed 
the most mitotic errors in total.     
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Table 3.10: Meiotic and mitotic errors as detected by FISH 
 Meiotic errors Mitotic errors 
Chromosome Monosomy Trisomy Total CG CL MND Total 
13 3 1 4 3 5 6 14 
18 1 1 2 2 8 2 12 
21 2 3 5 4 2 5 11 
X 1 1 2 5 3 1 9 
Y 0 0 0 1 1 0 2 
Total 7 6 13 15 19 14 48 
Table 3.10: Meiotic and mitotic errors detected by FISH. The number of errors detected 
for each of the five chromosomes tested by FISH is shown. CG: Chromosome gain. CL: 
Chromosome loss. MND: Mitotic non-disjunction. 
 
3.2.6.2 Chromosomal analysis by aCGH 
Testing all the chromosomes by aCGH showed that aneuploidy could affect all the 
autosomes and chromosome X as seen in figure 3.19, which shows the cumulative 
gains and losses detected at different developmental stages. Chromosome 18 
showed the highest number of errors, which were nine. Chromosomes 16, 17, 19 
and 22 showed eight errors each, whereas chromosome X showed only two errors. 
In total 60 errors were detected in arrested embryos, 29 in morulae and 34 in 
blastocysts. Within the blastocysts chromosome 22 showed the highest number of 
errors (five) and in the morulae four errors were seen for chromosome 16. In 
arrested embryos five errors were detected for chromosomes 17, 18 and 19.  
 
When splitting the errors in gains and losses in all embryos, several observations 
could be made (figure 3.20). For all the chromosomes that showed aneuploidy 55 
were losses and 68 were gains. Chromosomes five, fourteen and X showed no 
losses. More gains were seen amongst the small chromosomes, apart from 
chromosome 22 that showed six losses and two gains. Chromosome 17 showed the 
highest number of losses, which were six.  
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Figure 3.19: Overall chromosomal errors in embryos from PGD cycles 
Figure 3.19: Errors seen for each chromosome at different stages of embryo development 
are presented.  
 
 
Figure 3.20: Chromosomal gains and losses seen in all embryos of PGD 
cycles 
 
Figure 3.20: The overall number of gains detected for all chromosomes was higher than the 
number of losses.  
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Partial chromosomal changes could also be detected by aCGH. Only those changes 
that spanned more than 10Mb of one chromosome were considered as aneuploidies, 
as smaller changes could have been an artefact of unclear aCGH profiles. Ten 
partial changes were detected in eight embryos. Three embryos carried only these 
partial changes whereas the rest showed additional whole chromosome changes. 
Only one gain was seen for the long arm of chromosome 5. The rest were losses of 
either the long or short arms of several chromosomes. Of these eight embryos, two 
were blastocysts, three were morulae and three were arrested. The embryos that 
showed partial changes are listed in table 3.11.  
 
 
Table 3.11: Partial chromosomal changes detected by 
aCGH 
Embryo Partial chromosomal change 
B20.1.3 -10q22.3-qter (54Mb) 
B21.1.1 -6q14.1-qter (60Mb) 
B21.1.2 -8pter-p22 (17Mb) 
B21.1.6 +5q23.1-qter (63Mb), -6q14.3-qter (82Mb), -
12pter-12q21;.2 (61Mb) 
B22.3.3 -18q11-q13.2 (31Mb) 
B22.3.5 -5q33.3-qter (29Mb) 
B25.1.5 -10p15.2-p11.21 (32Mb) 
B25.1.9 -2q34-qter (27Mb) 
Table 3.11: List of embryos that showed partial chromosomal changes. Embryos 
B21.1.1, B21.1.2 and B22.3.5 carried only these partial aneuploidies. All the rest had 
additional whole chromosome changes.   
 
3.2.7 Comparison of aneuploidy in embryos from PGD and PGS 
cycles 
The aneuploidy level in embryos from PGD cycles as detected by FISH and aCGH 
was compared with the level of aneuploidy seen in embryos from couples that went 
through PGS and were considered infertile. All patients had attended the Centre for 
Reproductive and Genetic Health and therefore PGD and PGS cycles were 
performed under the same clinical setting. 
3.2.7.1 FISH analysis 
Comparison was performed with already published data from a study performed in 
our centre (Mantzouratou et al, 2007). Follow up analysis was performed on 
untransferred embryos from PGS cycles. For the comparison all mosaic types were 
grouped in diploid and aneuploid mosaics. It is important to highlight that in the PGS 
study out of the 50 mosaic embryos with a diploid cell line only five had a majority of 
diploid cells. As seen in figure 3.21 the distribution of diploid and diploid mosaic 
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embryos in the PGD-FISH group was significantly higher than in the PGS-FISH 
group, whereas chaotic embryos were more common in the PGS-FISH group 
(p<0.0001). No significant differences were seen among the distribution of haploid, 
aneuploid and aneuploid mosaic embryos between the two groups.  
 
Figure 3.21: Distribution of embryos according to chromosomal status after 
FISH analysis in PGD and PGS cycles 
Figure 3.21: Significant differences were seen in the diploid, diploid mosaic and chaotic 
embryos.  
 
3.2.7.2 aCGH analysis 
Comparison of the aneuploidy level in embryos analysed by aCGH was performed 
with embryos from patients that went through PGS analysis after blastocyst biopsy. 
For this reason only the blastocysts from the PGD-aCGH group were included in the 
comparison. These were 37 blastocysts that gave an interpretable aCGH result from 
14 cycles of ten couples that went through PGS for indications including advanced 
maternal age, recurrent miscarriage and repeated IVF failure. Details of the couples 
are found in table 3.12.  
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Table 3.12: Information of couples from PGS cycles with blastocyst 
biopsy Couple ID FA MA Indication No of 
cycles 
No of 
blastocysts 
B26 37 36 RIF 2 5 
B27 38 42 RIF 1 1 
B28 41 47 RIF/AMA 1 3 
B29 36 38 RM 1 1 
B30 44 50 AMA 1 2 
B31 43 41 RM/AMA 4 5 
B32 41 44 AMA 1 7 
B33 37 40 RM 1 3 
B34 44 44 AMA 1 4 
B35 34 39 RIF 1 6 
Average 39.5 (3.6) 42.1 (4.2)  Total 37 
Table 3.12: Couples that went through PGS post blastocyst biopsy. Information on 
female and male age, the indication for PGS, number of cycles and blastocysts for each 
couple are shown. (FA: female age, MA: male age, AMA: advanced maternal age, RIF: 
repeated IVF failure, RM: recurrent miscarriage) 
 
The detailed chromosomal classification and complement of each of these 
blastocysts is found in table 7.2 of Appendix B. Upon comparison no statistical 
significance was seen between the two groups, however, as shown in the graph in 
figure 3.22, the distribution of euploid blastocysts was higher in the PGD-aCGH 
group, while aneuploid and complex aneuploid blastocysts were higher in the PGS-
aCGH group. 
Figure 3.22: Distribution of blastocysts analysed by aCGH according to their 
chromosomal status in the PGD and PGS groups 
Figure 3.22: More euploid blastocysts were observed in the PGD group and more aneuploid 
and complex aneuploid in the PGS group, however, no significant differences were noted.  
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3.2.8 Summary of results for section 3.2: Aneuploidy in embryos 
from couples undergoing PGD 
 
 Chromosomal analysis by FISH using probes to detect abnormalities on five 
chromosomes showed that diploid mosaic embryos were more common in 
couples undergoing PGD. Chaotic, haploid and aneuploid embryos were the 
least common. Blastocysts were characterised only as diploid mosaic with 
more than 50% of diploid cells. The chaotic and haploid chromosomal 
constitutions were only seen in arrested embryos. 
 Chromosomal analysis by aCGH revealed that euploid and aneuploid 
embryos were almost equally distributed and a small proportion were 
complex aneuploid. The majority of blastocysts were euploid, whereas the 
majority of arrested embryos were complex aneuploid. 
 No significant differences were seen among the distribution of all 
chromosomal classifications between couples of young and older maternal 
age, apart from diploid embryos, characterised by FISH, which were 
significantly more in embryos from couples with maternal age >35 years.  
 Thirteen meiotic and 48 mitotic errors were observed in the embryos 
analysed by FISH. Monosomy was the most common meiotic error and 
chromosome loss the most common mitotic error.  
 No distinction between meiotic and mitotic errors could be made by aCGH. 
Chromosome 18 was found to be most commonly involved in errors. 
Chromosome loss was most frequently seen for chromosome 22 and 
chromosome gain was most frequently seen for chromosome 17. 
 Comparison of the aneuploidy level as determined after FISH analysis with 
that reported from PGS cycles revealed that the distribution of diploid mosaic 
embryos was significantly higher in the PGD group, whereas the distribution 
of chaotic embryos was significantly higher in the PGS group. 
 Comparison of the aneuploidy level in blastocysts from the PGD group 
analysed by aCGH with that of blastocysts from PGS cycles revealed no 
statistically significant differences. However, euploid blastocysts where more 
common in the PGD than the PGS group. 
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3.3 Investigation of recombination in preimplantation 
embryos 
Recombination was investigated in preimplantation embryos and their parents. This 
was performed by amplifying microsatellite polymorphic markers in five different 
chromosomes on whole genome amplified embryonic DNA and non-amplified 
genomic DNA from the parents. It was possible to identify cross-over events 
occurring in the oocyte and/or the sperm after establishing phase for each set of 
markers in the embryos. Aneuploidy analysis was also performed on the same WGA 
embryonic products by aCGH. 
 
3.3.1 Couple and embryo description 
 
In total 77 embryos were collected from six couples undergoing PGD and four 
couples that opted for PGS. The six families that were used for the recombination 
investigation after PGD for a single gene disorder (C1 – C6) were also used for the 
aneuploidy analysis by aCGH, described in section 3.2.1 (couples B20 – B25). 
Embryos from four couples (C7 – C10) were also analysed for recombination after 
PGS in order to detect any differences in the recombination frequency of couples of 
young maternal age and no fertility issues (PGD group) and those that were infertile 
(PGS group). Family data for both groups are presented in tables 3.13 and 3.14. 
The average female age for the PGD group was 31.5 years (4), the average male 
age was 33.3 (4.3) and the couples were treated for a variety of single gene 
disorders as presented in table 3.13. For the PGS group the average female and 
male age were 38.8 (2.6) and 38.8 (3) respectively. The indication for PGS for 
each couple is presented in table 3.14.  
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Table 3.13: Family data of the PGD group 
Family ID FA MA Disease 
C1 28 29 FAP 
C2 27 27 NF1 
C3 33 34 DM1 
C4 36 36 NF1 
C5 29 37 FAP 
C6 36 37 NF1 
Average 31.5 (4) 33.3 (4.3)  
 
Table 3.13: Families of the PGD group used in the recombination analysis. The female 
(FA) and male age (MA) as well as the diseases for which PGD was performed are indicated. 
(FAP: Familial adenomatous polyposis, NF1: Neurofibromatosis type 1, DM1: Myotonic 
Dystrophy type 1).  
 
 
 
 
 
 
 
Table 3.14: Family data of the PGS group 
Family ID FA MA Indication 
C7 41 42 AMA 
C8 41 35 RIF/AMA 
C9 36 40 RIF 
C10 37 38 RIF 
Average 38.8 (2.6) 38.8 (3)  
 
Table 3.14: Families of the PGS group used in the recombination analysis. Female and 
male ages and the indication(s) for PGS for each couple are shown. (AMA: Advanced 
maternal age, RIF: Repeated IVF failure).   
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Any possible effects of aberrant recombination in the morphology and chromosomal 
status of each embryo were also examined. Chromosomal classification post aCGH 
for these embryos was performed as described in the Materials and Methods 
section 2.5.2.7. Since only meiotic errors were of interest in this chapter, embryos 
were characterised as euploid when no change above or below the threshold for 
whole chromosomal gain or loss was observed for any of the chromosomes, 
aneuploid when one or two chromosomes showed an abnormality and complex 
aneuploidy when three or more chromosomes were involved in an abnormality. Out 
of the 53 embryos in the PGD group (table 3.15), 18 (34%) showed developmental 
arrest, 20 (38%) had reached the morula stage and 15 (28%) were blastocysts at 
day five or six. The chromosomal status was normal in 23 (44%) embryos, 16 (31%) 
were aneuploid, carrying one or two aneuploid chromosomes and 13 (25%) were 
complex aneuploid, carrying three or more aneuploid chromosomes. aCGH failed to 
produce a result in one embryo from this group (embryo C1.5).  
 
In the PGS group, 24 embryos were analysed, in which six (25%) were arrested, ten 
(42%) were morulae and eight (33%) had reached the blastocyst stage. Of the 24 
embryos, two had no interpretable aCGH result (embryos C7.6 and C9.5), five 
(23%) were euploid, 11 (50%) were aneuploid, with one or two aneuploid 
chromosomes and 6 (17%) were complex aneuploid with three or more 
chromosomes with an aneuploidy. Data for the embryos in the PGS group are found 
in table 3.16. 
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Table 3.15: Data of embryos in the PGD group 
Couple ID Embryo ID PN Morphology Chromosome status 
C1 
C1.1 2 Blastocyst Euploid 
C1.2 2 Morula Aneuploid 
C1.3 2 Blastocyst Complex aneuploid 
C1.4 2 Blastocyst Aneuploid 
C1.5 2 Arrested No result 
C1.6 2 Arrested Aneuploid 
C1.7 2 Blastocyst Euploid 
C1.8 0 Arrested Aneuploid 
C2 
C2.1 2 Morula Euploid 
C2.2 2 Morula Euploid 
C2.3 2 Morula Aneuploid 
C2.4 2 Morula Euploid 
C2.5 
C2.5 
2 Morula Euploid 
C2.6 2 Arrested Complex aneuploid 
C2.7 0 Morula Euploid 
C2.8 0 Morula Aneuploid 
C3 
C3.1 2 Blastocyst Euploid 
C3.2 2 Morula Euploid 
C3.3 2 Morula Complex aneuploid 
C3.4 2 Blastocyst Euploid 
C3.5 2 Morula Aneuploid 
C3.6 2 Morula Euploid 
C3.7 2 Arrested Complex aneuploid 
C3.8 2 Blastocyst Euploid 
C3.9 2 Arrested Complex aneuploid 
C3.10 2 Blastocyst Aneuploid 
C3.11 2 Morula Euploid 
C4 
C4.1 2 Morula Aneuploid 
C4.2 2 Arrested Complex aneuploid 
C5 
C5.1 2 Blastocyst Aneuploid 
C5.2 2 Blastocyst Euploid 
 
 
 
 
 
 
 
 
 132 
Table 3.15 (cont): Data of embryos in the PGD group 
Couple ID Embryo ID PN Morphology Chromosome status 
C6 
C6.1 2 Arrested Aneuploid 
C6.2 2 Blastocyst Euploid 
C6.3 2 Arrested Euploid 
C6.4 2 Blastocyst Euploid 
C6.5 2 Arrested Complex aneuploid 
C6.6 2 Blastocyst Euploid 
C6.7 2 Morula Complex aneuploid 
C6.8 2 Arrested Complex aneuploid 
C6.9 2 Blastocyst Complex aneuploid 
C6.10 0 Blastocyst Aneuploid 
C6.11 2 Arrested Complex aneuploid 
C6.12 2 Arrested Aneuploid 
C6.13 2 Morula Aneuploid 
C6.14 2 Arrested Euploid 
C6.15 2 Morula Aneuploid 
C6.16 2 Morula Euploid 
C6.17 2 Morula Complex aneuploid 
C6.18 2 Arrested Complex aneuploid 
C6.19 2 Arrested Euploid 
C6.20 1 Morula Aneuploid 
C6.21 1 Arrested Euploid 
C6.22 3 Arrested Euploid 
Table 3.15: List of the 53 embryos from PGD cycles used in the recombination 
analysis. The number of pronuclei seen after fertilisation, the developmental stage at day 
five or six as well as the chromosomal status, as defined by the aCGH result, of each 
embryo are shown. 
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Table 3.16: Data of embryos in the PGS group 
Couple ID Embryo ID PN Morphology Chromosome status 
C7 
C7.1 2 Morula Aneuploid 
C7.2 2 Arrested Aneuploid 
C7.3 2 Morula Aneuploid 
C7.4 2 Arrested Complex aneuploid 
C7.5 2 Morula Euploid 
C7.6 1 Morula No result 
C7.7 0 Arrested Complex aneuploid 
C8 
C8.1 2 Blastocyst Aneuploid 
C8.2 2 Blastocyst Complex aneuploid 
C8.3 2 Blastocyst Aneuploid 
C9 
C9.1 2 Morula Euploid 
C9.2 2 Arrested Aneuploid 
C9.3 2 Morula Euploid 
C9.4 2 Arrested Complex aneuploid 
C9.5 2 Arrested No result 
C9.6 2 Blastocyst Aneuploid 
C9.7 2 Morula Complex aneuploid 
C9.8 2 Morula Aneuploid 
C9.9 2 Morula Complex aneuploid 
C10 
C10.1 2 Blastocyst Aneuploid 
C10.2 2 Blastocyst Euploid 
C10.3 2 Blastocyst Aneuploid 
C10.4 2 Blastocyst Euploid 
C10.5 2 Blastocyst Aneuploid 
Table 3.16: List of the 24 embryos from PGS cycles used in the recombination 
analysis. The number of pronuclei seen after fertilisation, the developmental stage at day 
five or six and the chromosomal status, as defined by the aCGH result, of each embryo are 
indicated.  
 
3.3.2 WGA of samples using SurePlex 
Whole genome amplification was performed on whole embryos of the PGD group, 
on day five or six of development, post diagnosis for a single gene disorder. These 
embryos were not selected for transfer to the uterus, or cryopreservation due to the 
presence of a mutation or due to developmental arrest. Embryonic DNA in families 
C7 and C9 of the PGS group was amplified by WGA post screening for 
chromosomal aneuploidy on day five or six on whole embryos that were found to be 
aneuploid and/or were arrested and therefore unsuitable for transfer. WGA on 
embryos from families C8 and C10 was performed as part of the clinical PGS 
procedure on trophectoderm (TE) samples biopsied from blastocysts on day five or 
six. Recombination analysis for these embryos was performed on the same TE 
WGA products.   
 134 
WGA was performed using SurePlex (BlueGnome, UK). Success of the 
amplification was confirmed by running the amplified samples on a 2% agarose gel. 
A smear of brighter intensity at around 400 base pairs represented successful 
amplification and all amplified samples produced a smear. As mentioned in the 
Results section 3.3.1, one embryo from the PGD group (C1.5) and two embryos 
from the PGS group (C7.5 and C9.5) had no interpretable aCGH result, even though 
a smear was present, albeit fainter than the rest, on the agarose gel (figure 3.23 for 
embryos from families C1 and C7). This was probably due to experimental errors 
during aCGH for embryos C1.5 and C9.5, since those embryos produced good 
results post FPCR (performed on the same WGA product). Embryo C7.6 however 
produced poor result even after FPCR, as mentioned in the results section 3.3.3.2, 
indicating poor DNA quality of the embryo as a starting material for WGA.  
 
Figure 3.23: Agarose gel of WGA products of embryos from families C1 and 
C7 
 
 
 
 
 
 
 
 
Figure 3.23: An expected smear at around 400bp is present for all the embryos, however it 
is fainter for embryos C1.5 and C7.6, both of which produced no interpretable aCGH result. 
M: 100bp molecular weight marker. 
 
 
 
 
 
 
 
 
C7.3 C7.5 C7.2 C1.1 M C1.8 C1.3 C1.2 C1.4 C1.5 C1.6 C1.7 C7.4 C7.6 C7.7 C7.1 
500bp 
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3.3.3 FPCR amplification of STR markers 
Loci on chromosomes 1, 5, 16, 19 and 17 were examined for recombination. The 
first four were considered as recombination hotspots, whereas the latter as a 
recombination silent spot. Two STR marker loci were amplified on chromosomes 
one, five and 16, three on chromosome 19 and five on chromosome 17. Details of 
the markers are found on table 3.17. Figure 3.24 presents the exact chromosomal 
position of each set of markers, along with the genetic distance of each locus. 
 
 
Table 3.17: List of the markers used to amplify loci on five chromosomes to detect 
recombination. The chromosomal location (Ensembl release 60, www.ensembl.org) and 
type of the repeat of each marker are indicated. Genetic distances were calculated using 
data from Kong et al, 2010.  
 
 
 
 
 
 
Table 3.17: STR marker information 
Chromosome Marker Chromosomal location Genetic 
distance (cM) 
Type 
1 
D1S495 1p21.1 
102,561,360-
102,561,512 1.64 
Dinucleotide 
D1S486 1p21.2 
102,147,806-
102,147,958 
Dinucleotide 
5 
D5S1991 5p15.2 
14,876,610-
14,876,840 3.08 
Dinucleotide 
D5S2081 5p15.2 
13,476,968-
13,477,164 
Dinucleotide 
16 
D16S492 16q12.2 
54,656,244-
54,656,460 1.92 
Tetranucleotide 
D16S3053 16q12.2 
55,548,751-
55,548,994 
Dinucleotide 
17 
NF1int1 17q11.2 
29,466,325-
29,466,487 
0 
Dinucleotide 
D17S1307 17q11.2 
29,473,353-
29,473,561 
Dinucleotide 
NF1int17 17q11.2 
29,553,012- 
29553634 
Dinucleotide 
NF1int29 17q11.2 
29,569,864- 
29570488 
Dinucleotide 
D17S1166 17q11.2 
29,649,016-
29,649,216 
Dinucleotide 
19 
D19S219 19q13.32 
45,993,737-
45,993,910 
1.13 
Dinucleotide 
D19S207 19q13.32 
46,303,962-
46,304,113 
Dinucleotide 
D19S412 19q13.32 
47,010,982-
47,011,111 
Dinucleotide 
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Figure 3.24: Chromosomal position of each set of markers used for 
recombination detection 
 
Figure 3.24: The red line on each chromosome indicates the exact band on the 
chromosome where the set of markers is located.  
 
 
 
 
 
Chromosome 1 Chromosome 5 Chromosome 16 
Chromosome 17 
Chromosome 19 
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3.3.3.1 Conditions for amplification 
Depending on the fluorescent dye of each primer set and the size of the amplified product, 
markers were amplified in multiplexes if possible. This was performed in order to amplify 
more than one locus simultaneously and therefore reduce the number of reactions.  
 
Each primer set was first tested on all parental genomic DNAs in order to check the range of 
the size of the products and optimise the reaction conditions. Based on these results three 
multiplexes were developed. The first, a triplex, amplified both markers on chromosome 1 
plus one marker on chromosome 5, the second and third, both duplex reactions, amplified 
loci on chromosomes 17 and 19 respectively. All multiplex reactions were performed using 
the Qiagen multiplex kit, as described in the Materials and Methods, section 2.4.3.4. The rest 
of the markers were amplified in single reactions using either the High Fidelity or Taq 
polymerase (Materials and Methods, sections 2.4.3.2 and 2.4.3.3). Details on the conditions 
of all the FPCR reactions are found in table 3.18.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.18: Conditions of multiplex and single reactions to amplify STR markers. The 
HotStarTaq DNA polymerase was a component of the Qiagen multiplex kit that was used 
in all multiplex reactions.  
 
 
 
 
 
Table 3.18: Amplification conditions for STR markers 
Loci amplified Polymerase Annealing temperature (C) 
D1S486 HotStarTaq 60 
D1S495 
D5S1991 
D17S1166 HotStarTaq 60 
D17S1307 
D19S412 HotStarTaq 60 
D19S207 
D5S2081 High Fidelity 60 
D16S492 Taq 60 
D16S3053 Taq 60 
NF1int1 Taq 60 
NF1int17 Taq 60 
NF1int29 Taq 60 
D19S219 High Fidelity  58 
 138 
Figure 3.25 presents an example of the result obtained by the genetic analyser for 
the first multiplex, amplifying markers D1S495, D5S1991 and D1S486 for the female 
and male partner of family C1, as well as embryo C1.6.  
 
Figure 3.25: Example of genotyping of three STR markers 
 
Figure 3.25: This presents the result of the first multiplex, amplifying markers D1S495, 
D5S1991 and D1S486 for the two partners of family C1 and embryo C1.6. 
 
3.3.3.2 Marker amplification efficiency 
In total 14 markers were amplified by FPCR on 20 parental genomic DNA samples 
and 77 embryonic DNA samples that were previously amplified by WGA. Detailed 
results of all the markers for each sample are found in table 8.1 of Appendix C. 
Amplification of all 280 loci was successful on 20 genomic DNA samples from the 
parents. Of the 1078 loci amplified on the embryos, amplification failure was seen in 
31 loci (2.9%). Notably, 24 of the 31 cases of amplification failure were seen in 
embryos of the C7 family, indicating possible poor embryo quality. This was made 
apparent especially in embryo C7.6, which failed to produce an interpretable aCGH 
result and 10 out of the 14 markers failed to amplify. 
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Allele drop out (ADO) could also be detected for some loci in heterozygote samples. 
Heterozygosity was seen in 720 amplified loci and one allele failed to amplify in 38. 
Therefore, the ADO rate was 5.4%. These events were scored as definite ADO, in 
embryos that the segregation of allele markers was determined and a heterozygote 
result was expected. In some samples however, homozygote allele sizes may have 
been a result of ADO, recombination or aneuploidy. Homozygote results with a 
doubt to their origin were disregarded when calculating ADO and recombination 
frequencies.  
 
Amplification of multiple loci could also have detected possible contamination 
present in the amplified embryonic samples. Paternal contamination was not 
expected as fertilization was performed by ICSI to prohibit contamination by sperm. 
Maternal contamination was possible via cumulus cells surrounding the oocyte that 
were not removed prior to fertilisation. If contamination from cumulus cells had 
occurred it should have been detected in all loci amplified in an embryo as an extra 
maternal allele. No embryo had evidence of maternal contamination in all the loci 
examined. Extra alleles present in some embryos for loci on one chromosome but 
not the rest indicated trisomy for that chromosome and not maternal contamination 
or amplification artefacts as described in the example given in figure 3.28.  
 
3.3.3.3 Parental informativity 
In order to detect recombination, the segregation of the marker alleles needed to be 
determined on parental DNA. This was possible only when the parents were 
informative for the markers tested. Parental informativity for all the markers is shown 
in table 8.1 of Appendix C.  
 
For chromosomes 1, 5 and 16 two-marker sites were amplified. Heterozygosity of 
the parents for both markers as well as difference in the size of at least one marker 
allele between the parents were essential to detect recombination. For chromosome 
1, out of the 20 parents tested, ten were not informative. For chromosome 5, 14 and 
for chromosome 16, 11 were not informative. For chromosomes 17 and 19, five and 
three markers were tested respectively and amplification of more than two markers 
increased the ability to detect recombination as parental informativity was increased. 
Lack of informativity on these chromosomes occurred when an individual was 
homozygote for all the markers or was heterozygote for only one. Eight parents 
were not informative for chromosome 17 and six were not informative for 
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chromosome 19. It is important to note that the female partner of family C6 was 
affected with a whole deletion of the NF1 gene, on chromosome 17. All the markers 
for that chromosome were located within the gene and therefore only one allele was 
detected, rendering the female partner not informative for recombination detection 
for that locus. 
 
3.3.4 Recombination events 
Female and male recombination was detected by cross-over events occurring 
during meiosis in the formation of oocytes and sperm, which could be identified on 
informative loci only. On loci where two markers were tested a single cross-over 
event could be detected, whereas detection of double cross-over was possible on 
chromosomes 17 and 19, where five and three markers were tested respectively. 
When calculating the number of recombination events, double cross-over was 
regarded as two separate events.  
 
Correct segregation of the marker alleles on each parental chromosome was 
essential to confidently identify recombination. Initially all parents were genotyped 
for all the markers. With the expected marker allele sizes known, genotyping of the 
embryos was performed. The marker alleles in phase with each other were 
determined by the combination of parental alleles that resulted in the smallest 
recombination fraction in the embryos for that family, ie with the smallest number of 
recombinants. Families C4 and C5 included two embryos each. Haplotyping showed 
evidence of recombination, however, it was not possible to determine which embryo 
carried a recombined chromosome and which did not.  
 
Double recombinants could only be detected for the loci on chromosome 17 and 19 
as five and three markers were tested for them respectively. For chromosome 17 
only one embryo was identified as a double recombinant, of maternal origin (C3.1, 
Appendix C) in a family with a total of 11 embryos. Altering the segregation of the 
alleles to avoid the presence of an embryo with a double cross-over event would 
have increased the number of embryos with recombination to 10 out of 11, instead 
of two out of 11. As mentioned above, the haplotypes selected were those that 
produced the lowest number of recombinants. Four embryos showed evidence of 
double cross-over for chromosome 19 in families C1, C3 and C6. Both cases of the 
double cross-over in family C1 were paternal in origin, whereas the double events in 
families C3 and C6 (one each) were maternal.         
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Figures 3.26, 3.27, 3.28 and 3.29 show examples of different families in which 
cross-over events were identified on chromosomes 1, 16, 17 and 19 respectively. 
No recombination was detected on the chromosome 5 locus. 
 
As seen in figure 3.26, haplotyping of the parents and their eight embryos for the 
chromosome 1 locus revealed female recombination on embryo C1.3. A female and 
male cross-over event was detected on embryo C1.5 and embryo C1.8 carried only 
maternal alleles. This might have been a result of paternal cross-over, monosomy or 
ADO on one or both paternal alleles, depending on which paternal chromosome 
was inherited in that embryo. Loss of chromosome 1 was not seen by aCGH on that 
embryo, therefore monosomy was excluded. Since the source of this result was not 
apparent this embryo was not included in the calculation of the recombination 
frequency. Any other embryo with similar doubts was also excluded.   
 
Figure 3.26: Haplotyping of family C1 for the chromosome 1 locus 
Figure 3.26: Embryos C1.1, C1.2, C1.4, C1.5 and C1.7 established the phase of marker 
alleles. Embryos C1.3 and C1.5 showed deviation from the expected haplotypes, 
representing a female cross-over event in embryos C1.3 and C1.5 and a male event in 
embryo C1.5. Embryo C1.8 carried only the maternal alleles for that locus.   
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Figure 3.27 shows the haplotyping results for chromosome 16 for family C4. As 
mentioned above, this family consisted of two embryos only. Inheritance of the 
expected paternal alleles was seen on both embryos. The maternal allele sizes for 
the two markers, however, did not segregate in the same way in both embryos, 
indicating recombination in one of the two. Arbitrarily, embryo C4.2 was selected as 
the recombinant embryo. This assumption did not affect the final calculation of the 
recombination frequency. 
 
Figure 3.27: Haplotyping of family C4 for the chromosome 16 locus 
Figure 3.27: Female recombination occurred in one of the two embryos. Due to the number 
of embryos, it was not possible to determine which of the two carried the cross-over. Embryo 
C4.2 was arbitrarily selected as the recombinant.  
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The majority of cross-over events was seen on chromosome 19. An example is 
shown in figure 3.28. Female and male recombination events were detected in 
embryos C7.4 and C7.5 respectively. The site of the maternal cross-over was 
shown to be between the distal D19S219 and the middle D19S207 marker. The site 
of the paternal cross-over could not be detected, as the father was homozygote for 
the middle marker D19S207. Amplification failure occurred for markers in embryo 
C7.6, probably due to degraded embryo DNA, an indication of which was also given 
by a weak smear on the agarose gel and the fact that aCGH was not successful. 
Evidence for trisomy 19 was seen in embryo C7.7 as it carried the expected 
maternal alleles from both chromosomes and alleles from one paternal. However, 
gain of chromosome 19 was not detected by aCGH on that embryo. Maternal 
contamination as a source of the extra peaks was excluded since extra maternal 
alleles were not detected for any other chromosome with informative loci. The 
presence of random peaks, an artefact of the WGA, at the expected allele sizes in 
the analysis of the amplified products might be one explanation for these results.   
 
Figure 3.28: Haplotyping of family C7 for the chromosome 19 locus 
Figure 3.28: This family consisted of seven embryos. Embryo C7.8 failed to produce a result 
for this locus. Female recombination between markers D19S219 and D19S207 was detected 
in embryo C7.4. Male recombination was seen in embryo C7.5, however the site of the 
cross-over event could not be detected in the father, as he was homozygote for the middle 
marker D19S207. Embryo C7.7 carried both maternal chromosomes and one paternal.  
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Recombination in embryos was even detected for the silent spot on chromosome 17. 
Two embryos of family C10 showed male recombination between the markers 
D17S1307 and NF1int17, as presented in figure 3.29. Embryo C10.3 of the same 
family carried only one paternal chromosome 17, indicating monosomy for that 
chromosome. This aneuploidy was confirmed by loss of that chromosome in aCGH. 
 
Figure 3.29: Haplotyping of family C10 for the chromosome 17 locus 
 
 
Figure 3.29: Haplotyping of family C10 for the chromosome 17 locus. Male 
recombination was detected in embryos C10.1 and C10.2 between the markers D17S1307 
and NF1int17. Only one paternal chromosome was detected for embryo C10.3.  
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3.3.5 Recombination frequency 
Tables 3.19 and 3.20 present the cumulative embryo recombination results at each 
locus for each family in the PGD and the PGS group respectively. Female (Rec f) 
and male (Rec m) recombination frequencies were calculated separately as the 
number of cross-over events over the number of informative female (M f) and male 
(M m) meioses respectively. The total recombination frequency was calculated as 
the total number of female and male recombination events over the total number of 
female and male informative meioses:  
 
 
For example, the female partner of family C1, which consisted of eight embryos, 
was informative for the chromosomes 1 locus, therefore in eight informative meioses 
there were two female recombination events detected in two embryos. The 
recombination frequency was calculated to be 0.25 (2/8=0.25). Similarly and as the 
male partner of the same family was informative for this locus and one male 
recombination event was seen in one embryo the male recombination frequency 
was 0.13 (1/8=0.13). The total recombination frequency for family C1 for 
chromosome one was 0.19 [(2+1)/(8+8)=0.19].  The graphs in figure 3.30 
demonstrate the overall recombination frequency results per family and per 
chromosome.  
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Table 3.19: Informativity, recombination events and frequency for the PGD group. For each family and each locus the cumulative embryo results are 
presented. The number of embryos of each family is indicated in parentheses next to the family ID. The total results for all chromosomes for each family are 
indicated in the last column and the total results for all families for each chromosome are shown in the last row.  
Table 3.19: Recombination in the PGD group 
Family ID 
(no of 
embryos) 
 Chromosome 1 Chromosome 5 Chromosome 16 Chromosome 17 Chromosome 19 Total 
♀ ♂ Total ♀ ♂ Total ♀ ♂ Total ♀ ♂ Total ♀ ♂ Total ♀ ♂ Total 
C1 (8) Informativity 8 8 16 8 0 8 8 0 8 8 8 16 0 8 8 32 24 56 
Rec. events 2 1 3 0 0 0 2 0 2 0 0 0 0 6 6 4 7 11 
Rec. frequency 0.25 0.13 0.19 0 0 0 0.25 0 0.25 0 0 0 0 0.75 0.75 0.13 0.29 0.20 
C2 (8) Informativity 8 8 16 0 0 0 0 8 8 8 0 8 8 0 8 24 16 40 
Rec. events 0 1 1 0 0 0 0 0 0 2 0 2 1 0 1 3 1 4 
Rec. frequency 0 0.13 0.06 0 0 0 0 0 0 0.25 0 0.25 0.13 0 0.13 0.13 0.06 0.10 
C3 (9) Informativity 11 0 11 0 0 0 0 11 11 11 0 11 11 11 22 33 22 55 
Rec. events 0 0 0 0 0 0 0 0 0 3 0 3 2 3 5 5 3 8 
Rec. frequency 0 0 0 0 0 0 0 0 0 0.27 0 0.27 0.18 0.27 0.23 0.15 0.15 0.15 
C4 (2) Informativity 0 2 2 0 2 2 2 2 4 2 0 2 0 0 0 4 6 10 
Rec. events 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 1 0 1 
Rec. frequency 0 0 0 0 0 0 0.5 0 0.25 0 0 0 0 0 0 0.25 0 0.1 
C5 (2) Informativity 0 0 0 2 0 2 0 0 0 2 0 2 2 0 2 6 0 6 
Rec. events 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 1 0 1 
Rec. frequency 0 0 0 0 0 0 0 0 0 0.5 0 0.5 0 0 0 0.17 0 0.17 
C6 (22) Informativity 0 0 0 0 0 0 22 0 22 0 0 0 22 22 44 44 22 66 
Rec. events 0 0 0 0 0 0 4 0 4 0 0 0 4 0 4 8 0 8 
Rec. frequency 0 0 0 0 0 0 0.18 0 0.18 0 0 0 0.18 0 0.09 0.18 0 0.12 
Total Informativity 27 18 45 10 2 12 32 21 53 31 8 39 43 41 84 143 90 233 
Rec. events 2 2 4 0 0 0 7 0 7 6 0 6 7 9 16 22 11 33 
Rec. frequency 0.07 0.11 0.09 0 0 0 0.22 0 0.13 0.19 0 0.15 0.16 0.22 0.19 0.15 0.12 0.14 
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Table 3.20: Informativity, recombination events and frequency for the PGS group. For each family and each locus the cumulative embryo results are 
presented. The number of embryos of each family is indicated in parentheses next to the family ID. The total results for all chromosomes for each family are 
indicated in the last column and the total results for all families for each chromosome are shown in the last row.  
 
Table 3.20: Recombination in the PGS group 
Family ID 
(no of 
embryos) 
 Chromosome 1 Chromosome 5 Chromosome 16 Chromosome 17 Chromosome 19 Total 
♀ ♂ Total ♀ ♂ Total ♀ ♂ Total ♀ ♂ Total ♀ ♂ Total ♀ ♂ Total 
C7 (7) Informativity 7 7 14 0 7 7 0 0 0 7 7 14 7 7 14 21 28 49 
Rec. events 1 1 2 0 0 0 0 0 0 0 0 0 1 1 2 2 2 4 
Rec. frequency 0.14 0.14 0.14 0 0 0 0 0 0 0 0 0 0.14 0.14 0.14 0.10 0.07 0.08 
C8 (3) Informativity 0 0 0 0 3 3 3 0 3 3 0 3 3 3 6 9 6 15 
Rec. events 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Rec. frequency 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
C9 (9) Informativity 0 9 9 0 0 0 0 9 9 0 9 9 9 9 18 9 36 45 
Rec. events 0 0 0 0 0 0 0 0 0 0 0 0 1 1 2 1 1 2 
Rec. frequency 0 0 0 0 0 0 0 0 0 0 0 0 0.11 0.11 0.11 0.11 0.03 0.04 
C10 (5) Informativity 0 5 5 5 0 5 0 5 5 5 5 10 0 5 5 10 20 30 
Rec. events 0 0 0 0 0 0 0 0 0 0 2 2 0 0 0 0 2 2 
Rec. frequency 0 0 0 0 0 0 0 0 0 0 0.40 0.20 0 0 0 0 0.1 0.07 
Total Informativity 7 21 28 5 10 15 3 14 17 15 21 36 19 24 43 49 90 139 
Rec. events 1 1 2 0 0 0 0 0 0 0 2 2 2 2 4 3 5 8 
Rec. frequency 0.14 0.05 0.07 0 0 0 0 0 0 0 0.10 0.06 0.11 0.08 0.09 0.06 0.06 0.06 
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3.3.5.1 Recombination frequency per family 
As seen in graph A (figure 3.30) the highest female recombination frequency was 
seen in family C4, whereas the male of family C1 had the highest frequency. The 
same family had the highest total recombination frequency (0.2). Family C8 showed 
no recombination and families C4, C5 and C6 showed no male recombination.  
 
3.3.5.2 Recombination frequency per chromosome 
When analysing the recombination frequency per chromosome some differences 
were noted between the PGD and the PGS groups. No female or male 
recombination were recorded on chromosome 5 for both groups, even though it was 
regarded a recombination hot spot. Families of the PGS group showed no female 
recombination on chromosomes 16 and 17. This is not surprising, especially for 
chromosome 16, as only three female meioses were informative for that locus in the 
PGS group. Female recombination frequency was higher in the PGS group for 
chromosome 1 and lower for chromosome 19 when compared to the PGD group 
(figure 3.30B).  
 
No recombination events occurring in the sperm were detected on chromosome 16; 
also no male events were detected on chromosome 17 in the PGD group. Once 
again the informativity in that locus was very low with only eight male informative 
meioses. The male recombination frequencies observed for chromosomes 1 and 19 
were higher for the PGD group (figure 3.30C).  
 
When comparing the total recombination frequencies per chromosome (figure 
3.30D) the highest rates for chromosomes 1, 17 and 19 were observed in the PGD 
group. No recombination was observed for chromosome 16 in the PGS group. The 
overall total recombination for all chromosomes analysed was seen in the PGD 
group and was 0.14, compared to 0.06 of the PGS group. The difference was not 
statistically significant (p>0.05, t test).  
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Figure 3.30: Recombination frequency per family and per chromosome 
 
Figure 3.30: Graph A shows the different female, male and total recombination frequencies per family. Graphs B, C and D show the female, male and total 
recombination frequencies as seen per chromosome.  
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3.3.5.3 Sex and age effects on recombination frequency 
Figure 3.31 shows how recombination frequency changed with female and male age. 
No trend was observed on the rate with increasing female age, however a decline 
on the rate was observed with increasing male age.  
 
 
Figure 3.31: Effect of female and male age on recombination 
 
Figure 3.31: Graph A shows the recombination frequency observed in all the females, 
arranged according to increasing age and graph B the rate of all the males. 
 
 
Small differences were detected in the recombination frequency between females 
and males. As seen in figure 3.32, female recombination frequency was higher in 
the PGD group. On the other hand, no differences between the sexes were detected 
in the PGS group. Therefore, in all families female recombination frequency was 
higher than the male.  
 
Figure 3.32: Sex effect on recombination frequency 
Figure 3.32: Female and male recombination frequency for each group as well as the 
overall rates in both groups are indicated.  
A B 
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By combining all females and males in age groups additional differences were 
observed. Female and male recombination frequencies were higher in younger 
individuals of 35 years or less. Recombination frequency decreased as age 
increased in males and females but not significantly (p>0.05, t-test), the decrease 
observed among males was bigger than females. The only statistical significance 
observed was that the frequency of older men was significantly lower than the 
frequency observed in women of the same age group (p=0.04, t-test), as shown in 
the graph in figure 3.33.  
 
Figure 3.33: Differences in recombination frequencies between females and 
males of different age groups 
 
 
Figure 3.33: All individuals were separated according to their age and the average 
recombination frequency was calculated.   
 
3.3.5.4 Recombination frequency, chromosomal status and morphology 
Possible effects of recombination on the embryo chromosomal status as well as 
embryo morphology were also examined. In the total of 77 embryos analysed, 
cross-over events were detected in 30. Table 3.21 presents all these embryos that 
showed recombination, the individual embryo recombination frequencies as well as 
their chromosomal and development status. For each embryo the maximum female 
and male informative loci was five, since that was the number of loci investigated 
and, therefore, the maximum total number of informative loci was ten. The individual 
embryo recombination frequencies were calculated as the number of cross-over 
events seen in each embryo over the number of informative loci.  
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Table 3.21: Embryos in which recombination was detected. The embryo recombination frequency, chromosomal and developmental status are also 
indicated. The star (*) indicates embryos that showed recombination at the silent spot on chromosome 17. 
Table 3.21: Characteristics of embryos in which recombination was detected 
Embryo Female 
informative 
loci 
Female 
recombination 
events 
Female 
recombination 
frequency 
Male 
informative 
loci 
Male 
recombination 
events 
Male 
recombination 
frequency 
Total 
informative 
loci 
Total 
recombination 
events 
Embryo 
recombination 
frequency 
Chromosomal 
status 
Morphology 
C1.3 4 1 0.25 4 0 0.00 8 1 0.13 Complex aneuploid Blastocyst 
C1.4 4 1 0.25 4 0 0.00 8 1 0.13 Aneuploid Blastocyst 
C1.5 4 1 0.25 4 2 0.50 8 3 0.38 No result Arrested 
C1.6 4 1 0.25 4 2 0.50 8 3 0.38 Aneuploid Arrested 
C1.7 4 0 0.00 4 2 0.50 8 2 0.25 Euploid Blastocyst 
C1.8 4 0 0.00 4 1 0.25 8 1 0.13 Aneuploid Arrested 
C2.1* 3 1 0.33 2 0 0.00 5 1 0.20 Euploid Morula 
C2.5* 3 1 0.33 2 0 0.00 5 1 0.20 Euploid Morula 
C2.8 3 1 0.33 2 1 0.50 5 2 0.40 Aneuploid Morula 
C3.4* 3 2 0.67 2 0 0.00 5 2 0.40 Euploid Blastocyst 
C3.5* 3 1 0.33 2 0 0.00 5 1 0.20 Aneuploid Morula 
C3.8 3 0 0.00 2 1 0.50 5 1 0.20 Euploid Blastocyst 
C3.9 3 2 0.67 2 0 0.00 5 2 0.40 Complex aneuploid Arrested 
C3.10 3 0 0.00 2 1 0.50 5 1 0.20 Aneuploid Blastocyst 
C3.11 3 0 0.00 2 1 0.50 5 1 0.20 Euploid Morula 
C4.2 2 1 0.50 3 0 0.00 5 1 0.20 Complex aneuploid Arrested 
C5.2* 3 1 0.33 0 0 0.00 3 1 0.33 Euploid Blastocyst 
C6.2 2 1 0.50 1 0 0.00 3 1 0.33 Euploid Blastocyst 
C6.6 2 2 1.00 1 0 0.00 3 2 0.67 Euploid Blastocyst 
C6.8 2 1 0.50 1 0 0.00 3 1 0.33 Complex aneuploid Arrested 
C6.17 2 1 0.50 1 0 0.00 3 1 0.33 Complex aneuploid Morula 
C6.18 2 2 1.00 1 0 0.00 3 2 0.67 Complex aneuploid Arrested 
C6.22 2 1 0.50 1 0 0.00 3 1 0.33 Euploid Arrested 
C7.2 3 1 0.33 4 1 0.25 7 2 0.29 Aneuploid Arrested 
C7.4 3 1 0.33 4 0 0.00 7 1 0.14 Complex aneuploid Arrested 
C7.5 3 0 0.00 4 1 0.25 7 1 0.14 Euploid Morula 
C9.5 1 1 1.00 4 0 0.00 5 1 0.20 No result Arrested 
C9.6 1 0 0.00 4 1 0.25 5 1 0.20 Aneuploid Blastocyst 
C10.1* 2 0 0.00 4 1 0.25 6 1 0.17 Aneuploid Blastocyst 
C10.2* 2 0 0.00 4 1 0.25 6 1 0.17 Euploid Blastocyst 
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Figure 3.34A presents the comparison of the average recombination frequency of 
embryos with different chromosomal complements. Those that did not have an 
interpretable aCGH result were excluded from the analysis. The average 
frequencies of the euploid, aneuploid and complex aneuploid embryos were 0.29 
(±0.15), 0.23 (±0.1) and 0.31 (±0.19) respectively. Despite the fact that the average 
frequency of complex aneuploid embryos was the highest none of the differences 
were statistically significant. The average recombination frequencies at different 
development stages were also compared (figure 3.34B). The lowest frequency was 
recorded for morulae at 0.24 (±0.09), whereas arrested embryos showed the 
highest recombination frequency at 0.33 (±0.14). The rate of blastocysts was 0.27 
(±0.15). No statistical differences were detected within these groups. 
 
 
Figure 3.34: Differences in recombination frequency of euploid, aneuploid and 
complex aneuploid embryos and at different developmental stages 
 
Figure 3.34: Graph A shows the similar frequencies of diploid and aneuploid embryos. 
Arrested embryos showed the highest frequency, followed by blastocysts and morulae had 
the lowest (graph B).  
 
 
No recombination was detected in 47 embryos and the characteristics of those are 
found in table 3.22. Apart from investigating the effect of recombination in the 
chromosomes and the development within embryos that carried cross-over events, 
these embryos and those that did not show any recombination were also compared.  
 
 
 
 
 
 
 
 
 
 
 
 
A B 
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Table 3.22: Characteristics of embryos that showed no 
recombination 
Embryo Chromosomal status Morphology 
C1.1 Euploid Blastocyst 
C1.2 Aneuploid  Morula 
C2.2 Euploid  Morula 
C2.3 Aneuploid Morula 
C2.4 Euploid  Morula 
C2.6 Complex aneuploid Arrested 
C2.7 Euploid Morula 
C3.1 Euploid  Blastocyst 
C3.2 Euploid Morula 
C3.3 Complex aneuploid Morula 
C3.6 Euploid Morula 
C3.7 Complex aneuploid Arrested 
C4.1 Aneuploid Morula 
C5.1 Aneuploid Blastocyst 
C6.1 Aneuploid Arrested 
C6.3 Euploid Arrested 
C6.4 Euploid Blastocyst 
C6.5 Complex aneuploid Arrested 
C6.7 Complex aneuploid Morula 
C6.9 Complex aneuploid Blastocyst 
C6.10 Aneuploid Blastocyst 
C6.11 Complex aneuploid Arrested 
C6.12 Aneuploid Arrested 
C6.13 Aneuploid Morula 
C6.14 Euploid Arrested 
C6.15 Aneuploid Morula 
C6.16 Euploid Morula 
C6.19 Euploid Arrested 
C6.20 Aneuploid Morula 
C6.21 Euploid Arrested 
C7.1 Aneuploid Morula 
C7.3 Aneuploid Morula 
C7.6 No result Morula 
C7.7 Complex aneuploid Arrested 
C8.1 Aneuploid Blastocyst 
C8.2 Complex aneuploid Blastocyst 
C8.3 Aneuploid Blastocyst 
C9.1 Euploid Morula 
C9.2 Aneuploid Arrested 
C9.3 Euploid Morula 
C9.4 Complex aneuploid  Arrested 
C9.7 Complex aneuploid Morula 
C9.8 Aneuploid Morula 
C9.9 Complex aneuploid Morula 
C10.3 Aneuploid Blastocyst 
C10.4 Euploid Blastocyst 
C10.5 Aneuploid Blastocyst 
Table 3.22: List of embryos in which no cross-over events were detected. The 
chromosomal status and developmental stage are also indicated. 
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Figure 3.35 presents all the embryos; in graph A the embryos were grouped 
according to their chromosomal status. Within the euploid embryos the majority 
carried cross-over events, whereas the number of aneuploid and complex aneuploid 
embryos that showed no recombination was higher than those that did. Embryos 
that had reached the morula stage and did not show recombination were more than 
those that did and finally, arrested embryos and blastocysts with recombination 
were more common than those with no recombination. Comparison of these 
percentages did not reveal any significant differences (Fisher’s exact test, p>0.05).  
 
 
Figure 3.35: Embryos with and without recombination 
Figure 3.35: Embryos with or without recombination grouped according to the chromosomal 
status (A) or their stage of development (B).  
 
3.3.6 Parental origin of aneuploidy 
Amplifying polymorphic markers located on different chromosomes on DNA from 
parents and their embryos provided the ability to detect possible aneuploidies 
present in the embryos, as well as their parental origin. Moreover, the chromosomal 
status of each embryo was known through aCGH, therefore, any indication of 
aneuploidy seen with the STR markers could be confirmed in the aCGH result. 
Table 3.23 presents all the embryos with marker results that suggested aneuploidy, 
confirmation or not of this aneuploidy by aCGH as well as the parental origin of 
chromosomal abnormalities. The result of the markers on chromosome 17 for 
embryo C1.5, indicated monosomy 17, however no aCGH result was available for 
that embryo and was therefore was not included in this set of results.  
 
Seventeen embryos showed evidence of aneuploidy by the STR analysis in one 
locus. Of these 17 possible aneuploidies a true gain of loss of the chromosome was 
confirmed by aCGH in seven. These were five monosomies and two trisomies. The 
most commonly involved chromosome in changes that were confirmed by aCGH 
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was chromosome 16, seen in four cases of aneuploidy, chromosome 17 in two and 
chromosome 19 was involved in one aneuploidy. Maternally derived aneuploidies 
were the most common, as five were detected. The remaining two were paternally 
inherited.  
 
The possible aneuploidies as indicated by the STR markers that were not detected 
by aCGH were 10. Of these, seven showed possible monosomies and three 
trisomies. The indication of monosomy not confirmed by aCGH might have been a 
result of ADO, where expected heterozygote samples appeared as homozygote. For 
example, embryo C7.2 the paternal allele 212 for marker D16S429 on chromosome 
16 failed to amplify and since the parents were not informative for the other marker 
on chromosome 16 (D16S3053, both homozygote 240), a false indication of 
monosomy was given (appendix C). Possible uniparental disomy (UPD) was also 
detected for chromosome 16 in embryo C7.7 since that embryo had two maternal 
alleles for marker D16S492 and no paternal. This could not be confirmed by the 
other marker (D16S3053) due to homozygosity of the parents with the same allele 
size and also by aCGH since two pairs of chromosome 16 would have been present 
in the embryo, thus would result to a profile identical to a euploid sample.  
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Table 3.23: Embryos with indication of aneuploidy as detected by the STR markers. 
Presence of aneuploidies was confirmed by aCGH. The parental origin of the aneuploidy 
could also be detected with the use of the STRs.  
 
 
Table 3.23: Parental origin of aneuploidy, as detected by STR markers 
Embryo 
Aneuploidy 
detection by STR 
markers 
Confirmation of 
aneuploidy by 
aCGH 
Parental origin of 
error 
C1.8 Monosomy 
Chromosome 5 
Not confirmed Paternal 
C2.6 
Monosomy 
Chromosome 5 
Not confirmed Paternal 
C2.7 
Monosomy 
Chromosome 5 
Not confirmed Paternal 
C4.2 
Monosomy 
Chromosome 17 
Confirmed Maternal 
C6.5 
Monosomy 
Chromosome 16 
Confirmed Maternal 
C6.9 Trisomy 
Chromosome 16 
Confirmed Maternal 
C6.15 
Trisomy 
Chromosome 16 
Confirmed Paternal 
C6.20 
Monosomy 
Chromosome 19 
Not confirmed Paternal 
C7.2 
Monosomy 
Chromosome 16 
Not confirmed Paternal 
C7.4 
Monosomy 
Chromosome 16 
Confirmed Maternal 
C7.5 
Monosomy 
Chromosome 5 
Not confirmed Maternal 
C7.7 
UPD Chromosome 
16 
 
Trisomy 
Chromosome 19 
Not confirmed 
 
 
Not confirmed 
Maternal 
 
 
Maternal 
C8.2 
Trisomy 
Chromosome 19 
Not confirmed Paternal 
C8.3 
Trisomy 
Chromosome 19 
Not confirmed Paternal 
C9.1 Monosomy 
Chromosome 5 
Not confirmed Maternal 
C9.2 Not confirmed Maternal 
C9.8 
Monosomy 
Chromosome 19 
Confirmed Maternal 
C10.3 
Monosomy 
Chromosome 17 
Confirmed Paternal 
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3.3.7 Summary of results for section 3.3: Investigation of 
recombination in preimplantation embryos 
 
 FPCR amplification was highly successful on whole genome amplified 
embryos by SurePlex with a low amplification failure and allele drop out rate. 
 Detection of recombination in embryos using polymorphic markers was 
highly dependant on marker informativity. 
 Recombination frequency varied between families and individuals and it was 
higher in females than males. Chromosome 19 showed the highest 
recombination frequency among all chromosomes analysed, whereas no 
recombination events were detected on chromosome 5. Recombination 
frequency decreased with age in females and males, but the decrease 
observed in males was higher. Recombination frequency in females over 35 
is significantly higher than recombination frequency in males in the same 
age group. 
 No significant differences were observed in the recombination frequency of 
euploid, aneuploid and complex aneuploid embryos and embryos at different 
developmental stages.  
 The use of aCGH and polymorphic markers offered the ability to detect the 
parental origin of aneuploidy in some embryos. The majority of the 
aneuploidies were maternally derived.  
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4.1 Validation of aCGH for clinical use in PGS 
 
4.1.1 24sure array platform 
The first aim of the present study was the validation of the 24sure microarray 
platform for the analysis of all chromosomes in preimplantation embryos. The same 
platform has been widely used for clinical PGS cases and research studies. Fishel 
et al published the first aCGH analysis with 24sure on polar bodies from a 41-year 
old woman with a history of 13 failed IVF cycles, resulting in a live birth (Fishel et al, 
2010). Since then, 24sure has been used in PGS cycles to test blastomeres (Ata et 
al, 2012) and TE samples (Fragouli et al, 2011a). Despite the good clinical results in 
all applications, no validation on samples of known chromosomal status had been 
described at the start of this study. 
 
4.1.2 Use of cell lines for the validation 
Prior to clinical application, each technique needs to be validated to ensure 
efficiency, accuracy and, in the case of preimplantation diagnosis, speed of analysis. 
aCGH is a new technique for the detection of numerical chromosomal abnormalities 
in embryos and no clear guidelines of the steps that need to be undertaken for its 
validation are available. The European Society of Human Reproduction and 
Embryology (ESHRE) has published two sets of guidelines for PGD and PGS 
(Thornhill et al, 2005; Harton et al, 2011b; Harton et al, 2011c). These guidelines 
however, are restricted to PCR- and FISH-based analyses. Validation of each 
protocol is recommended on single cells of known genetic and/or chromosomal 
status. Testing in “spare” polar bodies, single blastomeres and trophectoderm cells 
prior to aCGH is advised (Harper and Harton, 2010) however, these are samples 
carrying unknown chromosomal complements. The ESHRE PGS task force has 
published two studies describing the technical and clinical aspects of the validation 
of aCGH in PGS post polar body biopsy (Geraedts et al, 2011, Magli et al, 2011). 
Validation using cell lines is ideal, since there is an a priori knowledge of their 
chromosomal status. Ovarian epithelial cell lines were used for the validation in this 
study.  
 
The chromosomal constitution of the four cell lines used, as well as the 
chromosomal stability within each line, was confirmed by FISH analysis. Results 
revealed that these lines were indeed stable, with the expected aneuploidies, 
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detected in lines TOV-21G and SKOV-3 and euploidy confirmed in lines IOSE11 
and IOSE 19 with acceptable rates (>90% of cells analysed for all cell lines).  
 
 
4.1.3 Analysis of single cells by aCGH after cleavage stage 
biopsy 
Several studies have been published describing the use of cell lines for the 
validation of aCGH at the single cell level. However, a variety of WGA techniques 
and array platforms were used. The use of MDA with BAC arrays was validated for 
the detection of aneuploidies on 12 single cells from aneuploid cell lines, as well as 
six cells with segmental rearrangements as small as 34Mb. All expected, whole and 
segmental chromosome changes, were successfully detected. Further validation of 
aCGH was performed on two embryos that were found to be aneuploid by FISH 
during PGS. Discrepancy between the aCGH and the FISH result was observed in 
one of the two embryos, which was attributed to mosaicism (Le Caignec et al, 2006). 
The use of GenomePlex for WGA, the method used in the present study for the 
validation of single cell aCGH, with BAC arrays has been described previously 
(Fiegler et al, 2007). Whole chromosome and segmental changes were detected in 
a small number of single cells from tumor cell lines, as well as patients with trisomy 
21 and Prader-Willi syndrome. The authors suggested that there was less variability 
in their results when compared to the study by Le Caignec et al, where MDA was 
used.  Fuhrmann et al described the ability to detect segmental changes as small as 
4.4 and 5Mb could be detected on single cancer cells using a BAC array (Fuhrmann 
et al, 2008). Although analysis by 24sure can detect changes bigger than 10Mb, the 
purpose of PGS is the accurate detection of whole chromosomal changes. Finally, 
blind analysis on 24 single cells from aneuploid cell lines was performed as part of 
validation of SNP arrays, which showed 100% accuracy (Treff et al, 2010a). 
 
This study describes the use of specific types of WGA (GenomePlex and SurePlex) 
in combination with the 24sure arrays (24sure) for which, no other validation using 
cell lines, has been described before. WGA by random fragmentation of the DNA 
and subsequent amplification, using GenomePlex was very efficient as 95% of the 
single cells were successfully amplified. The potential causes of WGA inefficiency or 
failure for the single cells include failed transfer of cells to the tubes during isolation 
and transfer of anucleate cells or cells with degraded DNA. Four of the amplified 
single cells produced a weak smear on the agarose gel. Subsequent aCGH analysis 
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failed for three out of these four cells. Despite the weak smears, these cells were 
analysed by aCGH in order to maximise the data in the validation process. During a 
PGS case, similar samples should still be analysed, as successful analysis is 
possible. This is supported by the one cell that was successfully analysed by aCGH 
despite the faint smear. Additionally, quality indicators provided by the software 
together with the aCGH result (discussed in the Discussion section 4.1.5) indicate 
the quality of the amplification. Blind aCGH analysis was performed on 40 single 
cells revealing, upon decoding, a 100% concordance in the aCGH result and the 
chromosomal status of the cells.  
 
 
4.1.4 Analysis of mosaic models by aCGH for PGS after 
blastocyst biopsy 
An alternative approach for chromosomal analysis in PGS is after blastocyst biopsy. 
Compared to cleavage stage embryo, blastocyst biopsy is thought to be more 
appropriate, as six to ten cells from the trophectoderm can be analysed as one 
sample therefore minimising problems faced during single-cell analysis. In addition, 
the levels of mosaicism are not as high at that stage. However, mosaicism can still 
be present in the blastocyst and studies have shown that the TE reflects the 
chromosomal constitution of the inner cell mass  (Evsikov and Verlinsky, 1998). 
Aneuploid and euploid cells were mixed in known ratios to analyse the effect of 
mosaicism in aCGH. All samples were successfully amplified by SurePlex. As 
described above, amplification of single cells by GenomePlex was successful on 
95% of cells. The 100% amplification efficiency in the mosaic samples might have 
been due to the increased number of cells in the starting material. These two WGA 
methods were based on a similar technology, including, fragmentation of the 
genome, library preparation and library amplification by universal primers. The 
library preparation is performed by an isothermal reaction during GenomePlex, 
whereas thermal cycling is used during SurePlex (data from 
www.rubicongenomics.com). Gutiérrez-Mateo et al, showed that GenomePlex had 
significantly higher rates of amplification failure when compared to SurePlex on 
single blastomeres. This indicated that SurePlex gives a better representation of a 
cell’s genome, even when the DNA is not of high quality (Gutiérrez-Mateo et al, 
2011).   
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Analysis of the log2 ratio for all clones on chromosome 10, showed an increasing 
trend of the ratio in all samples, as the proportion of aneuploid cells increased. 
However, variability was seen between the TE and blastocyst models as well as 
within the repeated samples of each model. The presence of cells with degrading 
DNA might affect the aCGH outcome. This might be more apparent in samples with 
fewer cells, as it was observed in this study. In the blastocyst model, where the total 
number of cells was 100, with 50% aneuploid cells, the log2 ratio was 0.4, compared 
to 0.28 for the TE model with the same proportion of aneuploid cells but only eight 
cells were in the sample in total.  
 
Vermeesch et al, have described the effect on aCGH of a sample containing 20% of 
a cell line with trisomy 13 and a normal cell line (Vermeesch et al, 2005). This 
resulted in an increase of the ratio for all the chromosome 13 clones. In this study, a 
shift from normality was observed when the percentage of aneuploid cells was over 
25%. A sample with 20% aneuploid cells was not analysed, but a small shift would 
have probably been detected. Moreover, the starting material in the experiment 
described by Vermeesch et al, was genomic DNA and not amplified material from a 
small number of single cells. Detection of low-level mosaicism might be easier in 
this type of samples.  
 
The effect of mosaicism on SNP arrays has also been described through the use of 
cell lines. Northrop et al, chose to mix single cells from male and female cell lines in 
known proportions and examine the change of the X chromosome when the 
samples were run against a female reference DNA (Northrop et al, 2010). A copy 
number change, as monosomy X, was detected when the proportion of male cells in 
the sample was over 25%, the same result that was obtained when 100% of male 
cells were present. This comes in contrast to the gradual change in the ratio 
observed in this study, as the number of aneuploid cells increased in the sample.  
 
Moreover, detection of mosaicism by aCGH when the proportion of aneuploid cells 
in the sample is 30% or more has been described in another study (Fragouli et al, 
2011a). This conclusion was drawn after TE biopsy and analysis by aCGH and 
further reanalysis by FISH on the remainder of the embryo, to confirm the findings. 
The mosaic models used in this study were prepared with precise knowledge on the 
ratio of aneuploid cells present in the sample, thus providing a better means of 
analysis of the effects of mosaicism, than analysing a biopsied sample containing an 
unknown ratio of aneuploidy. Overall, several studies, including this, have shown 
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that mosaicism can be detected by aCGH and SNP arrays. However, if the biopsied 
sample contains mosaic cells that are a result of mitotic non-disjunction, with 
reciprocal abnormalities (monosomy and trisomy), no error will be detected by any 
type of array, as the abnormalities will result in a ratio of zero. Abnormalities from 
mitotic non-disjunction will still be detected if the biopsied sample contains a clear 
majority of one of the two cell lines. 
 
 
4.1.5 Key quality indicators for aCGH 
As discussed in the Discussion section 4.1.3, the agarose gel was the first indicator 
of a successful WGA. Samples producing a bright smear were the ideal starting 
material for labelling and hybridisation on the arrays and were expected to produce 
a good aCGH result. The software, BlueFuse, provided indicators on the quality of 
each aCGH experiment. These were the percentage of clones included in the 
analysis, the signal to background ratio and the mean spot amplitude. In our lab, 
65% has been set as an acceptable value for the percentage of clones included as 
a threshold. Results with a percentage of clones, lower than the threshold are 
considered failed. The values of the clone inclusion of the mosaic TE models were 
compared with those of the mosaic blastocyst models.  Even though the number of 
cells in the TE groups was eight and in the blastocyst groups 100 the average 
percentage of clones included in the TE groups was 81.74%, higher than in the 
blastocyst groups, which was 77.71%. This was surprising as it was expected that 
aCGH on a larger number of cells would produce better quality result. The reason 
for this was probably the incorporation of high volume of PBS during isolation of the 
100-cell samples in the tube, which compromised the amplification of the samples.  
 
Aside from the quality of starting material, other factors that can influence the result 
are the time of the labelling and hybridisation. Experiments with different timings 
revealed that the combination that provided the best result, with the indicators well 
above the desired values, was long labelling for 18 hours and short hybridisation for 
three hours. Acceptable values were also obtained with three hours labelling and 16 
hours of hybridisation. Knowing that both these combinations will provide an 
interpretable result is beneficial when performing a PGS case, as experiments can 
be set up according to time availability.  
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4.1.6 Concordant results between blastocyst and TE 
Four blastocysts were biopsied and both the TE and the remainder of the embryos 
were analysed by aCGH. The purpose of this was twofold. First, this procedure 
acted as a “dry-run” case before such PGS cases were performed. The efficiency of 
the biopsy procedure was confirmed as all samples produced a result and 
embryologists confirmed re-expansion of the blastocyst post biopsy. The second 
purpose was to examine whether the results obtained from the TE sample were 
representative of the whole blastocyst. Overall, concordance between the TE and 
the blastocyst was confirmed in four embryos. However, this was not the case in a 
study, where analysis was performed in three different biopsied TE samples and the 
ICM from each blastocyst by SNP array (Northrop et al, 2010). Of the 50 blastocysts 
analysed, 24% showed discordant results between the four samples of each 
blastocyst. The rest were either all euploid or all presented the same aneuploidy. 
Within the blastocysts with discordant results, the authors did not find any 
preferential segregation of the abnormalities in the TE samples and findings were 
attributed to mosaicism.   
 
In this study, two of the four blastocysts were euploid and therefore confirmation 
could only be performed by the sex chromosomes, which was indeed achieved in 
both. The third pair showed loss of chromosome 21, which was present in both. 
Finally, the TE sample of the last pair seemed euploid, however the change of log2 
ratio did not correspond to a male or a female sample. Even though there was a 
shift for both chromosomes, it was below the 0.3 threshold for chromosome X and 
around -0.4 for chromosome Y, instead of -0.8, expected for female samples. This 
could be accredited to poor hybridisation, which may produce bad separation of the 
sex chromosomes. This could not have been the case though, as all TE samples 
were run together and a more dynamic change was observed in the other female TE 
sample. Moreover, all blastocyst samples were run together in a later, separate 
experiment and similar log2 ratios were observed for the sex chromosomes. All the 
above, indicated that this was possibly a triploid embryo with a 69,XXY karyotype. 
aCGH cannot detect ploidy in the sample, as the abnormality present in all 
chromosomes will be averaged out, giving a euploid result. If, however, there is a 
sex mismatch, in a polyploid sample, a separation in the sex chromosomes should 
be expected, though not as dynamic as in diploid samples, due to the false 
normalisation of the autosomes from the software. This also suggests that hypo- or 
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hyperploid samples carrying an extra aneuploidy for one of the autosomes should 
still be detected by aCGH.  
 
4.1.7 Follow-up analysis of untrasferred embryos by FISH 
Previous studies of CGH, where all the cells of untransferred embryos were 
analysed individually by FISH, have speculated that discordant results were due to 
mosaicism and/or technical artefacts (Gutiérrez-Mateo et al, 2011). In this study, 
reanalysis by FISH was performed on seven embryos, which were found to be 
aneuploid and thus not transferred, as well as one euploid that was not transferred 
due to bad morphology, after PGS cycles using aCGH. Blastocyst biopsy was 
performed on two embryos, whereas cleavage stage biopsy was performed on the 
remaining six. Probes for the FISH analysis were selected according to the 
aneuploidies detected by aCGH and their availability in the lab.  
 
An indication for mosaicism was detected in both blastocysts analysed by aCGH, 
with one (A1.1) carrying only that abnormality, whereas the other presented 
abnormalities affecting three chromosomes. FISH analysis for chromosome 14 that 
was deemed mosaic after aCGH, for embryo A1.1, revealed that 33% of the nuclei 
were monosomic for that chromosome. The average log2 ratio for that chromosome 
was -0.20, thus indicating mosaicism. From the mosaic TE models, as described in 
the Discussion section 4.1.4, a similar increase in the ratio was observed when the 
proportion of cells was between 25% and 37.5%. The mixing experiments were 
conducted with an aneuploid cell line carrying trisomy for chromosome 10, thus 
examining the effect in chromosomal gain. This cannot be extrapolated for 
chromosomal losses due to differences in the ratios. In a trisomic sample the 
theoretical ratio of the test over the reference DNA would be 3:2, whereas in a 
monosomic it would be 1:2. FISH analysis of all individual nuclei in the blastocyst 
can confidently reveal the true level of mosaicism in the remaining embryo. This was 
also made apparent with embryo A2.1, where chromosomes 1 and 5 had a log2 ratio 
of 0.24 and 0.25 respectively, but 88% and 85% of the total nuclei analysed, 
showed to carry that abnormality. A higher ratio was expected for both 
chromosomes, if the proportion of aneuploid cells was the same in the biopsied 
samples.  
 
Possible experimental and biological variation may be a feature of the aCGH result. 
The mixing experiments revealed that there was a small variation between samples 
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with the same starting material. For example, as seen in table 3.2 in the Results 
section, within the 8-cell group, the log2 ratio of sample 6(A) was 0.28, whereas the 
log2 ratio of sample 6(B) was 0.37. Both of these samples contained 75% of 
aneuploid cells and the difference in the log2 ratio revealed experimental variation. 
The aCGH results of the TE biopsied samples discussed here were indicative of 
mosaicism, a result of biological variation. This provided the knowledge that an 
abnormality was present but it was not possible to accurately predict the exact 
proportion of aneuploid cells present in the sample.  
 
Reanalysis of embryos found to be aneuploid after biopsy of single blastomeres, 
confirmed that mosaicism at that stage renders aCGH not to be representative of 
the chromosomal situation in the whole of the embryo. FISH analysis confirmed all 
the aneuploidies that were detected by aCGH, therefore aCGH did not give any 
false positive results. Of these five embryos, only one carried the aneuploidy 
detected by aCGH in all the nuclei analysed by FISH. In the rest the abnormality 
was seen only in a proportion of nuclei. Mitotic non-disjunction was also detected in 
one embryo, which carried both monosomic and trisomic cells for chromosome 15 
and aCGH had shown loss for that chromosome. The one embryo that was found to 
be euploid by aCGH on day three, was classified as diploid/chaotic mosaic by day 
five FISH analysis.  
 
4.1.8 Is PGS beneficial? 
PGS was regarded as a promising technique in aiding infertile couples during the 
first years of its application. However, several RCTs revealed that it was not 
beneficial and even resulted in reduced pregnancy rates in patients with AMA 
(Mastenbroek et al, 2011). This was attributed to technical and biological limitations. 
FISH analysis does not allow the enumeration of all chromosomes and therefore a 
lot of aneuploidies remained undetected. Moreover, the majority of PGS cases were 
performed at cleavage stage biopsy on single blastomeres, which due to mosaicism 
might not be representative of the chromosomal status of the remainder of the 
embryo. The complete enumeration of chromosomes by aCGH together with biopsy 
at stages when mosaicism may be less of a concern, polar body and TE, is an 
alternative that can overcome the above-mentioned limitations.  
 
Potential and true benefit of PGS performed with these procedures can only be 
uncovered through properly conducted RCTs. Indeed the ESHRE PGS task force 
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has performed a pilot study as the first step towards a multicentre RCT, examining 
the outcome of polar body testing by aCGH using the 24sure platform (Geraedts et 
al, 2011). Encouraging results were obtained after analysis of TE samples in a 
randomised pilot study, on good prognosis patients. Using the same platform, as the 
one used in this study, 24sure, it was revealed that the clinical and on-going 
pregnancy rates were significantly higher in couples that received PGS than those 
that did not (Yang et al, 2012). The choice of the patient cohort for randomisation in 
the study by Yang et al was couples with maternal age less than 35 years, with no 
previous IVF treatment, seeking IVF due to tubal or male factor. The reproductive 
potential in this group of couples is not comparable to those that normally choose to 
go through PGS, who are considered infertile. On average, 7.7 blastocysts were 
analysed per couple, a high number that is rarely achieved in couples that undergo 
PGS. The stage of transfer is another issue with blastocyst biopsy. aCGH analysis 
is possible within 24 hours, thus transfer may be performed on day six. However, 
data have suggested that transfer on day six may be close to the limit of the 
implantation window and dyssynchrony of the endometrium and the embryo may 
result on poor pregnancy rates (Van Voorhis and Dokras, 2008). Moreover, transfer 
of frozen/thawed embryos in a natural or mildly stimulated cycle may provide 
benefits in the receptivity of the endometrium, early implantation and the 
development of the placenta, since it reflects more the natural process (Pinborg, 
2012). 
 
Very recently, the validation of a new, rapid technique to detect imbalances in all 
chromosomes has been described (Treff et al, 2012). Quantitative real-time PCR 
(qPCR) was performed on samples containing five cells from cell lines of known 
karyotypes and TE samples biopsied from blastocysts. The chromosomal status of 
the blastocysts was previously determined by SNP arrays on TE biopsied samples 
from each embryo. The authors suggested that, with this selection of embryos, there 
was control over the chromosome abnormalities and the risks of mosaicism were 
minimised. Results were obtained in four hours, showing 97.6% reliability in the 
diagnosis post analysis of the cell lines and 98.6% consistency for the 24-
chromosome analysis in the blastocysts. Although, this seems a promising 
technique, especially when opting for a fresh transfer, further assessment is needed 
with RCTs.  
 
A lot of progress has also been observed in the field of whole genome sequencing 
of small amounts of DNA. Tests have been performed on biopsied samples from 
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blastocysts to detect the suitable method of amplification that will result in a 
template of sufficient quality for the sequencing (Peters et al, 2011). The 
introduction of the long fragment read (LFR) technology, describes the ability to 
perform whole genome sequencing and haplotyping on the DNA from 10 to 20 
single cells, following amplification by a modified MDA, the protocol found best 
suited for sequencing analysis in blastocysts (Peters et al, 2011). This type of 
sequencing provides information on the diploid genome with a low error rate, more 
sensitive than that provided by aCGH or SNP array analysis (Peters et al, 2012).  
 
Even if technology advances, the problems in the diagnosis generated by 
mosaicism will still be present. Mosaicism at the cleavage stage may result in the 
biopsy of cells not representative of the whole embryo. At the blastocyst stage, 
mosaicism is an issue and despite the fact that this study showed that it could be 
detected by aCGH in TE samples, its true level on the remainder of the embryo will 
never be known. The only stage when mosaicism does not pose any risks is the 
oocyte. Therefore, analysis of both polar bodies in couples that are at high risk of 
maternal errors, like those with AMA, by aCGH may be the only stage in which PGS 
will actually be of benefit. However, even at that stage some biological limitations 
should be taken into consideration. Depending on the segregation of the sister 
chromatids in meiosis II, following premature separation of the chromatids in 
meiosis I, the zygote will be euploid or aneuploid. Identification of reciprocal errors in 
both polar bodies indicates a euploid zygote (Scott et al, 2012a). However, 
anaphase lag may cause chromosomal loss in one of the polar bodies, with no 
reciprocal changes in the other polar body or the zygote (Handyside et al, 2012). 
This observation, together with the fact that errors that are paternal in origin cannot 
be detected, highlight the fact that polar body biopsy will never be 100% accurate of 
the chromosomal status of the zygote.  
 
Other approaches in IVF may aid reproductively challenged couples to become 
pregnant that do not involve invasive techniques. For example, one study has 
shown that single blastocyst transfer in women older than 35 has resulted in a high 
pregnancy rate of 51.1% (Davis et al, 2008). Moreover, the use of time-lapse 
imaging of in vitro embryo development can provide a tool for predicting blastocyst 
formation from as early as day two of development (Wong et al, 2010). Time-lapse 
imaging does not affect embryo quality, blastocyst formation and pregnancy rates, 
as described in a study analysing embryos from female donor cycles (Cruz et al, 
2011). Preliminary data of a study investigating the length of early divisions in 
 170 
diploid and aneuploid murine preimplantation embryos, showed that diploid embryos 
divided faster (Elaimi et al, in preparation). 
 
4.2 Aneuploidy in embryos from couples undergoing PGD 
The second aim of this thesis was to determine the aneuploidy level in embryos 
from couples undergoing PGD for single gene disorders. In the majority of cases the 
only indication for IVF is for the purpose of PGD. Embryos are generated in vitro for 
biopsy, diagnosis and ultimately transfer of unaffected embryos. These couples do 
not necessarily face fertility problems, since some of them may already have a child 
or have gone through the termination of an affected pregnancy. Others choose not 
to get pregnant to avoid the risk of an affected pregnancy, but their young age and 
fertility checks before IVF can suggest their good fertility status. Aneuploidy in the 
embryos of this cohort of patients may be the reason for a lack of pregnancy, in 
spite the transfer of high quality, free of mutation, embryos. In some cases, 
aneuploidy may be the source of error during PGD (Delhanty et al, 1997). For 
example, monosomy of the chromosome carrying the disease-causing gene will 
result in a false negative result in the analysis of an autosomal dominant mutation. 
The detection of both parental genomes through the incorporation of linked to the 
disease-causing gene, polymorphic markers in the PGD protocol is a way to detect 
aneuploidy. The absence of one or the presence of one extra parental allele will 
result in the deviation from the expected haplotype in heterozygote samples.  
 
A small number of studies have presented data on the chromosomal constitution of 
embryos from young and presumably fertile patients. Two of them (Munné et al, 
2006 and Reis Soares et al, 2003) performed analysis on embryos from cycles with 
oocyte donors. In both, the data used were clinical results performed by FISH on 
single blastomeres biopsied from cleavage stage embryos with no follow-up 
analysis on the remainder of untransferred embryos. Munné et al compared the 
results with embryos from patients undergoing PGS, which were divided into 
subgroups according to maternal age. In the donor group (average maternal age: 
25.6), the rate of chromosomally abnormal embryos was high (57%), however, 
significantly less than the rate of chromosomally abnormal embryos in all the PGS 
groups. The second study by Reis Soares et al, compared the results of the donor 
group, with that of a group of couples undergoing PGD for X-linked diseases. The 
same set of probes was used for both groups. Despite the fact that the maternal age 
in the donor group was lower than in the PGD group (27 and 31 years), the 
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frequency of abnormalities in embryos of the donor group was significantly higher 
than the PGD group (56.5% and 37.3%). Both studies attributed the high rate of 
chromosomal abnormalities in the stimulation used in donor cycles, which was 
aggressive in order to produce a large number of follicles. This hypothesis was 
contradicted after the analysis of embryos from IVF cycles with no ovarian 
stimulation. Aneuploidy was still present in these embryos at a rate of 36.4%, 
despite the fact that the maternal age was low (mean 31.4 years) (Verpoest et al, 
2008).   
 
4.2.1 Chromosomal analysis by FISH 
In total, 86 embryos were analysed by FISH and successful analysis was possible in 
82.5%. FISH failure could be attributed to fault in the fixation of the embryos on the 
microscope slide, but also to degraded DNA material. Failure of FISH reanalysis of 
day five embryos at an even higher rate of 23% has been previously described and 
was attributed to degeneration of the embryos (Baart et al, 2006). A five-probe set 
was used, analysing chromosomes 13, 18, 21, X and Y in two consecutive FISH 
rounds. This choice of probes is preferred by other groups for analysis, as it covers 
chromosomes that are at high risk of involvement in aneuploidy. Diploidy, 
aneuploidy and mosaicism differed at each developmental stage.  
 
Uniform diploidy and aneuploidy were only seen in arrested embryos and morulae. 
Similar to this study, analysis of 50 embryos by FISH, revealed diploid embryos at 
only the cleavage and morula stages. The authors suggested that the fourth mitotic 
division of an embryo is the one generating most blastomeres with an aneuploidy 
(Gonzalez-Merino et al, 2003). Even though the embryonic genome is activated 
during the cleavage stage, maximum expression for the majority of embryonic 
genes occurs at the blastocyst stage (Wells et al, 2005). This can explain the fact 
that errors in mitosis can occur in later cell divisions. Moreover, it can provide an 
explanation for the presence of diploid embryos in only the cleavage and morula 
stages. The presence of maternal transcripts could have aided in the normal 
progression of embryos during the first stages of preimplantation development. 
However, failure of expression of genes, post EGA, responsible for correct 
chromosome segregation, cell cycle control and apoptosis might have led to 
developmental arrest.  
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Mosaicism was detected at all stages, however only diploid mosaic morulae and 
blastocysts were seen. The rate of mosaicism increased from 67% at the morula 
stage to 100% at the blastocyst. The chaotic embryos observed were all arrested. 
The overall rate of 50% diploid mosaic embryos is in line with other studies 
examining aneuploidy at all developmental stages (Bielanska et al, 2002). FISH 
analysis allowed the distinction between errors in meiosis and mitosis. In total, 13 
meiotic and 48 mitotic errors were detected. Among the mitotic errors, chromosome 
loss (CL) was more frequent, followed by chromosome gain (CG) and mitotic non-
disjunction. The frequency in the type of mitotic errors varies among studies. Some 
have reported CL as the most frequent and others CG (Fragouli et al, 2011a). 
Monosomy was more frequent within the meiotic errors, an observation made by 
other groups as well (Gonzalez-Merino et al, 2003). On the other hand, monosomy 
rates might be overestimated by FISH due to technical issues. Hybridisation failure 
of one of the two chromosomes in a diploid sample and overlapping signals may 
occur during FISH (Ruangvutilert et al, 2000b) and may result in the false scoring of 
a diploid cell as monosomic. 
 
All 15 blastocysts analysed by FISH were found to be diploid mosaic and all of them 
consisted of 50% to 90% of diploid cells. Mosaicism in the blastocyst has been 
described in many studies, in which FISH was used. Similar findings, with no 
aneuploid and only diploid or diploid mosaic blastocysts from routine IVF patients, 
have been described after the use of the same set of probes (Ruangvutilert et al, 
2000a). In a study by Fragouli et al, aneuploid and diploid mosaic blastocysts were 
identified 32.7% of 52 blastocysts analysed and only around 6% of all blastocysts 
contained more than 50% of diploid cells (Fragouli et al, 2011a). This substantial 
difference in the proportion of diploid cells seen in the present study could be due to 
various reasons. First, the average maternal age in the study by Fragouli et al, was 
36, compared to the younger 32.5 in this study and second, nine probes were used 
compared to only five in this study. Consequently, fewer errors were detected in our 
cohort of blastocysts due to younger maternal age and possible inability to detect 
some errors due to the small number of probes. Similar findings in blastocysts were 
described by Baart et al, 2006, where the proportion of mosaic blastocysts was 45% 
in a cohort of couples of maternal age similar to this study (average age 33.1 years). 
Again the number of probes was higher than this study, as ten chromosomes were 
tested. Analysis of blastocysts by Bielanska et al, revealed, a proportion of diploid 
mosaic blastocysts similar to the one described in this study, at 90.9%, when only 
three chromosomes were tested (Bielanska et al, 2002). The average number of 
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diploid cells within the blastocysts was 78.2%, slightly higher than the number seen 
in this study, 71.6%, probably due to the two additional probes used here.   
4.2.2 Chromosomal analysis by aCGH 
aCGH allows the complete enumeration of the chromosomes, as well as the 
detection of aneuploidies on chromosomes not analysed by FISH, resulting in 
different chromosomal classification of embryos. The ideal way to examine 
aneuploidy in embryos is through complete disaggregation and analysis of all 
individual cells by CGH, which, however, is difficult to perform in advanced embryos 
(morulae and blastocysts) due to compaction of cells. For this reason 
disaggregation studies are limited to cleavage stage embryos. Uniformly euploid, 
mosaic and chaotic embryos have been described after disaggregation and analysis 
of all cells by mCGH (Voullaire et al, 2000, Wells and Delhanty, 2000) and aCGH 
(Mertzanidou et al, 2012). In this study, it was not possible to determine whether the 
aneuploidies seen by aCGH were meiotic or mitotic in origin, as analysis was 
performed in whole embryos. Embryos were scored as euploid; aneuploid when one 
or two chromosomes were affected and as complex aneuploid when three 
chromosomes or more were affected. This type of scoring has been previously 
described (Voullaire et al, 2007). Embryos carrying abnormalities affecting two 
chromosomes can lead to a pregnancy, as described in the analysis of spontaneous 
abortions (Guerneri et al, 1987). In this study, aneuploid embryos were divided in 
the two groups, aneuploid and complex aneuploid, in order to differentiate between 
those that could lead to implantation and pregnancy and those that would not.  
  
Within the 52 embryos analysed successfully by aCGH, the level of euploid and 
aneuploid embryos was almost equal (38% and 37% respectively), whereas 25% of 
embryos were found to be complex aneuploid. Of the 123 errors detected in all 
embryos, 55 were chromosome losses and 68 were gains. The wide scale studies 
of embryos using FISH have revealed that monosomy occurs more often than 
trisomy (Munné et al, 2004). However, samples scored as monosomic after FISH 
may be a result of hybridisation failure. The results in this study support that, as 
trisomy occurred more often than monosomy.  
 
Studies on blastocysts using either mCGH or aCGH have revealed that errors 
affecting all chromosomes may lead to aneuploidy. Frequencies of errors within the 
chromosomes may vary. In this study, chromosome 22 was the most commonly 
affected with five errors. The rest of the chromosomes showed one or two errors, 
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apart from chromosomes 2, 5, 6, X and Y that showed no change. This comes in 
contrast with the findings by Fragouli et al, 2010, who reported that the sex 
chromosomes were most frequently involved in errors (Fragouli et al, 2010). 
Abnormalities affecting chromosome 22 has been seen as the predominant error in 
some studies (Fragouli et al, 2011a), whereas other studies have reported 
chromosome 16 to show most frequent abnormalities (Rius et al, 2011). 
 
4.2.2.1 Segmental chromosomal changes 
Eight out of 52 embryos analysed by aCGH (15%), two blastocysts, three morulae 
and three arrested at the cleavage stage, showed evidence of segmental changes. 
Seven embryos carried one change and one carried three. Chromosomal material 
was lost in all, except one. Five embryos had additional aneuploidies. In three 
embryos, the sole abnormality detected, was the segmental change that involved 
whole chromosome arms, the termini, or changes within one arm. The smallest 
change detected was 17Mb, whereas the largest was 82Mb, which involved the loss 
of the q arm of chromosome 6. Smaller segmental changes were not scored, as 
they may have been artefacts of the amplification.  
 
Similar to whole chromosome changes, segmental aberration can be derived from 
errors in meiosis or mitosis (Voet et al, 2011) as previously described in studies 
using comprehensive chromosome analysis to examine cleavage stage embryos 
(Voullaire et al, 2000, Wells and Delhanty, 2000). Different studies have reported 
various rates of segmental aneuploidies using different array platforms, different 
cohorts of patients and embryos of different developmental stages. Voullaire et al 
reported an 8% incidence of segmental changes by mCGH in single blastomeres of 
patients with RIF (Voullaire et al, 2002). A higher rate of 30% has been reported 
elsewhere (Daphnis et al, 2008). This was, however, the result of analysing single 
blastomeres from day three embryos, where segmental aneuploidy as whole 
chromosome aneuploidy is detected more often. A study of untransferred day five 
embryos from AMA cases (average age 42.4 years) revealed segmental changes in 
31.8% of embryos, a higher percentage to that reported here (Rius et al, 2011). a 
recent study examining only one chromosome in PGD cycles of carriers with 
structural chromosomal abnormalities showed that chromosome breakage is 
independent of maternal age (Xanthopoulou et al, 2012). Vanneste et al reported 
segmental abnormalities in embryos from patients similar to our cohort (couples 
undergoing PGD, with no known fertility issues), analysed by SNP arrays. Analysis 
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of all blastomeres from disaggregated day three or four embryos showed a 
segmental aneuploidy at a rate of 70% of all embryos analysed (Vanneste et al, 
2009). The high rate of changes observed could be due to the fact that the 
resolution of SNP arrays is much higher than that of mCGH or aCGH. In the present 
study evidence of segmental aneuploidies was seen in 15% of embryos. However, 
the sample size is small, the patients had a variety of different indications and 
results were drawn from embryos at different developmental stages, so no 
comparison with the above-mentioned studies was performed.  
 
Fragile sites are specific loci in the genome that cause chromosome instability and 
result in chromosome breakage. Over 100 fragile sites of variable frequencies have 
been identified in the general population. Several of the rare fragile sites are 
associated with disease, whereas common fragile sites can be detected in all 
individuals (Durkin and Glover, 2007). A link between the segmental errors 
observed here and fragile sites can be made as each fragile site occurs at a known 
chromosome band (Debacker and Kooy, 2007). aCGH can detect the site of 
chromosome breakage, however, due to low resolution, it might not be the exact 
corresponding band where the break occurred. Of all the segmental changes 
observed, those occurring on the q arm of chromosomes 2, 6, 10 and 18 were 
adjacent or close to a common fragile site. The remaining abnormalities did not 
correspond to a common or a rare site. In conclusion, the presence of a fragile site 
can be the explanation of chromosome breakage, resulting in segmental errors.  
 
4.2.3 Parental origin of chromosomal errors 
Polymorphic markers used for investigating recombination, as discussed in section 
4.3, provided the ability to detect aneuploidy for the chromosomes on which the 
markers where located, and in some cases the parental origin of the aneuploidy. 
Since aneuploidy in these samples was also examined with aCGH, possible 
aneuploidies detected by the markers were confirmed in the aCGH result. In total, 
seven cases of aneuploidy were detected by both techniques in seven embryos. Of 
these, five were maternal errors, two were paternal, one incidence of monosomy for 
chromosome 17 and one trisomy for chromosome 16. The maternally derived 
aneuploidies included two cases of monosomy for chromosome 16, one monosomy 
17, one trisomy 16 and finally one monosomy 19. The overall results agree with the 
literature, in that maternal errors are more common than paternal.  
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Information on the parental origin of aneuploidies is usually derived from families of 
affected liveborns or aborted fetuses. Therefore, only those aneuploidies that can be 
present in an established pregnancy can be analysed. Trisomy 16, an abnormality 
that has been examined extensively, among those detected, and has been found to 
originate in a 100% of cases from errors in maternal meiosis (Hassold et al, 1995). 
Interestingly, in this study, a second case of trisomy 16 that was paternally derived 
was detected, something which does not agree with findings in established 
pregnancies. Four of the five cases of monosomy that were detected were 
maternally derived. Since 45,XO condition is the only type of monosomy not causing 
early miscarriage; no other data on the origin of autosomal monosomies are 
available from pregnancies. Similarly, no information is available regarding 
abnormalities on chromosome 17, which in this study was caused by an error that 
was paternal in origin.  
 
Analysis of the parental origin of aneuploidy is possible by SNP arrays through the 
use of informative SNPs and has been presented upon analysis of single 
blastomeres from cleavage stage embryos (Johnson et al, 2010; Rabinowitz et al, 
2012). In the study by Rabinowitz et al, all cases of meiotic trisomies were maternal, 
whereas paternal and maternal monosomies occurred in similar frequencies. 
Results were obtained from single blastomeres biopsied from embryos of PGS 
cycles and healthy egg donors. Johnson et al, identified maternal trisomies in 
significantly higher rate than paternal trisomies and again maternal and paternal 
monosomies occurred with the same frequency. Analysis was performed on 26 
disaggregated embryos. In the present study, the parental origin could only be 
detected in a small number of embryos, due to lack of informativity and the small 
number of STR markers analysed. It can be confidently concluded that all trisomies 
detected were due to errors occurring in meiosis, since two alleles from one parent 
together with one allele from the other were observed. The stage of error in 
monosomies, could not be determined with confidence as the loss of one parental 
chromosome could have occurred in mitosis. 
 
One case of UPD was detected for chromosome 16. Both maternal alleles were 
detected and no paternal for that chromosome. UPD could not be detected by 
aCGH as the end result was two chromosomes, similar to a euploid sample with bi- 
parental inheritance. UPD detection is possible by SNP arrays and was described 
by Rabinowitz et al, in 0.16% of all chromosomes analysed. It was observed that 
UPD occurred in blastomeres with a large number of aneuploid chromosomes 
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(Rabinowitz et al, 2012). In this case, the embryo presenting UPD was 
characterised as complex aneuploid and was arrested at the cleavage stage. The 
chromosomal classification could have been a result of a high number of mitotic 
errors. If trisomy 16 was present in the embryo, resulting from an error in maternal 
meiosis, then loss of the paternal chromosome during the mitotic divisions could 
have resulted in maternal UPD.      
 
4.2.4 Fate of chromosomally abnormal embryos 
FISH analysis revealed that only diploid mosaic embryos with a proportion of diploid 
cells higher than 50% reached the blastocyst stage. Arrested embryos were 
characterised diploid, haploid, aneuploid, aneuploid mosaic or chaotic. All of the 
abnormal constitutions could be the aetiology of developmental arrest. It was 
surprising that all diploid embryos detected by FISH were arrested. Interestingly, 
when dividing the couples according to age, the only statistical significance was 
observed in the distribution of diploid embryos, which was higher in the older age 
group. The most reasonable explanation is that errors in chromosomes not 
investigated with the probe set used, have led to embryo arrest. This was also 
observed in another study using the same number of probes (Gonzalez-Merino et al, 
2003). The vast majority of arrested embryos were either haploid, aneuploid, 
aneuploid mosaic and chaotic. A very small proportion of arrested embryos were 
diploid. This confirms the fact that haploid embryos and embryos with extreme 
mosaicism do not have the ability to develop normally.  
 
Barbash-Hazan et al analysed 83 embryos on day three by FISH. All embryos were 
found to be aneuploid. These were reanalysed on day five, to examine the embryos’ 
ability to self-correct. Of all the aneuploid embryos, 9.7% showed self-correction in 
100% of cells and 13.2% had more than 50% of diploid cells. This study also 
presented a linear correlation between self-correction and developmental potential 
(Barbash-Hazan et al, 2009). The reduction of the mosaicism level prior to 
blastocyst formation through self-correction or developmental arrest has also been 
suggested by other groups (Evsikov and Verlinsky 1998, Bielanska et al, 2002). It 
has been suggested than diploid mosaic embryos with low level of aneuploid cells, 
still have the ability to form a viable fetus (Voullaire et al, 2000). All blastocysts in 
this study were diploid mosaic with more than 50% of diploid cells. There is 
evidence that apoptosis occurs during preimplantation embryo development, 
probably in order to eliminate cells with chromosomal abnormalities (Hardy, 1999). 
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Therefore, normally developing embryos with a high proportion of diploid cells may 
have the ability to destroy aneuploid cells through apoptosis.  Within the embryos 
analysed by aCGH, the rate of complex aneuploid embryos decreased with 
development. Within blastocysts, euploid embryos were significantly more than 
complex aneuploid. Since mosaicism cannot be accurately detected by aCGH it can 
be assumed that a small proportion of aneuploid cells could have been present in 
those that were scored as euploid.  
 
Aneuploidy in the preimplantation embryo may result in confined placental 
mosaicism (CPM). Trisomies affecting the autosomes are the predominant type of 
aneuploidy detected in the cases of CPM (Lestou and Kalousek, 1998). CPM 
abnormalities may be a result of meiotic or post zygotic error and if they are 
confined in extra-embryonic tissue they can result in normal prenatal development 
and live birth (Lebedev, 2011). On the other hand, embryos with autosomal 
monosomy most probably cannot achieve implantation, which was concluded after 
determining an extremely low rate of monosomies, at 0.75% in samples from 
spontaneous abortions (Guerneri et al, 1987). Among the blastocysts analysed by 
aCGH four were found to be aneuploid. All of them carried a loss of at least one 
chromosome and therefore transfer of these could have probably led to implantation 
failure.  
 
4.2.5 Comparison of aneuploidy levels in embryos from PGD and 
PGS  
The results of the aneuploidy analysis in embryos from couples undergoing PGD 
was directly compared with results from PGS cycles, performed at the CRGH. This 
was advantageous as, couples treated in the same clinical setting, with similar 
stimulation protocols, embryo culture and biopsy methods were compared, thus, 
eliminating any bias that can arise through these factors. Embryos analysed by 
FISH were compared with already published follow up data from PGS cycles 
(Mantzouratou et al, 2007). Comparison of embryos analysed by aCGH was 
performed between embryos from PGS after blastocyst biopsy at the CRGH and the 
blastocysts from the PGD group. These samples were selected for the comparison 
as no aCGH follow up data were available and results from PGS cycles after 
cleavage stage biopsy may not be representative of the chromosomal constitution in 
the remainder of the embryo. Comparison was not performed with the arrested 
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embryos and the morulae of the PGD group, as they were at different 
developmental stages. 
 
It was observed that, among embryos analysed by FISH, the distribution of diploid 
mosaic embryos was significantly higher in the PGD than the PGS group. It is worth 
noting that, in the PGS group, only one embryo consisted of more than 50% diploid 
cells, whereas all, apart from two, diploid mosaic embryos in the PGD group carried 
more than 50% diploid cells. On the contrary, chaotic embryos were significantly 
more in the PGS group. Evidence has shown that the cases of mitotic non-
disjunction are more frequent in embryos from couples of advanced maternal age. It 
has been suggested that since the embryonic genome is not active during the first 
mitotic division, and mRNA and proteins are similar to those found in the oocyte, 
errors that occur frequently in meiosis, like non-disjunction in oocytes of advanced 
maternal age, will continue to occur in mitosis (Munné et al, 2002). This cannot be 
the case here, though, as the rate of mitotic non-disjunction in embryos of the PGD 
group was 29%, slightly higher than the 24% rate observed by Mantzouratou et al. 
The number of chromosomes examined by Mantzouratou et al was six, whereas five 
chromosomes were examined in this study. It is possible that the aneuploidy level 
would have increased if an additional chromosome was examined. The differences 
of the distribution of diploid mosaic (50% in PGD versus 14% in PGS) and chaotic 
embryos (9% in PGD versus 59.1% in PGS) were large and would probably still 
remain similar if one more chromosome was analysed. The presence of significantly 
more aneuploid and mosaic embryos than euploid in embryos from PGS cycles has 
been observed before (Rubio et al, 2007). Here, the proportion of diploid mosaic 
embryos, in the PGD group, was higher than the sum of aneuploid, aneuploid 
mosaic, haploid and chaotic embryos and very close to reaching significance 
(p=0.0510, Fisher’s exact test).  
 
When comparing embryos analysed by aCGH, no significant differences were 
observed. However, the proportion of euploid embryos was higher in the PGD group, 
whereas the number of complex aneuploid embryos was higher in the PGS group. 
The average maternal age in the PGS groups was 38.5 years and in the PGD 
groups 32 years. The proportion of aneuploid embryos, analysed by FISH and 
aCGH, was higher in the PGS groups than in the PGD groups, confirming the well-
accepted fact that aneuploidy increases with maternal age.  
 
 
 180 
4.2.6 Would diagnosis of a disease-causing mutation together 
with aneuploidy screening be beneficial? 
All of the above findings suggest that aneuploidy is present in embryos of couples 
undergoing PGD for monogenic disorders. However, the type of errors may not be 
as severe as those seen in embryos from PGS couples. Distinct differences, made 
apparent after FISH analysis, include fewer incidences of meiotic errors in embryos 
from PGD cycles. Embryos that seem to develop normally contain a high proportion 
of diploid cells, suggesting that low-level aneuploidy may not affect implantation or a 
healthy pregnancy. According to the latest ESHRE data collection of the PGD 
consortium, the pregnancy rate in PGD cycles for single gene disorder per embryo 
transfer is 29% (Goossens et al, 2012). This can be attributed to chromosomal 
errors that remain undetected, as chromosomal screening is not the primary 
purpose of PGD. Therefore, genetic analysis of the disease, combined with 
chromosomal analysis will aid to the selection of embryos free of the mutation as 
well as euploid.  
 
Direct PCR on biopsied samples, using primers on chromosomes 13, 16, 18, 21, 22 
and X, together with primers to detect a genetic disorder has already been 
described. Studies report a high pregnancy rate of 54%, even in patients of 
advanced maternal age (Rechitsky et al, 2006, Verlinsky et al, 2006). With recent 
technological advances, it is now possible to perform mutation detection and 
aneuploidy analysis more effectively. Following WGA, the same product can be 
used for chromosomal analysis by aCGH, as well as analysis of the mutation by 
PCR amplification of suitable loci. Moreover, this can be performed simultaneously 
with the use of SNP arrays. However, there are many issues that need to be taken 
under consideration.  
 
As in PGS, the timing of biopsy is critical. Polar body biopsy provides the ability to 
detect chromosomal errors and genetic mutations that are present in the oocyte. In 
certain countries embryo biopsy is prohibited by law and therefore polar body biopsy 
is the only option. Analysis of the first polar body has been described for autosomal 
recessive and X-linked dominant disorders (Griesinger et al, 2009). In cases of the 
diagnosis of autosomal recessive diseases following embryo biopsy, 75% of the 
embryos will be normal or carriers and therefore suitable for transfer. However, if 
polar body biopsy is performed and only the maternal genome is analysed, 50% of 
embryos will theoretically be available for transfer, those that are normal and those 
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that are carriers of the paternal mutation. Moreover, polar body biopsy cannot be 
performed for cases where the male partner carries an autosomal dominant 
mutation. Cleavage stage biopsy, which is the most common stage of biopsy in 
PGD, is hampered by mosaicism. Blastocyst biopsy might be the ideal choice, but 
mosaicism can still cause a misinterpretation of both the chromosomal and genetic 
status of the embryo.  
 
Another point to consider is that the number of embryos available for transfer will be 
markedly reduced. As seen by the FISH results, the vast majority, 82% of embryos 
analysed, had at least one aneuploid cell. This is most important in cases of 
autosomal dominant disorders, where theoretically only 50% of embryos will be free 
of the mutation. Reduction in the number of embryos available for transfer was 
observed after simultaneous diagnosis of structural chromosomal rearrangements 
and numerical abnormalities by aCGH (Alfarawati et al, 2011). Of the embryos 
analysed, after biopsy at different developmental stages, 22.3% were balanced for a 
translocation as well as euploid and therefore available for transfer. However, a 
further 28.9% were balanced for a translocation but carried aneuploidies and were 
not transferred. In a different study, analysis of chromosomes on single blastomeres 
from cleavage stage embryos in cases of structural chromosomal rearrangements 
showed that 16% of embryos were normal or balanced for every chromosome, 
whereas 27.3% were normal or balanced for the chromosomal rearrangement but 
carried aneuploidies in other chromosomes (Fiorentino et al, 2011). The pregnancy 
rate in Alfarawati et al did not increase when compared to cases when FISH was 
used for the detection of the rearrangements. However, the authors noted that the 
risk of miscarriage was reduced. Fiorentino et al reported a high pregnancy rate, at 
70.6% per embryo transfer, which was significantly higher than that reported by the 
PGD consortium on cases where FISH was used.  
 
The recent RCT on young couples using aCGH on trophectoderm biopsied samples, 
described in section 4.1.8 of the Discussion, showed significantly higher pregnancy 
rates in the cycles with chromosomal screening than those without screening. The 
availability of a test that screens for chromosome aneuploidies, together with the 
genetic diagnosis of a disease, could be potentially offered to all PGD patients. As in 
PGS, positive outcome can only be determined by RCTs. However, the additional 
limitation in embryo transfer imposed by the presence of a mutation needs to be 
considered.  
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4.3 Investigation of recombination in preimplantation 
embryos 
The third aim of this thesis was the investigation of recombination in preimplantation 
embryos. This was performed as a pilot study. The chromosomal status of all 
embryos was also determined by aCGH, in order to detect any links between 
recombination and aneuploidy. Until very recently no other studies on embryo 
recombination had been published. Taylan and Altiok presented a study on 
recombination within the major histocompatibility complex (MHC) on preimplantation 
embryos (Taylan and Altiok, 2012). As recombination is essential for proper 
segregation of the chromosomes in meiosis, it was hypothesized that recombination 
in embryos showing developmental arrest or aneuploid embryos could be different 
to developing, euploid embryos. Recombination was investigated in a different way 
compared to the majority of published studies. Instead of analysing recombination 
frequency using a large number of markers across the genome and across 
generations, in this study, recombination was analysed using few markers within 
generations in families with a large number of embryos. The embryos analysed here 
may not reflect the general population. The vast majority of them would not have 
resulted in a live birth. Therefore, investigating recombination in this set of samples 
could provide an important insight in the differences between the general population 
and embryos that arrest in development.  
 
4.3.1 FPCR amplification on WGA products 
WGA on single cells is possible, however, the efficiency of the technique is 
compromised by the small DNA amount of the starting material resulting in high 
ADO rates. The quality of the product is also dependent on the type of the cell and 
the type of lysis used (Glentis et al, 2009). SurePlex was selected for WGA in these 
samples. The main reason for this choice was the need to perform both haplotype 
and aneuploidy analysis in the same sample. The efficiency of the amplification was 
determined in the first part of this thesis through the validation of aCGH. 
Amplification efficiencies of 95% on single cells and 100% in samples containing 
eight and 100 cells were observed. All the samples, analysed here, were either 
whole embryos at different developmental stages, or TE biopsied samples. As 
expected, all samples produced a smear on a 2% agarose gel, representing 
successful amplification.  
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In total 14 polymorphic marker loci were amplified by fluorescence PCR (FPCR) on 
the 77 embryonic samples, corresponding to 1078 loci. The rates of amplification 
failure and allele drop out (ADO) observed, were 2.9% and 5.4% respectively. 
Overall, the ADO rate reported here is considerably lower than that reported in other 
studies, where single cells were analysed (Spits et al, 2006; Renwick et al, 2007), 
due to the fact that the number of cells in the majority of the embryos was over 10, 
therefore, reducing the possibility of ADO.  
 
4.3.2 Ability to detect recombination in embryos 
Although STR markers are more informative than SNPs, the lack of multiple STRs 
close to the selected regions limited the detection of recombination in embryos. 
Moreover, marker informativity was essential in order to identify recombination. At 
the sites where two markers were tested, in chromosomes 1, 5 and 16 apart from 
heterozygosity, difference in the size of the parental alleles was also essential. In 
chromosomes 17 and 19, where five and three markers were tested respectively, 
cross-over events could be detected if the individual was heterozygote for at least 
two of three markers, on chromosome 19, and two or three markers on 
chromosome 17. However, difference in the size of the marker alleles between the 
parents was still essential. Five loci were analysed for 20 parents, a total of 100 
possible informative meioses. It was not possible to detect recombination in 48% of 
all loci analysed, in all parents, due to lack of informativity. Therefore, only parents 
that were informative for recombination detection markers were considered to have 
informative meioses. In chromosomes 1, 5 and 16, where two markers were tested, 
detection of single recombination events was possible, whereas in chromosomes 17 
and 19, where more markers were investigated, double recombination events could 
have been detected and these were considered as two separate events.  
 
The recombination frequency for females, males, as well as the total frequency for 
each family and chromosome was calculated, considering the number of events and 
the number of informative meioses. This introduced bias in the analysis, as limited 
informative meioses that showed recombination, could have resulted in a high 
recombination frequency, possibly not representative of the true recombination 
frequency. However, as informativity was a matter of equal chance between the 
individuals, comparisons between frequencies were still performed in an attempt to 
retrieve information.   
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4.3.3 Recombination frequency and families, chromosomes, sex 
and age 
Differences in the total recombination frequency between families were observed. 
The range of the total frequency was zero (family C8) to 0.20 (family C1). The only 
family with no recombination detected consisted of just three embryos. All the 
families in the PGS group showed lower recombination frequencies than the PGD 
group. The total recombination frequency for each family was calculated considering 
both female and male recombination. It is well known that recombination varies 
between individuals (Cheung et al, 2007) and this was confirmed here.  
  
Several observations could be made, when looking at the total recombination 
frequency of each chromosome. Despite being a recombination hotspot, no 
recombination was detected on chromosome 5 for any of the families and no 
recombination was seen on chromosome 16 in the PGS group. Another 
contradictory result to population analysis was identified for the locus on 
chromosome 17, which was a recombination silent spot, as recombination events 
were detected in both groups. All markers on that locus were located within the NF1 
gene. Population studies have shown that recombination occurs preferentially 
outside genes (McVean et al 2004). The recombination frequency of all families in 
both groups was found to increase as the length of the chromosome decreased. 
Again, this is a well-established feature of recombination (Kong et al, 2002). Finally, 
the highest rate was observed on chromosome 19, which is in line with previous 
studies (Dib et al, 1996).  
 
Differences were observed between males and females. It has been shown that a 
sequence variation within the RNF212 gene is a source of differences in the 
recombination frequency between the sexes. The haplotypes of two SNPs within the 
gene are associated with low recombination frequency in females and the highest in 
males (Kong et al, 2008). Overall, recombination frequency was higher in females 
than males. The recombination frequency around the telomeres of the 
chromosomes is higher in males, whereas in females, higher recombination is 
observed close to the centromeres in the general population (Broman et al, 2002). 
In this study, the most telomeric set of markers was on chromosome 19. Indeed the 
male recombination frequency of all families was higher than female only for that 
chromosome. Variation among individuals, as well as between the sexes, was also 
observed in the study Taylan and Altiok. Recombination was detected on single 
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blastomeres from embryos of PGD cases for HLA (human leukocyte antigen) 
compatibility (Taylan and Altion, 2012). Higher recombination was observed in 
maternal chromosomes than paternal, the same finding with this study. 
 
When families were divided in groups according to age it was observed that the 
recombination frequency decreased for both sexes over the age of 35. The 
decrease was bigger in males than females. The only statistical significance was 
observed between the average recombination frequency in women and men over 35 
years and it was higher in women. The effect of age in recombination is not clear. 
The ”production line” hypothesis, in maternal gametogenesis of mice, states that 
there is a higher degree of recombination in the oocytes formed first and that 
oocytes are ovulated in the same order as they were formed (Henderson and 
Edwards 1968). This would mean that oocytes from young women would have 
higher recombination than oocytes from older women. This is in line with what 
observed in this study. However, a large study on 70000 individuals showed that 
recombination frequency increased with maternal age (Kong et al, 2004). The 
authors hypothesized that, through a selection process, there is a higher chance of 
an oocyte with more recombination events to lead to a normal pregnancy. The study 
by Kong et al, was performed in already established families. The recombination 
frequency increased with maternal age because these women had a high 
recombination count. This contradicts the findings of this study and emphasises the 
fact that there are differences in preimplantation embryos that in the vast majority 
will not lead to a successful pregnancy and delivery, compared to what happens in 
the general population.  
 
4.3.4 Recombination frequency in embryos. Effects on 
chromosomal status and morphology 
Recombination frequency was examined within the families and also from the 
embryo perspective, in order to detect links between recombination with aneuploidy 
and development. A recombination frequency was calculated for those embryos in 
which cross-over events were detected. This was achieved by considering the 
number of loci tested and the number of events seen. Embryo recombination 
frequency was determined as the number of recombination events detected in each 
embryo over the number of informative meioses per embryo, which was maximum 
five, equal to the number of loci investigated. The chromosomal status was 
examined by aCGH and embryos were classified as described in section 4.2.2.  
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No significant differences were noted in the average recombination frequency of 
euploid, aneuploid and complex aneuploid embryos and of embryos at different 
developmental stages. A higher rate was observed in arrested embryos, followed by 
the rate of blastocysts and morulae, but of no significance. Chromosomal and 
developmental status was also compared between those embryos that showed 
recombination and those in which recombination was not detected at all. 
Recombination was observed in 30 of the 77 embryos analysed (39%), whereas no 
recombination events were observed in 47 embryos. Embryos with no 
recombination were also observed in the study by Taylan and Altiok.  Again no 
statistical significant differences were observed, however the majority of euploid 
embryos, showed recombination, whereas the majority of aneuploid and complex 
aneuploid embryos did not. When comparing the two groups of embryos according 
to morphology, it was observed that embryos that showed recombination were more 
among the arrested and blastocyst groups, whereas the proportion of morulae that 
did not show recombination was higher than those that did. The recombination 
machinery is closely linked to the correct segregation of the chromosomes during 
meiosis. No recombination was detected in the majority of aneuploid and complex 
aneuploid embryos, indicating that in those embryos that possibly carried meiotic 
errors, errors in recombination were also present.  
 
4.3.5 Analysis of recombination in embryos 
Cross-over events were detected through the use of polymorphic markers, however 
this was limited by marker uninformativity and several events might have been 
missed. Moreover, the use of polymorphic markers was only possible when the 
correct haplotypes of parents and embryos were generated. This can only be 
performed with confidence when a large number of progeny exists. A newly 
developed technique, direct determining phasing (DDP) allows molecular 
haplotyping of the whole genome from single cells (Fan et al, 2011). Chromosomes 
are released from a metaphase cell and amplified by MDA. Direct amplification of 
each homologous chromosome does not require the need of parental genomes in 
order to prepare the haplotypes. Recombination events can even be detected with 
only one offspring. The ability to perform this type of technology on a single cell is 
fascinating, especially for the world of preimplantation genetics. Its main drawback, 
however, is the fact that metaphase cells are needed as a starting material, which 
are not easily obtained from embryos.  
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Double recombination events were observed in five embryos. Four of these events 
occurred on the chromosome 19 locus and one on chromosome 17. Two of the 
events on chromosome 19 were observed in the same family (C1), which also 
showed the highest recombination frequency among all the families investigated. 
While the chance of a double recombination event occurring is much less likely than 
a single event, without other families from previous generations, the correct phasing 
of alleles could not be confirmed. This was a limitation of the present study and the 
rational determining the allelic phase from the lowest recombination frequency for 
any family was used because the largest genetic distance between any of the 
markers was only 3.08cM. Double cross-over in preimplantation embryos, within a 
region of 3.81cM, has been reported elsewhere during PGD for HLA typing 
(Fiorentino et al, 2005).  
 
No significant differences in recombination frequency were observed between the 
embryos of the PGD and PGS groups. This may be due to the limitations of this 
study imposed by the use of microsatellite markers and the small number of 
embryos analysed. The most suitable technique to identify recombination in 
embryos, that is now becoming available, is SNP arrays. Genotyping of parents and 
embryos with SNP arrays and subsequent identification of recombination as well as 
chromosomal abnormalities has been described through the use of “Karyomapping” 
(Handyside et al, 2010). This would provide a far more detailed insight on 
recombination.  However, other investigations may unveil differences in these 
groups. It has been suggested that variation in the PRDM9 protein, that controls 
recombination hotspots, may be present in women with recurrent miscarriages, as 
well as infertility and therefore produce a high rate of aneuploid embryos (Cheung et 
al, 2010). Analysis of the protein and its coding gene, PRDM9, in these women and 
fertile women could confirm this assumption.  
4.4 Conclusion 
The main topic of this thesis was aneuploidy in preimplantation embryos. Detection 
of aneuploidy by aCGH, the level of aneuploidy in embryos from PGD cycles, as 
well as recombination in preimplantation embryos were investigated. Validation of 
aCGH using the 24sure platform was described. Blind analysis of single cells from 
epithelial cell lines revealed 100% concordance between the aCGH result and the 
chromosomal status of the cells. This indicated that 24sure analysis, could 
confidently detect aneuploidies in single blastomeres biopsied from cleavage stage 
embryos. Validation of 24sure following blastocyst biopsy was performed by 
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examining the effect of mosaicism on the aCGH result. Mosaicism could be 
detected by aCGH and the result could also indicate the number of aneuploid cells 
present in the sample. Concordant results between biopsied TE samples and the 
remainder of the blastocysts further validated aCGH for PGS following blastocyst 
biopsy. However, aCGH may be hampered by biological limitation, as observed by 
FISH follow-up on PGS cases where aCGH was used. The aCGH result did not 
always represent the chromosomal status of the embryo, especially following biopsy 
at cleavage stage. Several RCTs are underway in order to determine the clinical 
efficacy of aCGH in PGS. 
 
Very few studies on the aneuploidy level of embryos from couples undergoing PGD 
for single gene disorders have been published. FISH and aCGH were used to 
determine that level. Diploid mosaic embryos were the predominant type of embryos, 
whereas chaotic and haploid embryos were the least common, among embryos 
analysed by FISH. aCGH revealed that the distribution of euploid and embryos with 
aneuploidies affecting one or two chromosomes was almost equal whereas 
embryos with three or more aneuploidies were the minority. Embryo aneuploidy was 
found to be reduced in more advanced developmental stages. FISH analysis of 
blastocysts revealed that they were all diploid mosaic with more than 50% of cells 
being diploid, whereas aCGH showed that the majority of blastocysts were euploid. 
Important differences between the two techniques were highlighted. The stage of 
chromosomal error could be determined by FISH, with mitotic errors being more 
common than meiotic. This was not possible by aCGH, however with this technique 
it was revealed that all chromosomes were affected by an error, whereas only five 
chromosomes were examined by FISH. Analysis of the parental origin of 
aneuploidies in embryos analysed by aCGH revealed that maternal errors are more 
common, however a paternal meiotic error not in agreement with studies on 
established pregnancies was also identified. Aneuploidy occurred in a lower 
frequency in embryos from PGD cycles when compared to data from PGS cycles.  
 
Recombination was investigated in embryos of known chromosomal status, from 
PGD and PGS cycles, with the use of STR markers on loci of high and low 
recombination. Findings that were in line with data from population studies were 
observed. These included, individual and chromosome variability in recombination 
frequency, a higher recombination frequency in females than in males, higher 
recombination in telomeric regions in males than females and the fact that the 
highest recombination frequency was detected on chromosome 19. However, no 
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recombination was detected on the recombination hot spot on chromosome 5 and 
recombination was detected on the recombination silent spot on chromosome 17, 
which was not in agreement with population studies.  Recombination was detected 
in the majority of euploid embryos, whereas no recombination was seen in the 
majority of aneuploid and complex aneuploid embryos. This indicated that 
mechanisms leading to meiotic recombination may relate to mechanisms that lead 
to meiotic aneuploidy.  
 
All the three aims were covered using different techniques. FISH and aCGH were 
used for the detection of aneuploidy and recombination was investigated by PCR 
analysis. SNP arrays, an emerging technique in preimplantation genetics, could 
have covered all the technical needs of this thesis. Chromosomal copy number and 
genotyping analysis through haplotyping, which are both possible with SNP arrays, 
could have provided data on aneuploidy and recombination respectively. As with 
aCGH, the clinical effectiveness of SNP arrays in screening for chromosomal 
aneuploidy in preimplantation embryos still needs to be confirmed by RCTs. 
However, their use in a research setting is already proving highly valuable as a lot of 
information can be acquired through one experiment. Study of recombination in the 
whole genome of embryos, with the high-resolution analysis that SNP arrays 
provide, will examine whether the findings presented here by the pilot study are 
indeed representative of the recombination status in human embryos.  
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Table 6.1: Appendix A - Embryos analysed for chromosomes 13, 18, 21, X and Y by FISH  
Embryo No of 
pronuclei 
Morphology Number of nuclei 
1
st
/2
nd
 round 
Number of diploid cells (%) Embryo classification 
 13/21 X/Y/18  
B1.1.1 2 Arrested 3/3 0 0 Chaotic 
B2.1.1 2 Morula 26/24 23 (88%) 17 (71%) Diploid/aneuploid/chaotic mosaic 
B2.1.2 2 Arrested 2/2 0 0 Aneuploid/chaotic mosaic 
B2.1.3 2 Blastocyst 93/98 78 (84%) 86 (88%) Diploid/chaotic mosaic 
B2.1.4 2 Morula 65/50 46 (71%) 33 (66%) Diploid/chaotic mosaic 
B2.1.5 2 Morula 44/44 37 (84%) 38 (86%) Diploid/chaotic mosaic 
B2.2.1 2 Blastocyst 38/38 31 (82%) 26 (68%) Diploid/chaotic mosaic 
B2.2.2 2 Morula 9/11 0 0 Aneuploid/chaotic mosaic 
B2.2.3 2 Morula 16/16 13 (81%) 14 (88%) Diploid/chaotic mosaic 
B2.2.4 2 Morula 6/6 3 (50%) 3 (50%) Diploid/chaotic mosaic 
B3.1.1 2 Arrested 4/4 0 1 (25%) Aneuploid/chaotic mosaic 
B3.1.2 2 Arrested No signals - - No result 
B3.1.3 0 Arrested No signals - - No result 
B3.1.4 0 Arrested 4/4 0 0 Aneuploid/chaotic mosaic 
B4.1.1 0 Arrested 1/3 0 1 (33%) Chaotic 
B4.1.2 0 Arrested 2/2 0 0 Haploid 
B5.1.1 3 Arrested 4/4 4 (100%) 4 (100%) Diploid 
B6.1.1 2 Arrested 1/3 0 1 (33%) Chaotic 
B6.1.2 2 Arrested 6/2 0 0 Haploid 
B6.1.3 2 Arrested 6/3 0 0 Haploid 
B7.1.1 3 Morula No signals - - No result 
B7.2.1 2 Morula 13/14 9 (69%) 10 (71%) Diploid/chaotic mosaic 
B7.2.2 2 Morula 17/9 9 (53%) 9 (100%) Diploid/chaotic mosaic 
B7.3.1 2 Arrested 2/2 2 (100%) 2 (100% Diploid 
B7.3.2 2 Blastocyst 27/24 25 (93%) 21 (88%) Diploid/chaotic mosaic 
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Table 6.1: Appendix A (cont.) - Embryos analysed for chromosomes 13, 18, 21, X and Y by FISH 
 
Embryo No of 
pronuclei 
Morphology Number of nuclei 
1
st
/2
nd
 round 
Number of diploid cells (%) Embryo classification 
 13/21 X/Y/18  
B8.1.1 2 Blastocyst 42/42 33 (79%) 28 (67%) Diploid/aneuploid/chaotic mosaic 
B8.1.2 2 Arrested 3/3 0 0 Aneuploid/chaotic mosaic 
B8.1.3 2 Arrested No signals - - No result 
B8.1.4 2 Arrested 2/2 2 (100%) 2 (100%) Diploid 
B8.1.5 2 Arrested No signals - - No result 
B8.1.6 0 Arrested 1/3 0 0 Chaotic 
B9.1.1 2 Morula 12/11 2 (17%) 6 (55%) Diploid/chaotic mosaic
* 
B9.2.1 2 Arrested 4/4 0 2 (50%) Aneuploid/chaotic mosaic 
B9.2.2 2 Arrested 2/1 0 1 (100%) Aneuploid 
B10.1.1 2 Morula No signals - - No result 
B10.1.2 2 Blastocyst No signals - - No result 
B10.1.3 2 Morula No signals - - No result 
B10.1.4 2 Morula 15/15 8 (53%) 12 (80%) Aneuploid/chaotic mosaic 
B10.1.5 0 Arrested No signals - - No result 
B11.1.1 2 Arrested 7/7 1 (14%) 3 (43%) Chaotic 
B11.1.2 2 Morula 3/3 0 2 (67%) Aneuploid 
B11.1.3 2 Blastocyst 24/17 22 (92%) 10 (59%) Diploid/aneuploid/chaotic mosaic 
B11.1.4 2 Blastocyst 5/5 3 (60%) 3 (60%) Diploid/chaotic mosaic 
B11.1.5 2 Arrested 2/1 2 (100%) 1 (100%) Diploid 
B11.1.6 2 Blastocyst 21/10 12 (57%) 9 (90%) Diploid/chaotic mosaic 
B12.1.1 2 Morula 2/2 2 (100%) 2 (100%) Diploid 
B13.1.1 2 Morula No signals - - No result 
B13.1.2 2 Arrested No signals - - No result 
B13.1.3 2 Blastocyst No signals - - No result 
B13.1.4 2 Arrested No signals - - No result 
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Table 6.1: Appendix A (cont.) - Embryos analysed for chromosomes 13, 18, 21, X and Y by FISH 
 
Embryo No of 
pronuclei 
Morphology Number of nuclei 
1
st
/2
nd
 round 
Number of diploid cells (%) Embryo classification 
 13/21 X/Y/18  
B13.1.5 2 Blastocyst 39/36 26 (67%) 24 (67%) Diploid/chaotic mosaic 
B13.1.6 2 Blastocyst No signals - - No result 
B13.2.1 2 Morula 17/17 12 (71%) 10 (59%) Diploid/chaotic mosaic 
B13.2.2 2 Blastocyst 65/39 41 (63%) 19 (49%) Diploid/aneuploid/chaotic mosaic 
B13.2.3 2 Morula 39/38 32 (82%) 31 (82%) Diploid/chaotic mosaic 
B13.2.4 0 Morula 33/34 28 (85%) 27 (79%) Diploid/chaotic mosaic 
B13.2.5 0 Blastocyst 37/35 32 (86%) 32 (91%) Diploid/chaotic mosaic 
B14.1.1 2 Morula 11/11 7 (64%) 8 (73%) Diploid/chaotic mosaic 
B14.1.2 2 Arrested 2/2 2 (100%) 2 (100%) Diploid 
B14.1.3 2 Morula 9/9 6 (67%) 8 (89%) Diploid/chaotic mosaic 
B14.1.4 2 Arrested 3/3 0 3 Aneuploid 
B15.1.1 2 Arrested 2/2 0 0 Chaotic 
B15.1.2 2 Arrested No signals - - No result 
B15.1.3 2 Arrested No signals - - No result 
B16.1.1 2 Blastocyst 86/73 79 (92%) 56 (77%) Diploid/aneuploid/chaotic mosaic 
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Table 6.1: Appendix A – Detailed results of embryos analysed by FISH to detect aneuploidy. Embryo IDs are given as the couple number, followed by the 
cycle number and the embryo number in each cycle. The numbers are separated by a dot. Probes for chromosomes 13, 18, 21, X and Y were used in two 
consecutive FISH rounds. The number of pronuclei and developmental stage of each embryo are indicated. Also the number of analysable nuclei in each round and 
the number of diploid cells detected in each FISH round are shown. The chromosomal classification of each embryo is presented in the last column. 
*
Diploid/chaotic 
mosaic embryos with <50% of diploid cells.  
 
Table 6.1: Appendix A (cont.) - Embryos analysed for chromosomes 13, 18, 21, X and Y by FISH 
 
Embryo No of 
pronuclei 
Morphology Number of nuclei 
1
st
/2
nd
 round 
Number of diploid cells (%) Embryo classification 
 13/21 X/Y/18  
B17.1.1 2 Morula 12/12 12 (100%) 11 (92%) Diploid 
B17.1.2 2 Morula 8/7 8 (100%) 7 (100%) Diploid 
B17.1.3 2 Morula 5/5 5 (100%) 5 (100%) Diploid 
B18.1.1 2 Morula 20/18 12 (60%) 15 (83%) Diploid/chaotic mosaic 
B18.1.2 2 Arrested 10/10 1 (90%) 9 (91%) Aneuploid 
B18.1.3 2 Arrested 5/5 5 (100%) 5 (100%) Diploid 
B18.1.4 2 Blastocyst 38/35 24 (63%) 26 (74%) Diploid/chaotic mosaic 
B18.1.5 2 Arrested 17/15 15 (88%) 14 (93%) Diploid 
B18.1.6 2 Morula 15/15 10 (67%) 13 (87%) Diploid/chaotic mosaic 
B18.1.7 2 Blastocyst 53/51 43 (81%) 45 (88%) Diploid/chaotic mosaic 
B18.1.8 2 Morula 28/26 25 (89%) 20 (77%) Diploid/chaotic mosaic 
B18.1.9 2 Arrested No signals - - No result 
B19.1.1 2 Morula 18/18 12 (67%) 16 (89%) Diploid/aneuploid/chaotic mosaic 
B19.1.2 2 Morula 10/9 0 0 Aneuploid/chaotic mosaic 
B19.1.3 0 Blastocyst 6/6 4 (67%) 7 (78%) Diploid/chaotic mosaic 
B19.1.4 3 Morula No signals - - No result 
B19.1.5 2 Morula 12/12 4 (33%) 5 (42%) Diploid/chaotic mosaic
* 
B19.1.6 2 Morula 14/13 13 (93%) 13 (100%) Diploid 
B19.1.7 2 Arrested No signals - - No result 
B19.1.8 2 Arrested No signals - - No result 
B19.1.9 3 Morula 12/11 8 (67%) 10 (91%) Diploid/chaotic mosaic 
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7 Appendix B
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Table 7.1: Appendix B - Embryos from PGD cycles analysed by aCGH 
Embryo 
No of 
pronuclei 
Morphology Classification Chromosomal complement 
B20.1.1 2 Blastocyst Euploid 46,XY 
B20.1.2 2 Morula Aneuploid 45,XX,-1 
B20.1.3 2 Blastocyst Complex aneuploid 
60,XY,+3,+7,+8,+9,-10q22.3-
qter 
+11,+12,+13,+15,+17,+18,+19,+
20, +21,+22 
B20.1.4 2 Blastocyst Aneuploid 44,XX,-7,-22 
B20.1.5 2 Arrested No result - 
B20.1.6 2 Arrested Aneuploid 45,XX,-12 
B20.1.7 2 Blastocyst Euploid 46,XX 
B20.1.8 0 Arrested Aneuploid 47,XX,+22 
B21.1.1 2 Morula Aneuploid 46,XY,-6q14.1-qter 
B21.1.2 2 Morula Aneuploid 46,XY,-8pter-p22 
B21.1.3 2 Morula Aneuploid 45,XX,-4 
B21.1.4 2 Morula Euploid 46,XX 
B21.1.5 2 Morula Euploid 46,XX 
B21.1.6 2 Arrested Complex aneuploid 
41,XX,-2,-3,+5q23.1-qter,-
6q14.3-qter,+7,+9,-11,-12pter-
12q12.2,+13,-16,-17,-18,-19,-20 
B21.1.7 0 Morula Euploid 46,XX 
B21.1.8 0 Morula Aneuploid 47,+4 
B22.1.1 2 Blastocyst Euploid 46,XY 
B22.1.2 2 Morula Euploid 46,XX 
B22.1.3 2 Morula Complex aneuploid 
53,XY,+3,+4,+9,+11,+15,+16,+1
8 
B22.2.1 2 Blastocyst Euploid 46,XX 
B22.2.2 2 Morula Aneuploid 47,XX,+20 
B22.2.3 2 Morula Euploid 46,XX 
B22.3.1 2 Arrested Complex aneuploid 43,XX,-2,-12,-18 
B22.3.2 2 Blastocyst Euploid 46,XY 
B22.3.3 2 Arrested Complex aneuploid 
45,XX,-13,+16,+17,-18q11-
q13.2,-19 
B22.3.4 2 Blastocyst Aneuploid 45,XX,-18 
B22.3.5 2 Morula Aneuploid 46,-5q33.3-qter 
B23.1.1 2 Morula Aneuploid 45,XY,-2 
B23.1.2 2 Arrested Complex aneuploid 
50,XX,+5,+8,-9,+13,+14,-15,-
17,+18,+19,+21 
B24.1.1 2 Blastocyst Aneuploid 45,XX,-22 
B24.1.2 2 Blastocyst Euploid 46,XY 
B25.1.1 2 Arrested Aneuploid 47,XXY 
B25.1.2 2 Blastocyst Euploid 46,XY 
B25.1.3 2 Arrested Euploid 46,XX 
B25.1.4 2 Blastocyst Euploid 46,XY 
B25.1.5 2 Arrested Complex aneuploid 
43,XY,-6,-10p15.2-q11.21,-13,           
-16,+18,-19 
B25.1.6 2 Blastocyst Euploid 46,XY 
B25.1.7 2 Morula Complex aneuploid 48,XXY,-6,+7,-10,+11,+15 
B25.1.8 2 Arrested Complex aneuploid 
42,XX,-1,+5,-7,-9,+10,-12,-19,-
21 
B25.1.9 2 Blastocyst Complex aneuploid 
44,XY,-1,-2q,-4,-9,+10,-11,-
13,+14,    -15,+16,+17,+19,+20,-
21,-22  
B25.1.10 1 Blastocyst Aneuploid 46,XX,+4,-16 
 222 
 
Table 7.1: Appendix B (cont.) - Embryos from PGD cycles analysed by 
aCGH 
Embryo No of 
pronuclei 
Morphology Classification Chromosomal complement 
B25.2.1 2 Arrested Complex aneuploid 44,XX,+1,-2,+6,-7,-8,+14,-
15,+17,+18,-21,-22 
B25.2.2 2 Arrested Aneuploid 47,XX,+17 
B25.2.3 2 Morula Aneuploid 45,XX,-22 
B25.2.4 2 Arrested Euploid 46,XY 
B25.2.5 2 Morula Aneuploid 47,XX,+16 
B25.2.6 2 Morula Euploid 46,XX 
B25.2.7 2 Morula Complex aneuploid 54,XY,+5,+7,+14,+16,+17,+18,+
19,+21 
B25.2.8 2 Arrested Complex aneuploid 43,XY,+2,-4,-20,-21 
B25.2.9 2 Arrested Euploid 46,XX 
B25.2.10 1 Morula Aneuploid 47,XX,+16 
B25.2.11 1 Arrested Euploid  46,XX 
B25.2.11 3 Arrested Euploid  46,XY 
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Tables 7.1 and 7.2: Appendix B – Details of embryos from PGD and PGS cycles analysed 
by aCGH. Embryo IDs are given as the couple number, followed by the cycle number and the 
embryo number in each cycle. Each number is separated by a dot. The number of pronuclei, as 
scored by the embryologists, embryo morphology (for embryos from PGD cycles), the 
chromosomal classification and complement of each embryo are provided. All embryos from 
PGS cycles were blastocysts part of the clinical PGS program, where TE biopsy was used. The 
aCGH result is the clinical result for each embryo.  
Table 7.2: Appendix B (cont.) - Embryos from PGS cycles 
analysed by aCGH 
Embryo 
No of 
pronuclei 
Classification Chromosomal complement 
B26.1.1 2 Aneuploid 45,XY,-14 
B26.2.1 2 Euploid 46,XY 
B26.2.2 2 Aneuploid 45,XY,-17 
B26.2.3 2 Euploid 46,XY 
B26.2.4 2 Aneuploid 47,XX,+22 
B27.1.1 2 Aneuploid 47,XX,+16 
B28.1.1 2 Aneuploid 47,XX,-10 
B28.1.2 2 Complex aneuploid 50,XY,+16,+17,+21,+22 
B28.1.3 2 Aneuploid 49,XY,+4,+5 
B29.1.1 2 Euploid 46,XY 
B30.1.1 2 Aneuploid 48,XX,+4,+5 
B30.1.2 2 Complex aneuploid 43,XO,-11,-19,-22 
B31.1.1 2 Aneuploid 44,XY,-13,-22 
B31.2.1 2 Aneuploid 45,XY,-13 
B31.3.1 2 Complex aneuploid 47,XY,+9,+15,-18 
B31.3.2 2 Complex aneuploid 46,XXY,-4,+15,-16 
B31.3.3 2 Complex aneuploid 47,XX,+7,-20,+21 
B32.1.1 2 Aneuploid 44,XY,-13,-21 
B32.1.2 2 Aneuploid 45,XY,-18 
B32.1.3 2 Aneuploid 45,XX,-22 
B32.1.4 2 Euploid 46,XY 
B32.1.5 2 Euploid 46,XX 
B32.1.6 2 Aneuploid 46,XX,-18,+19 
B32.1.7 2 Aneuploid 47,XX,+9 
B33.1.1 2 Euploid 46,XX 
B33.1.2 2 Aneuploid 47,XX,+2 
B33.1.3 2 Euploid 46,XY 
B34.1.1 2 Complex aneuploid 47,XY,+1,-7,+8,+19 
B34.1.2 2 Complex aneuploid 45,XY,-8,+13,-16 
B34.1.3 2 Complex aneuploid 47,XY,+16,-18,+22 
B34.1.4 2 Aneuploid 46,XX,-4q32.2-qter 
B35.1.1 2 Euploid 46,XX 
B35.1.2 2 Euploid 46,XX 
B35.1.3 2 Aneuploid 45,XY,-9 
B35.1.4 2 Euploid 46,XX 
B35.1.5 2 Aneuploid 48,XX,+7,+20 
B35.1.6 2 Aneuploid 45,XY,-19 
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8 Appendix C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 225 
 
 
 
 
Table 8.1: Appendix C - Polymorphic marker results of all parents and embryos analysed for recombination. The results for all the 
loci for each parent and embryo are shown. Also information on the informativity of the parents is provided. In heterozygote samples each 
allele is separated with a “/” and in the embryos the maternal allele is given first followed by the parental.  
 
Key: 
Yellow: Loci where recombination was detected 
Orange: Loci where double recombination was detected 
Pink: Loci that showed evidence of possible aneuploidies 
Green: Heterozygote samples that showed definite allele drop out (ADO) 
Purple: Loci that had either recombination or ADO. These samples caused doubt of their status and were not included in the calculation of 
the recombination frequency. 
Blue: Sites that showed amplification failure 
 
 
 
 
 
 
 
 
Table 8.1: Appendix C - Polymorphic marker results for recombination detection 
 Chromosome 1 Chromosome 5 Chromosome 16 Chromosome 19 
Sample D1S495 D1S486 D5S1991 D5S2081 D16S492 D16S3053 D19S219 D19S207 D19S412 
C1 ♀ 
154/166 232/236 212/218 218/216 198/220 242/244 165 213 151/153 
Informative Informative Informative Not informative 
C1 ♂ 
166/170 238/236 210/216 218 220 242/244 163/165 215/211 156/166 
Informative Not informative Not informative Informative 
C1.1 166 236/238 212/210 218 220 244 165/163 213/ADO 151/156 
C1.2 166 236/238 212/210 218 220 244 165 213/211 151/166 
C1.3 154/166 236/238 218/210 216/218 220 244 165 213/211 153/166 
C1.4 166/170 236 218/216 216/218 220 242/244 165 213/211 153/166 
C1.5 166/170 232/238 218/210 AF 220 244 165 213/211 151/156 
C1.6 154/166 232/238 212/210 218 220 242/244 165/163 213/211 151/156 
C1.7 166 236/238 212/216 218 220 244 165/163 213/211 153/156 
C1.8 166 236/ADO? 218 216 198/220 242/244 165 213/211 151/156 
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Table 8.1: Appendix C (cont.) -  Polymorphic marker results for recombination detection 
 Chromosome 1 Chromosome 5 Chromosome 16 Chromosome 19 
Sample D1S495 D1S486 D5S1991 D5S2081 D16S492 D16S3053 D19S219 D19S207 D19S412 
C2 ♀ 
170/164 236/234 210/216 217 217/224 242 171/175 215/217 143/152 
Informative Not informative Not informative Informative 
C2 ♂ 
168/160 236/232 210/216 215 217/228 242/246 161 211/215 164 
Informative Not informative Informative Not informative 
C2.1 164/168 234/236 216/210 217/215 224/228 242/246 175/161 217/211 152/164 
C2.2 170/168 236 216/210 217/215 224/217 242 171/161 215 143/164 
C2.3 164/160 234/232 216/210 217/215 224/217 242 171/161 215 143/164 
C2.4 170/168 236 216/210 217/215 224/228 242/246 175/161 217/211 152/164 
C2.5 164/160 234/232 216/210 217/215 224/228 242/246 175/161 217/211 152/164 
C2.6 164/160 234/232 216 217 224/217 242 175/161 ADO/211 152/ADO 
C2.7 164/168 234/236 216 217 217/228 242/ADO? 171/161 215/211 143/ADO 
C2.8 164/160 234/236 ADO/210 217/215 217 242 175/161 217/215 143/164 
C3 ♀ 
170/166 236/238 210/216 217 220 205/224 152/163 198/214 164/156 
Informative Not informative Not informative Informative 
C3 ♂ 
164 236 216 215/225 242/244 240/242 161/165 211/215 166/164 
Not informative Not informative Informative Informative 
C3.1 166/164 238/236 216 217/215 220/205 244/240 152/161 198/211 164/166 
C3.2 166/164 238/236 210/216 217/225 220/205 242/240 152/161 198/211 164/166 
C3.3 170/164 236 216 217/215 220/205 242/240 152/161 198/211 164/166 
C3.4 166/164 238/236 216 217/215 220/224 244/242 163/165 214/215 156/164 
C3.5 166/164 238/236 216 217/215 220/205 242/240 152/161 198/211 164/ADO? 
C3.6 166/164 238/236 216 217/215 220/205 242/240 152/ADO 198/211 164/ADO? 
C3.7 166/164 238/ADO 210/216 217/225 220/205 244/240 152/161 198/211 164/166 
C3.8 170/164 236 216 217/225 220/205 242/240 163/165 214/215 156/166 
C3.9 170/164 236 210/ADO 217/225 220/205 244/240 163/165 198/215 156/164 
C3.10 170/164 236 216 217/225 220/205 244/240 163/165 214/215 156/166 
C3.11 166/164 238/236 216 217/225 220/205 244/240 163/165 214/215 156/166 
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Table 8.1: Appendix C (cont.) - Polymorphic marker results for recombination detection 
 Chromosome 1 Chromosome 5 Chromosome 16 Chromosome 19 
Sample D1S495 D1S486 D5S1991 D5S2081 D16S492 D16S3053 D19S219 D19S207 D19S412 
C4 ♀ 
162 236 210/216 218 216/221 240/243 146/165 213/215 152/164 
Not informative Not informative Informative Not informative 
C4 ♂ 
151/162 234/236 212/216 216/220 200/223 244/241 146/165 213/215 154 
Informative Informative Informative Not informative 
C4.1 162/151 236/234 210/216 218/220 216/223 240/241 ADO/165 213/215 152/154 
C4.2 162 236 216 218/220 221/200 240/244 146/165 213/215 164/154 
C5 ♀ 
168/170 236 210/216 215/225 209/221 242 161/165 213/211 162 
Not informative Informative Not informative Informative 
C5 ♂ 
164/166 236 210/216 217 221 242 161 213 164/166 
Not informative Not informative Not informative Not informative 
C5.1 170/164 236 210 215/217 209/221 242 165/161 211/213 162/166 
C5.2 168/164 236 210 215/217 221 242 165/161 211/213 162/166 
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Table 8.1: Appendix C (cont.) - Polymorphic marker results for recombination detection 
 Chromosome 1 Chromosome 5 Chromosome 16 Chromosome 19 
Sample D1S495 D1S486 D5S1991 D5S2081 D16S492 D16S3053 D19S219 D19S207 D19S412 
C6 ♀ 
152/163 236 209 214/216 216/212 236/242 171/163 198/213 154/152 
Not informative Not informative Informative Informative 
C6 ♂ 
161/165 236 208/214 216 216 240/242 153/163 198/213 164/156 
Not informative Not informative Not informative Informative 
C6.1 163/165 236 209/208 214/216 216 236/240 171/153 198 154/164 
C6.2 163/165 236 209/214 216 216 242/240 171/153 198 154/164 
C6.3 163/161 236 209/214 214/216 212/216 242/240 163/153 213/198 152/164 
C6.4 152/161 236 209/208 214/216 216 236/240 163/153 ADO/198 152/164 
C6.5 163/161 236 209/214 216 216 240 ADO?/163 198/213 154/156 
C6.6 163/161 236 209/208 214/216 212/216 236/242 171/153 198 152/164 
C6.7 163/161 236 209/214 214/216 212/216 242/240 171/163 198/213 154/ADO 
C6.8 163/165 236 209/214 216 212/216 236/242 163/153 213/198 152/164 
C6.9 163/165 236 209/208 214/216 212/216 242+236/240 163/153 213/198 152/164 
C6.10 163/165 236 209/ADO 216 212/216 242/240 163 213 152/156 
C6.11 163/165 236 209/208 214/216 216 236/242 163 213 152/156 
C6.12 163/ADO 236 209/214 214/ADO 216 236/240 171/153 198 154/164 
C6.13 152/165 236 209/214 216 216 236/242 171/163 198/213 154/156 
C6.14 152/165 236 209/214 216 216 236/242 163 213 152/156 
C6.15 152/161 236 209/208 214/216 216 236/240+242 171/163 198/213 154/156 
C6.16 152/165 236 209/208 216 216 236/240 163 213 152/156 
C6.17 163/161 236 209/214 216 212/216 242 171/163 198/213 152/156 
C6.18 ADO/161 236 ADO/214 216 216 ADO/240 163 198/213 152/156 
C6.19 152/161 236 209/208 214/216 212/216 242/240 163/153 ADO/198 152/164 
C6.20 ADO/161 236 209/208 216 216 AF 163 213 152 
C6.21 152/165 236 209/208 214/ADO 216 242/240 171/163 198/ADO 154/156 
C6.22 ADO/161 236 209/208 214/ADO 212/216 236/240 163/153 213/198 152/164 
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  Table 8.1: Appendix C (cont.) - Polymorphic marker results for recombination detection 
 Chromosome 1 Chromosome 5 Chromosome 16 Chromosome 19 
Sample D1S495 D1S486 D5S1991 D5S2081 D16S492 D16S3053 D19S219 D19S207 D19S412 
C7 ♀ 
150/168 238/236 208 217/215 197/216 240 146/165 211/215 162/164 
Informative Not informative Not informative Informative 
C7 ♂ 
152/164 236/238 211/208 217/215 212 240 161/163 211 143/152 
Informative Informative Not informative Informative 
C7.1 168/164 236/238 AF AF 197/212 AF 146/163 211 162/152 
C7.2 150/164 236/238 208/211 217 216 240 146/163 211 162/152 
C7.3 168/164 ADO?/238 208 217/ADO? 216/212 AF 146/163 211 162/152 
C7.4 150/164 238 AF 217 212 240 165/163 211 162/152 
C7.5 150/164 AF ADO/211 217 197/212 AF 165/161 215/211 164/152 
C7.6 ADO/164 AF AF AF AF 240 AF AF AF 
C7.7 150/ADO 238 ADO/211 AF 197/216 240 146+165/163 211 162/+164/152 
C8 ♀ 
165 235/232 209 214/219 197/217 240/242 153/165 198/217 156 
Not informative Not informative Informative Informative 
C8 ♂ 
165/171 237 207/211 217/215 197/205 240 165/161 213/215 143/152 
Not informative Informative Not informative Informative 
C8.1 165 235/237 209/211 214/215 217/205 242/240 153/165 198/213 156/143 
C8.2 165/171 235/237 209/211 214/215 217/205 242/240 165/161 217/215 156/152 
C8.3 165 235/237 209/211 214/215 197/205 240 153/161 198/215 156/152 
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Table 8.1: Appendix C (cont.) - Polymorphic marker results for recombination detection 
 Chromosome 1 Chromosome 5 Chromosome 16 Chromosome 19 
Sample D1S495 D1S486 D5S1991 D5S2081 D16S492 D16S3053 D19S219 D19S207 D19S412 
C9 ♀ 
159 236 209 217 221 235/241 175/165 215/213 162/151 
Not informative Not informative Not informative Informative 
C9 ♂ 
157/163 238/236 209 217/215 205/217 243/241 163/167 213 166/164 
Informative Not informative Informative Informative 
C9.1 159/163 236 209 ADO/215 221/205 235/243 175/163 215/213 162/166 
C9.2 159/157 236/238 209 ADO/215 221/217 235/241 175/167 215/213 162/164 
C9.3 159/157 236/238 209 217/215 221/217 235/241 175/167 215/213 162/164 
C9.4 159/157 236/ADO? 209 217 221/217 241 175/167 215/213 162/164 
C9.5 159/163 236 209 217/215 221/217 235/241 165/163 213 162/166 
C9.6 159/163 236 209 217 221/205 241/243 165/167 213 151/166 
C9.7 159/163 236 209 217/215 221/205 235/243 165/163 213 151/166 
C9.8 159/157 236/238 209 217/215 221/217 235/241 163 213 166 
C9.9 159/157 236/238 209 217 221/205 235/243 165/167 213 151/166 
C10 ♀ 
159/163 236 208/214 215/217 200/217 239 146 213 162/166 
Not informative Informative Not informative Not informative 
C10 ♂ 
152/168 238/236 210 213/217 220/228 241/236 162/165 213/217 154/166 
Informative Not informative Informative Informative 
C10.1 159/152 236/238 208/210 215/213 200/228 239/236 146/165 213/217 162/166 
C10.2 163/168 236 208/210 215/217 217/220 239/241 146/162 213 162/154 
C10.3 163/168 236 208/210 215/213 200/220 239/241 146/162 213 166/154 
C10.4 163/168 236 214/210 217/213 200/220 239/241 146/162 213 166/154 
C10.5 159/168 236 208/210 215/217 200/228 239/236 146/162 213 162/154 
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Table 8.1: Appendix C (cont.) - Polymorphic marker results for 
recombination detection 
 Chromosome 17 
Sample NF1int1 D17S1307 NF1int17 NF1int29 D17S1166 
C1 ♀ 
164/166 208 212/216 136 189/191 
Informative 
C1 ♂ 
164 208 208/212 136 191/189 
Informative 
C1.1 164 208 212/208 136 189/191 
C1.2 166/164 208 216/212 136 191/189 
C1.3 166/164 208 216/212 136 191/189 
C1.4 ADO?/164 208 212 136 191/189 
C1.5 AF 208 212/ADO 136 AF 
C1.6 164 208 212/208 136 189/191 
C1.7 164 208 212/208 136 189/191 
C1.8 164 208 212 136 189 
C2 ♀ 
162/160 205 221/229 165/161 195 
Informative 
C2 ♂ 
164 208 216 165/167 199 
Not informative 
C2.1 160/164 205/208 221/216 165/167 195/199 
C2.2 160/ADO 205/208 229/216 161/165 195/199 
C2.3 162/164 205/208 221/216 165 ADO/199 
C2.4 162/164 205/208 221/216 165 195/199 
C2.5 160/164 205/208 221/216 165 195/199 
C2.6 AF 205/208 221/ADO 165 195/199 
C2.7 162/164 205/208 221/216 165 195/199 
C2.8 162/164 205/208 221/216 165 195/199 
C3 ♀ 
160/164 200/208 223/212 157/136 195/189 
Informative 
C3 ♂ 
164 208 208/210 136 191 
Not informative 
C3.1 160/164 200/208 223/210 157/136 195/191 
C3.2 160/164 200/208 223/208 157/136 195/191 
C3.3 160/164 200/208 223/208 157/136 195/191 
C3.4 ADO/164 200/208 212/210 136 195/191 
C3.5 160/164 ADO/208 223/210 157/136 189/191 
C3.6 164 208 212/210 136 189/191 
C3.7 160/ADO 200/208 223/210 157/136 195/191 
C3.8 164 208 212/210 136 189/191 
C3.9 160/164 200/208 223/210 157/136 195/191 
C3.10 164 208 212/210 136 189/191 
C3.11 160/164 200/208 223/210 157/136 195/191 
C4 ♀ 
164 208 215/213 163/136 198/199 
Informative 
C4 ♂ 
164 208 212 138 189/198 
Not informative 
C4.1 164 208 215/212 163/138 198 
C4.2 164 208 212 138 189 
C5 ♀ 
160/164 200/208 227/219 157/136 195/191 
Informative 
C5 ♂ 
164 208 212 136 189/191 
Not informative 
C5.1 160/164 200/208 227/212 157/136 195/191 
C5.2 164 208 219/212 136 195/189 
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Table 8.1: Appendix C (cont.) - Polymorphic marker results for 
recombination detection 
 Chromosome 17 
Sample NF1int1 D17S1307 NF1int17 NF1int29 D17S1166 
C6 ♀ 
164 208 212 138 188 
Not informative 
C6 ♂ 
164 208 210/212 136 188 
Not informative 
C6.1 164 208 212 136 188 
C6.2 164 208 210 136 188 
C6.3 164 208 212/210 138/136 188 
C6.4 164 208 212 138/136 188 
C6.5 164 208 212 138/136 188 
C6.6 164 208 212/210 138/136 188 
C6.7 164 208 212 136 188 
C6.8 164 208 212 136 188 
C6.9 164 208 210 136 188 
C6.10 164 208 210 136 188 
C6.11 164 208 212 138/136 188 
C6.12 164 208 210 136 188 
C6.13 164 208 212 136 188 
C6.14 164 208 212 136 188 
C6.15 164 208 212 138/136 188 
C6.16 164 208 212/210 138/136 188 
C6.17 164 208 212/210 138/136 188 
C6.18 164 208 212/210 138/136 188 
C6.19 164 208 212/210 138/136 188 
C6.20 164 208 212 138 188 
C6.21 164 208 212 138 188 
C6.22 164 208 210 136 188 
C7 ♀ 
158/166 208/204 216/221 169/163 198 
Informative 
C7 ♂ 
162/164 204/208 212/239 138/161 189/198 
Informative 
C7.1 AF 204/208 216/239 169/161 198 
C7.2 AF 208 216/212 169/138 198 
C7.3 AF 204/208 216/239 169/161 198 
C7.4 AF 204/208 216/239 169/161 198 
C7.5 AF 204/208 216/239 169/161 198 
C7.6 AF 204/208 AF 163/161 AF 
C7.7 AF 208 216/ADO 169/161 198 
C8 ♀ 
164 204/208 211 136/138 191/189 
Informative 
C8 ♂ 
164 208 211 136 189 
Not informative 
C8.1 164 204/208 211 136 191/189 
C8.2 164 204/208 211 136 191/189 
C8.3 164 204/208 211 136 191/189 
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Table 8.1: Appendix C (cont.) - Polymorphic marker results for 
recombination detection 
 Chromosome 17 
Sample NF1int1 D17S1307 NF1int17 NF1int29 D17S1166 
C9 ♀ 
164 208 212/214 136 191 
Not informative 
C9 ♂ 
162/164 204/208 217/229 161/163 210/198 
Informative 
C9.1 AF 208 212/229 136/163 191/198 
C9.2 164 208 214/229 136/163 191/198 
C9.3 162/164 208/204 214/217 136/161 191/210 
C9.4 164/162 208/204 212/217 136/161 191/210 
C9.5 164/162 208/204 214/217 136/161 191/210 
C9.6 164/162 208/204 214/217 136/161 191/210 
C9.7 164 208 214/229 136/163 191/198 
C9.8 164/162 208/204 214/217 136/161 191/210 
C9.9 AF 208/204 212/217 136/161 191/210 
C10 ♀ 
166/164 208 212/215 136/163 191/198 
Informative 
C10 ♂ 
164/162 208/204 215/221 136/163 187/198 
Informative 
C10.1 166/ADO 208/204 212/215 136 191/187 
C10.2 166/ADO 208/204 212/215 136 191/187 
C10.3 164 208 215 163 198 
C10.4 166/162 208/204 212/221 136/163 191/198 
C10.5 166/162 208/204 212/221 136/163 191/198 
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